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Abstract 
 
Ovarian cancer is a devastating disease affecting millions of women worldwide. Initially 
successful chemotherapy using platinum-based drugs is often followed by a relapse after 
which platinum therapy is usually ineffective and prognosis poor. The mechanism by which 
platinum resistance develops and its reversal to a more sensitive phenotype are of major 
interest in modern medical oncology, especially for ovarian cancer which has overall low 
survival rates. In this study, different types of in vivo-derived and in vitro cell models of 
platinum resistance were examined within a metabolic context using ¹H NMR spectroscopy 
and bioinformatics-based approaches to test the hypothesis that a metabolic signature of a 
platinum resistance phenotype could be defined. The in vitro-derived cell models of platinum 
resistance focused on the study of the Mlh1 gene, whose loss of expression has been shown to 
play a role in the development of resistance to platinum drugs and mitochondrial dysfunction. 
A comparative metabolic analysis of a transient Mlh1 expression cell model (HEK-293T) 
involving kidney cell lines of common genetic background and the ovarian cancer cell lines 
A2780 and its platinum resistant sub-line CP70 of well-established Mlh1 status was 
conducted. This resulted in the definition of a metabolic signature associated with Mlh1 
expression, which included metabolites such as glutathione, alanine, myo-inositol and 
phosphocholine. It also achieved to associate the loss of MLh1 to mitochondria. The in vivo-
imitating cell model focused on the normoxic & hypoxic baseline metabolic profiling of 
isogenic ovarian cancer cells that were clinically sensitive (PEA1 and PEO1) or resistant 
(PEA2 and PEO4) to platinum. The ¹H NMR-generated results showed oxygen level-related 
changes in glucose, lactate, pyruvate, acetate, and choline-related metabolites. Overall, this 
study managed to contribute towards the understanding of platinum resistance in ovarian 
cancer through a metabolic spectrum using a variety of analytical and methodological tools. 
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HIF: hypoxia inducible factor 
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HEK 293T: human embryonic kidney 293T 
 
HMG: high mobility group 
 
MAS-NMR: magic angle spinning nuclear magnetic resonance 
 
HRT: hormone replacement therapy 
 
JRES: J-resolved   
 
LDH: lactate dehydrogenase  
 
JNK: c-jun N-terminal kinase 
 
MAPK: mitogen-activated protein kinase   
 
MDR: multi-drug resistance 
 
MFC: median fold change 
 
Mlh1: mutL homolog 1 
 
MMR: mismatch repair 
 
mRNA: messenger ribonucleic acid  
 
mtDNA: mitochondrial DNA 
 
MRI: magnetic resonance imaging 
 
NCI: National Cancer Institute  
 
NER: nucleotide excision repair 
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NMR: nuclear magnetic resonance  
 
NOESY: nuclear Overhauser effect spectroscopy  
 
O-PLS: orthogonal – partial least squares  
 
PBS: phosphate buffer saline 
 
PC: phosphocholine  
 
PCA: principal components analysis  
 
PCOS: polycystic ovary syndrome  
 
PA: peritoneal ascites  
 
PE: pleural effusion 
 
P-gp: p-glycoprotein  
 
pH: potentiometric hydrogen ion concentration 
 
PI3K: phosphoinositide-3-kinase 
 
PLS; partial least squares  
 
PMS2: postmeiotic segregation increased 2 
 
PR: pattern recognition 
 
PRM: platinum resistance model  
 
RPMI: Roswell Park Memorial Institute 
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RECIST: response evaluation criteria in solid tumours  
 
RNA: ribonucleic acid  
 
ROS: reactive oxygen species 
 
SD: standard deviation 
 
SEM: standard error of the mean  
 
SRB: sulforhodamine-B 
 
STOCSY: statistical total correlation spectroscopy 
 
TCA: trichloroacetic acid  
 
TSP: trimethylsilylpropionate  
 
WHO World Health Organisation  
 
XIAP: X-linked inhibitor of apoptosis 
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1.1 Cancer and ovarian cancer  
 
1.1.1 What is ovarian cancer? 
Ovarian cancer is one of the most common gynaecological malignancies, and, as the name 
suggests, is a cancer of the ovarian tissues (Melnikov, Scholtens et al. 2009). It‟s the fourth 
most common cancer affecting females in England and Wales with the majority of all 
incidents occurring in women until the age of 85 (Dos Santos Silva, Maclean et al. 2003). 
 
Types of ovarian cancer 
Ovarian tumours can be divided into the a number of categories depending on the type of 
cells they are formed from and include: epithelial carcinomas, which are the most common, 
and where the tumours are derived from the surface cells of the ovary (Auersperg, Wong et 
al. 2001), germ cell tumours, where the cancer cells are derived from the egg-producing 
gonads (ovaries) but are less common than epithelial carcinomas (Auersperg, Wong et al. 
2001), as well as sex cord stromal tumours, which are relatively rare, and derive from a 
special type of ovarian tissue, the sex cords.  (Irving, Carinelli et al. 2005). The above can be 
further divided into some broader categories like metastatic and miscellaneous (Nucci 2009).  
  
Symptoms and signs  
Ovarian cancer has been termed the “silent killer” since most of the signs and symptoms 
make their appearance late in the tumour‟s development, when the cancer has reached an 
advanced stage (Jasen 2009). The most common symptoms include one or more of the 
following:  abdominal pain and increased abdominal size, back pain, bloating, constipation, 
fatigue, urinary urgency, or a combination of the above (Goff, Mandel et al. 2004). 
 
Staging 
Staging in cancer is a way of assessing more effectively the extent to which a cancerous 
growth has spread in a patient‟s body from the initial locus of development. According to 
FIGO (Federation International of Gynaecology and Obstetrics), the main stages in ovarian 
cancer are four and can be seen in table 1.1 (Greene 2002):  
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Stage I - growth of tumour is only limited to the ovaries 
Stage 1a – limited to one ovary and external capsule is non-raptured, there are also  
no ascites, while the washings are negative 
Stage 1b – similar to stage 1a, but growth is present in both ovaries 
Stage 1 - similar to stage 1a or 1b but the capsule has ruptured, while there are ascites 
and the washings are positive 
 
Stage II - growth of tumour has spread to more than one of the ovaries and may also 
extend to the pelvic tissues 
Stage IIa - extension or metastasis to the uterus or fallopian tubes, the washings are 
negative and there are also no ascites present 
Stage II - similar to stage IIa but with extension of the cancer to more pelvic areas 
Stage IIc - similar to stage IIa or IIb but with cancerous growths on the surface of 
either ovary and may also involve ruptured capsules, ascites with cancerous cells and 
positive peritoneal washings 
 
Stage III - growth of the tumour in one or both ovaries involving metastases to more 
organs outside the pelvic area 
Stage IIIa - tumour is confined in the pelvic area but also has microscopic implants to 
abdominal peritoneal areas 
Stage IIIb - similar to IIIa but with macroscopic metastases outside the pelvic tissues, 
with tumours less than 2 cm in size 
Stage IIIc - metastases outside the pelvis, with tumours more than 2 cm in diameter. 
Patients may also be lymph node-positive 
 
Stage IV - metastases in distant tissues such as the liver or extra-peritoneal areas like 
the brain 
Table 1.1 – FIGO stages of ovarian cancer (Greene 2002). 
 
Grading 
There are four main grades of ovarian cancer relating to cytological features, based on 
Broder‟s classification (Vacher-Lavenu et al): grade 1, which involves well differentiated 
cancerous growths without nuclear atypia, followed by grade 2 with moderately differentiated 
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growths without nuclear atypia. Grade 3 includes moderately/well differentiated growths with 
nuclear atypia, while grade 4 involves poorly differentiated or undifferentiated growths with 
nuclear atypia. It can, thus, be easily deducted that the higher the grade of the tumour, the 
faster it grows and the least favourable prognosis it has.  
 
Statistics  
About 1 to 2% of women in the developed world are affected by ovarian cancer (Emma and 
Usha 2005) while the risk of a woman developing ovarian cancer in her lifetime is about 1 in 
80 in Europe (Tsigkou, Marrelli et al. 2007). The survival rates for ovarian cancer are 
dependent on the stage of the tumour at the time of diagnosis (Chan, Fuh et al. 2008). 
 
Risk & prevention factors 
Ovarian cancer is a multifaceted disease; however there are various factors that may 
influence its development:  
 
In one collaborative study, reduced ovarian cancer risk was noted in women who had 
breastfed when compared to women who had never breastfed (Whittemore, Harris et al. 
1992). Another collaborative study examining this issue also showed a significant reduction 
in risk for women who kept breastfeeding for at least 18 months (Danforth, Tworoger et al. 
2007). It was also reported that nulligravid women who made attempts to achieve becoming 
pregnant for over five years were in increased risk for developing ovarian cancer compared to 
women whose attempts lasted for less than a year (Ness, Cramer et al. 2002). Additionally, in 
a collective group of 12 case studies which involved 2197 patients, the use of the oral 
contraceptive pill had been reported to bring about a strong protective effect against the 
development of ovarian cancer (Whittemore, Harris et al. 1992). The risk reduces even more 
with increasing years of use, where women who have used the contraceptive pill for more 
than three years have increased associated benefit compared to women who have never used 
it (Rosenberg, Palmer et al. 1994). Sterilisation through tubal ligation has also been shown to 
confer  protection against ovarian cancer, and it does not seem to decrease significantly over 
time, whereas hysterectomy is also linked to a reduced risk (Green, Purdie et al. 1997); 
(Hankinson, Hunter et al. 1993); (Kjaer, Mellemkjaer et al. 2004). On the contrary, hormone 
replacement therapy (HRT) has been linked to an increased risk of ovarian cancer. The 
results of this study indicated a higher risk when administering oestrogen-only replacement 
therapy when compared to oestrogen-progestin replacement therapy (Zhou, Sun et al. 2008). 
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Another study by the European Prospective Investigation into Cancer and Nutrition exhibited 
that obese post-menopausal women, with a BMI more than 30, have an increased risk in 
relation to women who have a BMI below 25, which is considered to be a normal and healthy 
weight (Lahmann, Cust et al. 2010). Polycystic ovary syndrome (PCOS), a very common 
disorder affecting millions of women, had initially been linked to an increased risk of 
endometrial cancer (Norman, Dewailly et al. 2007). However, even though there are some 
preliminary data suggesting a link between PCOS and ovarian cancer, the existing scientific 
data are not sufficient to draw a certain conclusion (Schildkraut, Schwingl et al. 1996); 
(Solomon 1999). Other meta-analytic studies on analgesic drugs such as paracetamol gave 
some evidence that frequent use can reduce the ovarian cancer risk (Bonovas, Filioussi et al. 
2006). However, findings from other studies have produced inconsistent results ((Merritt, 
Green et al. 2008); (Wernli, Newcomb et al. 2008); (Schildkraut, Moorman et al. 2006); 
(Hannibal, Rossing et al. 2008). Furthermore, a recent review of human carcinogens such as 
tobacco, alcohol, coal smoke, and salted fish as indicated by the International Agency for 
Research on Cancer, had concluded that there is sufficient evidence to link smoking with 
ovarian cancer (Secretan, Straif et al. 2009). Finally, women whose relatives have had 
ovarian cancer are in increased risk of developing the disease (Granstrom, Sundquist et al. 
2008) or women with hereditary syndromes such as Lynch syndrome have  also been found 
to be at higher risk ((Ramsoekh, Wagner et al. 2009). At higher risk for epithelial ovarian 
cancer are also women with mutated alleles for BRCA1 and BRCA2 (Antoniou, Pharoah et al. 
2003) or MMR genes (Peltomaki and Vasen 2004). 
 
Prognosis 
Prognosis in ovarian cancer is usually poor and the mortality rate can be very high due to the 
lack of sensitive early detectors of the disease, which allows for the formation of new 
tumours through the extensive spreading of cancer cells into distant tissues. However, the 
good news is that survival trends in England have increased in recent years which could be 
attributed to cancer care improvements (Rachet, Maringe et al. 2009). 
 
Diagnosis & screening  
Early-stage ovarian cancer is difficult to diagnose before it spreads into more advanced 
disease stages due to the majority of the symptoms being non-specific and therefore of little 
value in diagnosis (Rossing, Wicklund et al. 2010). Most women (around 70%) are diagnosed 
with ovarian cancer at stage III or IV with widespread metastases (Rustin, Bast et al. 2004). 
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Diagnosing cancer in patients may involve the use of various analytical platforms and/or 
standard wet laboratory tests:  
 
1.1.2 Techniques in the diagnosis and examination of cancer. 
These include standard imaging techniques such as X-rays and ultrasound examinations or 
more advanced techniques such as CT (Computerised Tomography) scans and PET (Positron 
Emission Tomography). CT scans can help in determining if the cancer has spread into other 
organs or lymph nodes and involves the injection of a high-contrast dye into the patient 
followed by multiple three-dimensional scans of the patient‟s full body (Jung, Lee et al. 
2002). In oncology, PET scanning employing the use of tracer fluorodeoxyglucose (FDG), 
called FDG-PET, is a very widely used method (Weber 2007). FDG is a glucose analogue 
that is taken up by cells and phosphorylated by hexokinase, with the latter showing enhanced 
concentrations in aggressive tumours (Andrei, Shutian et al. 2005). The advantage of this 
method is that FDG is no further metabolized leading to strong radio-labelling in cancer cells 
(Andrei, Shutian et al. 2005). As a result, FDG-PET can be used not only in cancer diagnosis, 
but also in staging, and as a monitoring system. There are also other analytical methods that 
are used not as much for diagnostic purposes at the moment but are very important for the 
generation of cancer biomarkers or helpful metabolic-related data. Such methodological tools 
include nuclear magnetic resonance (NMR) which is described in more detail in the 
methodology chapter (chapter 2).  
 
Other helpful investigations that may help with diagnosis include the detection of the 
following tumour markers: 
 
Serum Beta Human Chorionic Gonadotropin (BHCG), which is usually present in females 
where pregnancy is possible but also in females suspected of ovarian cancer (Fishman, Raam 
et al. 1975). Another important marker is CA-125, which is commonly found on many 
epithelial tumours, and is useful in the diagnosis and monitoring of the disease, as well as in 
the early detection in patients with recurrent disease (Panza, Pacilio et al. 1988). Other 
ovarian cancer markers include TATI, CASA,  TPA, or CYFRA21-1a and even genetic 
markers such as Ras oncogenes or C-erb2 proto-oncogenes (Mazurek, Niklinski et al. 1998).  
 
Physical examinations can also be useful in diagnosis. These can involve bimanual pelvic 
examination or examination of the liver, spleen, diaphragm, omentum and retroperitoneal 
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lymph nodes since these are some of the main sites of ovarian cancer metastases (Smith 
1979). On the occasions where ovarian cancer is confirmed, a full hysterectomy in the 
abdominal area may be performed, including omenectomy, para-aortic and lymph node 
sampling or peritoneal biopsies (Stuart 2003).  
 
Biopsies might also be performed if necessary, and are usually achieved through surgical 
procedures such as laparotomy or laparoscopy after which suspicious masses are removed 
and sent for further lab analysis  (Spencer, Anderson et al. 2006).  
 
1.1.3 Treatment 
For the treatment of ovarian cancer surgery is usually the first-line of approach. It is also used 
for obtaining tissue samples for histological analysis or for de-bulking purposes. In advanced 
disease progression, debulking surgery (where as much malignant tissues are removed) is 
usually necessary, as it can assist towards a better response to subsequent drug treatment 
(Stuart 2003). Radiation therapy may also be used, but this is mostly applied on smaller areas 
and more localised tumours during the early stages of the disease, as it is more effective this 
way rather than on larger cancer areas (Fujiwara, Suzuki et al. 2002). Finally, chemotherapy, 
which has always been the general standard of care for ovarian cancer  through the usage of 
highly different methods and drug combinations, may also be deemed necessary (McGuire 
and Markman 2003).  
 
1.1.4 Chemotherapy 
 
1.1.4.1 Chemotherapeutic agents in ovarian cancer 
There is a great variety of chemotherapeutic drugs used in the treatment of ovarian cancer.  
Their use depends on parameters such the grading and staging of the cancer, and more 
generally, the overall health of the patient. Such drugs include anthracyclines like 
doxorubicin, alkylating agents like melphalan, spindle poisons like paclitaxel and docetaxel, 
antimetabolites such as gemcitabine and platinum-based compounds such as cisplatin or 
carboplatin, as well as the topoisomerase I inhibitor topotecan. (Berkenblit and Cannistra 
2005) However, some of the most common treatments against ovarian cancer involve 
platinum-based drugs: 
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Platinum anti-cancer drugs have been one of the most important chemotherapy treatments in 
the treatment of malignancies for many years and some of the most widely used and effective 
chemotherapeutics agents even today (Boulikas and Vougiouka 2003). Their most important 
characteristic from which their anticancer activity stems from is their ability to elicit DNA 
damage. 
 
1.1.4.1.1 Cisplatin   
The oldest and perhaps the most famous platinum drug is cisplatin (cis 
diaminodichloroplatinum), a compound that works by inhibiting the production of genetic 
material in the cell by the formation of specific interactions with the cellular DNA. It was 
accidentally discovered by Barnett Rosenberg van Camp and his colleagues at Michigan State 
University in the middle of the 20
th
 century, while examining bacterial growth inhibition with 
the use of electric currents (Rosenberg, Vancamp et al. 1965). They discovered that 
electrolysis of the platinum electrodes generated cisplatin, which in turn stopped cell division 
in E. coli bacteria (Rosenberg, Vancamp et al. 1965). A series of experiments was then 
followed to examine the outcomes of the various platinum complex treatments on human 
leukemic cells (L1210) and on sarcomas implanted in rats. It was then concluded that cis-
PtCl2(NH3)2 was the most effective platinum compound, hence commencing the „career‟ of 
cisplatin in medical cancer treatments (Rosenberg, VanCamp et al. 1969); (Zwelling, 
Anderson et al. 1979).  
 
Since its discovery, cisplatin is still a major chemotherapeutic agent in the treatment of 
ovarian cancers, long after being first-introduced for its treatment in 1973. However, the 
discovery of various toxicities associated with cisplatin treatment resulted in the development 
of additional related drugs such as carboplatin, which could be considered as effective as 
cisplatin, but with fewer side-effects (Kelland 2007) as it causes less neurotoxicity, 
ototoxicity, and less severe nausea than cisplatin (Adams, Kerby et al. 1989). However it still 
has other disadvantages since it is more myelotoxic (Kerr, Lewis et al. 1990). 
 
The cytotoxicities associated with platinum drugs like cisplatin and carboplatin are thought to 
be caused by the generation of platinum-DNA adducts such as mononadducts, intrastrand and  
interstrand crosslinks, or DNA-protein crosslinks (Fichtinger-Schepman, van Dijk-
Knijnenburg et al. 1995). The prevailing notion is that intrastrand crosslinks are the ones 
most responsible for the cytotoxicity as shown by an experiment on Chinese hamster ovary 
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cells (CHO), where the majority of such lesion development co-incided with a  maximum 
peak in cytotoxicity (Fichtinger-Schepman, van Dijk-Knijnenburg et al. 1995). Some 
conflicting opinions exist though, as earlier experiments by Zwelling L.A et al had found an 
in vitro correlation between cytotoxicity and interstrand crosslinks in L1210 cells (Zwelling, 
Anderson et al. 1979). According to McHugh et al, however, it‟s the intrastrand crosslinks 
that mostly contribute to the platinum drugs‟ cytotoxic effects (McHugh, Sones et al. 2000). 
Several more efforts attempting to reduce platinum cytotoxity as well as to overcome 
development of resistance to the platinum drugs have resulted in the development of other 
platinum-based drugs such as oxaliplatin, satraplatin and picoplatin (Kelland 2007); 
(Boulikas and Vougiouka 2003). 
 
Structure of cisplatin 
Cisplatin contains a platinum central atom surrounded by two chlorides and two NH3 groups 
in the cis position, hence its name, (Jamieson and Lippard 1999) as illustrated in the figure 
below: 
 
Figure 1.1 - Chemical structure of cisplatin (schematic supplied by author). 
 
Mechanism of cisplatin action & apoptosis 
Cisplatin is water-soluble; once inside the cell, its chloride ions dissociate because of the low 
chloride concentration, resulting in a reactive diamine-platinum complex, which reacts with 
water molecules during a hydrolytic reaction (Jamieson and Lippard 1999). Following that, 
cisplatin can bind to the N7 nitrogen atoms of DNA bases, preferentially those of guanine and 
adenine (Eastman 1987); (Singer 1977). As already mentioned, the cisplatin complex acts 
through the formation of DNA adducts, most of them intrastrand cross-links (Pinto and 
Lippard 1985). The DNA damage caused by cisplatin is recognized by the cell‟s DNA 
damage recognition machinery, which includes proteins such as high mobility group proteins 
(HMG) as well as mismatch repair complexes like hMSH2 or hMutSα (Jamieson and Lippard 
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1999). These proteins are the starting point of a cascade of cell survival or apoptotic signals, 
which depends on their intensity as well as the crosstalk between the involved effectors (such 
as the p53 - or the p73- tumour suppressor genes). The protein kinase signal transduction 
pathway is then activated, which, in turn, activates p53 causing the cell cycle to arrest at the 
G2/M checkpoint. Whenever the DNA damage to the cell is beyond repair, apoptosis occurs 
through the Bax and caspase pathway.  
 
Figure 1.2 summarises the sequence of events following cisplatin exposure. 
 
 
Figure 1.2 - An overview of pathways involved in mediating cisplatin-induced cellular 
effects. Cell death or cell survival will depend on the relative intensity of the signals 
generated and the crosstalk between the pathways involved. (Figure and text taken 
from “Cisplatin: mode of cytotoxic action and molecular basis of resistance” by (Siddik 
2003). 
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1.1.5 Development of resistance to platinum drugs 
Women with ovarian cancer may initially have a well-received and effective response to 
platinum-based chemotherapy, however as time passes, many ovarian carcinomas can 
become refractory, with the patients dying from progressive chemoresistant disease (Agarwal 
and Kaye 2003). Cancer tumours are said to be sensitive when they appear to readily respond 
to chemotherapy and resistant to platinum when they fail to respond to the treatment either at 
the start of the treatment or at a later stage (Robinson 1993).  Resistance can be either 
intrinsic (already present at the time of diagnosis) or acquired, developing after a period of 
drug administration (Malpas and Rohatiner 1996). According to Response Evaluation Criteria 
in Solid Tumours (RECIST) group, the progression of disease for the duration of the therapy 
is defined as a 20% increase in the total sum of the biggest diameter of the target, such as the 
ovary, or non-target lesion (Therasse, Arbuck et al. 2000). 
 
1.1.5.1 Mechanisms of platinum resistance  
Ovarian cancer cells can exhibit resistance to cisplatin (and platinum in general) due to a 
variety of different factors since there are various fates for platinum once inside the cell. It is 
still unclear, however, which of these factors contribute most in acquired drug resistance in 
clinical situations – where progress is many times hindered by the lack of sensitive methods 
in detecting the crucial drug-induced cellular effects.  
 
A schematic overview of the main mechanisms of platinum resistance is presented in figure 
1.3. 
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Figure 1.3 – Schematic representation of basic mechanisms of platinum drug resistance 
(figure and text taken from (Kartalou and Essigmann 2001). 
 
More specifically, platinum and cisplatin resistance can be linked to:  
 
Reduced intracellular drug accumulation 
Reductions in intracellular drug concentrations between 20–70% have been reported in a 
variety of cisplatin resistant cell lines in the order of 3 to 40-fold (Kelland 1993). However, 
this is not directly analogous to the strength of resistance (Johnson, Laub et al. 1997). 
 
The reduced intracellular drug accumulations can be attributed to a variety of parameters 
such as low dose, low bioavailability, insufficient  distribution, increased metabolism (high 
first-pass metabolism), increased excretion, increased plasma protein binding, low binding to 
target tissues, altered drug diffusion, decreased drug uptake or increased drug efflux or both 
(Lai, Ozols et al. 1988); (Stewart 2007).  
 
Linked to altered drug concentrations is the development of multi-drug resistance (MDR) 
where tumour cells develop resistance even to drugs functionally and structurally distinct to 
platinum, such as the anthracyclines. For example, the MDR gene product p-glycoprotein (P-
gp) drug efflux pump is involved in the alterations of intracellular drug accumulation, and has 
been associated with resistance to chemotherapeutic agents (Smith, Carmeli et al. 1993); 
(Wada, Saikawa et al. 1999); (Wada, Saikawa et al. 1999). 
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It is noteworthy that many platinum drugs are usually transported into the cells through the 
hCtr1 transporter in the plasma membrane, which is also a transporter for copper. Apart from 
hCtr1, other copper-transporting protein transporters include the ATP7A and ATP7B gene 
products, whose increased expression has been linked to increased resistance and poor 
survival in ovarian cancer (Samimi, Safaei et al. 2004); (Komatsu, Sumizawa et al. 2000) 
(Katano, Kondo et al. 2002). 
 
Increased drug detoxification and inactivation  
This can take effect as a result of the platinum drug binding to thiol-containing antioxidants 
like glutathione (Kelland 2007) or metallothioneins (low-molecular weight proteins with a 
high affinity for heavy metals), which are catalysed by glutathione-S-transferase (GST-π) 
(Gottesman and Pastan 1993), and whose increased concentrations have been associated with 
increased cisplatin resistance in various in vivo murine & human models (Kelley, Basu et al. 
1988); (Kasahara K Fau - Fujiwara, Fujiwara Y Fau - Nishio et al. 1991). There is also a link 
between high GST-π levels, poor prognosis, and resistance to platinum in ovarian cancer 
(Green, Robertson et al. 1993); (Sakamoto, Kondo et al. 2001). However, in phase II clinical 
trials, where attempts to bypass thiol-mediated detoxification were examined, the tested 
platinum analogue (ZD0473), which does not bind to thiol compounds, did not produce better 
results than carboplatin (Gore, Atkinson et al. 2002) indicating the pathway might not be a 
crucial factor in resistance development. 
 
Enhanced DNA repair 
Resistance can also be attributed to increased ability to repair DNA often in association with 
increased removal or increased bypass of DNA-cisplatin adducts (Stewart 2007); (Kartalou 
and Essigmann 2001); (Ferry, Hamilton et al. 2000). 
 
On occasions of increased DNA adduct repair the apoptotic process may be reduced. For 
example, in an early study, cell lines derived from patients before (PEO1) and after (PEO4) 
the clinical appearance of platinum resistance were compared and showed that the PEO4 line 
had nearly 3-fold more repair synthesis than its more sensitive predecessor (Lai, Ozols et al. 
1988). However, as with other mechanisms of resistance, increased DNA repair is not always 
present in all cells resistant to cisplatin (Schmidt and Chaney 1993). 
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The nucleotide excision repair (NER) pathway is the pathway responsible for the removal of 
platinum adducts and the repair of DNA damage (Kelland 2007). Cellular dysfunctions in the 
NER pathway leads to cisplatin hypersensitivity, whereas its reestablishment restores 
sensitivity to normal levels (Chaney and Sancar 1996); (Furuta, Ueda et al. 2002). The NER 
complex consists of at least 17 proteins, but increased expression of even a small number of 
rate-limiting proteins (like topoisomerase II, ERCC1, XPA, and BRCA1) is enough to 
increase the repair capacity in resistant cells (Liu 2009). 
 
Topoisomerase II, for example, is associated with repair of DNA crosslinks caused by 
cisplatin, and it is often the case where its clinical overexpression is linked to the onset of 
cisplatin resistance (Ali-Osman, Berger et al. 1993); (Hengstler, Lange et al. 1999). 
Furthermore, increases in ERCC1 mRNA levels in patient tumours that are no longer 
sensitive to cisplatin have been noted (Dabholkar, Vionnet et al. 1994). Similarly, 
overexpression of the XPA gene, which contributes to enhanced repair, has been linked to 
cisplatin resistance (Dabholkar, Vionnet et al. 1994). On the contrary, testicular tumours, 
which usually are cisplatin-sensitive, produce very low levels of XPA and ERCC1/XPF 
(Koberle, Masters et al. 1999). Ovarian cancer cells showing BRCA1 overexpression were 
also shown to be cisplatin resistant and BRCA1-dependent DNA repair is thought to be 
responsible for this (Husain, He et al. 1998). Additionally, BRCA1 silencing was shown to 
increase cisplatin sensitivity, while its overexpression in ovarian cancer cells in mice was 
shown to increase cisplatin resistance (Sylvain, Lafarge et al. 2002). 
 
Decreased DNA mismatch repair (MMR) can also contribute to resistance usually in cells 
deficient in MMR proteins such as hMLH1, hMSH2, hMSH6, hMutL  (heterodimer of 
hMLH1 and PMS2) and hMutS  (heterodimer of hMSH2 and hMSH6) (Duckett Dr Fau - 
Drummond, Drummond Jt Fau - Murchie et al. 1996); (Mello, Acharya et al. 1996; Fink, 
Nebel et al. 1998); (Stewart 2007); (Vaisman, Varchenko et al. 1998); (Zdraveski, Mello et 
al. 2000). MMR genes are needed for genome surveillance after replication. Their gene 
products correct mismatches from DNA replication and evade proofreading (Schofield and 
Hsieh 2003); (Kunkel and Erie 2005). Most mutations are found in the Mlh1 gene (50%), and 
this makes it a highly important gene during carcinogenesis (Tanaka, Zaman et al. 2009). 
Downregulation of such genes are routinely observed on occasions of cisplatin resistance 
(Aebi, Kurdi-Haidar et al. 1996); (Drummond, Anthoney et al. 1996); (Fink, Nebel et al. 
1996); (Brown, Hirst et al. 1997); (Vaisman, Varchenko et al. 1998). Loss of MMR in 
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cisplatin resistant cells is also linked to microsatellite instability and decreased apoptosis 
(Anthoney, McIlwrath et al. 1996); (Mayer, Gillis et al. 2002). Cell lines deficient in the 
MMR genes hMLH1 or hMSH2 were generally found to be resistant to cisplatin in in vitro 
experiments (Brown, Hirst et al. 1997).  This is usually caused through the hypermethylation 
of the hMLh1 promoter (Plumb, Strathdee et al. 2000) while microsatellite instability in 
ovarian tumours after treatment with cisplatin was reported to have links to loss of hMLH1 
expression (Watanabe, Koi et al. 2001).Treatment with 2‟-deoxy-5-azacytidine (DAC), which 
works by inhibiting DNA methyltransferase enzymes, re-sensitized the cells to cisplatin 
(Plumb, Strathdee et al. 2000) by decreasing the hypermethylation of the hMLH1 promoter, 
and has also been used in combination with carboplatin (Longley and Johnston 2005).  
 
There are many reports indicating that increased tolerance to cisplatin adducts is also 
significant in cisplatin resistance ((Johnson, Laub et al. 1997); (Siddik Zh Fau - Mims, Mims 
B Fau - Lozano et al. 1998); (Yoshida M Fau - Khokhar, Khokhar Ar Fau - Siddik et al. 
1998). Loss of apoptotic signalling, as mediated through mutation of genes such as p53 
(Haupt, Berger et al. 2003) is indeed a factor contributing to the lack of cisplatin efficiency in 
the cells. For example, loss of function of the tumour suppressor p53 gene through mutation 
is observed in about a half of all cancers (Hollstein, Sidransky et al. 1991); (Soussi 2000). 
Tumour cells with defects in p53-mediated apoptotic pathway fail to activate cell death, thus, 
enabling the cells to become tolerant to DNA damage (Kastan, Onyekwere et al. 1991); 
(Hartwell and Kastan 1994); (Pietenpol, Tokino et al. 1994); (Siddik Zh Fau - Mims, Mims B 
Fau - Lozano et al. 1998). 
 
MAPK subfamily members (i.e. p38, JNK, and ERK) are also linked to cisplatin function. 
However, whether MAPK pathway defects mediate cisplatin resistance is still not very clear, 
as there are various conflicting studies in existence. The MAPK pathway leads to the 
activation of transcription factors  such as c-Myc, c-Fos, and c-Jun (Robinson and Cobb 
1997); (Martin-Blanco 2000) which are overexpressed in cisplatin resistant cells, while their 
decreased expression resensitizes them to the drug (Kartalou and Essigmann 2001); (Pan B 
Fau - Yao, Yao Ks Fau - Monia et al. 2002). 
 
Other factors can include overexpression of HER-2/neu and the PI3-K/Akt pathway.  
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Evasion of apoptosis 
Overexpressed apoptotic inhibitors, such as survivin and XIAP can also enhance resistance 
(Asselin, Mills et al. 2001); (Ikeguchi, Liu et al. 2002) by acting directly or indirectly on the 
function of caspases, which are important effector apoptotic molecules. Activation of 
caspases 3, 8, and 9 is decreased in cisplatin resistant cells (Henkels Km Fau - Turchi and Jj 
1997); (Blanc C Fau - Deveraux, Deveraux Ql Fau - Krajewski et al. 2000); (Asselin, Mills et 
al. 2001); (Ono Y Fau - Nonomura, Nonomura N Fau - Harada et al. 2001). This inhibition 
could be due to loss of Fas expression after cisplatin treatment, decreasing, thus, the 
apoptotic signals (Qin and Ng 2002). 
 
Other factors important in the regulation of apoptosis are Bcl-2 family members, which are 
located in the mitochondria as homodimers or heterodimers, and can be either proapoptotic 
(i.e. BAX) or antiapoptotic (i.e.Bcl-2and Bcl-xL) (Farrow and Brown 1996); (Hanahan and 
Weinberg 2000); (Schuler and Green 2001); (Gebauer, Mirakhur et al. 2000). Overexpression 
of Bcl-2 is associated with cisplatin resistance, sometimes with an increase in glutathione 
levels (Hockenbery, Oltvai et al. 1993); (Chiao, Carothers et al. 1995).  Increased levels of 
Bcl-xL have also been reported in resistant cells (Gebauer, Mirakhur et al. 2000), possibly 
through inhibition of the negative regulator Bad (Hayakawa, Ohmichi et al. 2000). 
Contradictory results also exist, though; Bcl-2 overexpression was found to be linked to 
improved survival of cisplatin-receiving ovarian cancer patients (Herod, Eliopoulos et al. 
1996) which is a reminder of our limited knowledge regarding apoptosis and development of 
resistance.  
 
Figure 1.4 below illustrates the complex multifactorial features of platinum drug resistance.  
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Figure 1.4 - Mechanisms involved in inhibiting the apoptotic signal in cisplatin-resistant 
tumour cells. More than one mechanism is usually observed in resistant cells, and this 
contributes to the multifactorial nature of cisplatin resistance (figure and text taken 
from “Cisplatin: mode of cytotoxic action and molecular basis of resistance” by (Siddik 
2003). 
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1.1.6 Hypoxia in cancer and drug resistance 
Hypoxia is another important factor in the development of platinum resistance. Its presence in 
tumours, where the oxygen concentration is very low, was first proposed by Thomlinson and 
Gray while observing the distribution of necrosis in blood vessels (Thomlinson and Gray 
1955) even though it was already known that hypoxic cells were resistant to death by ionizing 
radiation (Gray, Conger et al. 1953). 
 
The rapid expansion of tumour cells usually surpasses vascular growth, leading to an 
inadequate cancer growth blood supply, thus, resulting in the creation of a hypoxic 
environment which significantly limits oxygen availability in mitochondrial respiration and 
ATP synthesis (Xu, Pelicano et al. 2005).  This results in the cancer cells up-regulating the 
glycolytic pathway for energy production (Guppy 2002). Hypoxia is, thus, important in 
cancer as it has the ability to aggravate the intensity of the Warburg effect (explained further 
below) and to facilitate tumour survival, thus, resulting in an aggressive phenotype.  
 
The effect of oxygen on regulating glucose metabolism is known as the Pasteur Effect and is 
mediated through several kinase pathways (Hardie 2000); (Seta, Spicer et al. 2002). The 
increased glycolysis in cancer cells is not always due to dysfunctional mitochondria but it can 
also be induced by the tumour microenvironment through overexpression of various 
glycolytic enzymes (Mathupala, Rempel et al. 2001). 
 
There are many ways by which hypoxia may adversely affect cancer drug treatment, but most 
commonly hypoxia hinders cancer therapy by promoting tumour cell resistance to 
conventional chemotherapeutic drugs in a variety of ways: 
 
In hypoxia, the alkylating agents and platinum compounds‟ function may be reduced due to 
the enhanced activity of DNA repair enzymes (Ebert, Gunther et al. 2000). Hypoxia may also 
enhance the production of proteins responsible for the development of drug resistance (i.e. 
metallothioneins) (Murphy, Laderoute et al. 1994). It can also lead to genome changes such 
as selection of cells with p53 mutations (Graeber, Peterson et al. 1994) which results in drug 
resistance through loss of apoptotic potential. Furthermore, the heterogeneous hypoxic 
tumour blood-flow results in poor and irregular blood supply, leading to restricted drug 
distribution (Vaupel, Kallinowski et al. 1989); (Vaupel, Thews et al. 2001); (Aoife, David et 
al. 2003). 
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In hypoxia, drugs with short half-life in the body may also have trouble reaching the target 
tumour tissues in time to be effective (Brown 1999). In addition, sometimes the location of 
viable hypoxic cells very close to the blood vessels may create an obstacle in terms of 
physical delivery, as bulky chemotherapeutic drugs may need to penetrate many layers to 
reach the targets (Sutherland 1988); (Tannock 1982); (Durand 1989); (Teicher, Holden et al. 
1990). 
 
Low pH is also sometimes found in hypoxic tumour areas. Even though the intracellular pH 
usually remains at normal levels, the extracellular pH may be quite low (Harris 2002) 
resulting in a pH gradient which hinders the intracellular drug accumulation creating a 
problem for drugs that are weak bases (adriamycin) (Skovsgaard 1977). Situations where 
drugs are dependent on oxygen for maximum function (Teicher, Lazo et al. 1981) may also 
be problematic. For example, in an early study (Teicher, Holden et al. 1987) normoxic 
tumour cells showed bigger sensitivity to melphalan, compared to their counterparts that were 
placed under hypoxic conditions. Since hypoxia  causes cells to cycle more slowly or even 
make them enter cell cycle arrest, drugs like alkylating agents and antimetabolites that act on 
specific cell-cycle phases or on highly-cycling cells may have reduced effectiveness 
(Amellem and Pettersen 1991). Finally, hypoxic tumours in general are prone to select for a 
more malignant and metastatic phenotype (Ivan, Kondo et al. 2001); (Huang, Gu et al. 1998); 
(Lu, Forbes et al. 2002) by increasing mutations (Jaakkola, Mole et al. 2001) and expression 
of angiogenetic genes (Huang, Arany et al. 1996), making subsequent attempts at treatment 
either through surgery radiation or chemotherapy even more difficult. An example is the 
hypoxia induced transcription factor HIF-1 gene product (a dimer of HIF-1α and HIF-1β 
subunits). HIF-1α expression is associated with poor prognosis and resistance to therapy in 
cancers, including ovarian cancer (Sutherland 1988); (Tannock 1982) as it in turn stimulates 
more transcription genes involved in angiogenesis and glycolysis (Huang, Arany et al. 1996). 
 
Therefore, hypoxia has a crucial adverse role in cancer prognosis not only because of its 
negative effects on drug resistance but also because it can directly promote a more malignant 
phenotype. However, the unique features associated with hypoxia, caused by the very low 
oxygen concentrations and even the presence of necrosis, not normally found in healthy 
normoxic tissues, could act as potential exploitable targets in cancer therapy.  
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Figure 1.5 - In this figure the structural and functional effects of hypoxia, HIF-1 and 
VEGF on tumour microcirculation, cancer metabolism and therapies are illustrated. 
The vicious circles that occur are also shown. (Modified with permission from: Baronzio 
et al. Anticancer Res 1994; 14:1145-1154.) - (Figure and text taken from (Baronzio, 
Hager et al. 2006). 
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1.1.7 The role of mitochondria in platinum resistant cells  
In recent years, the role of mitochondria in platinum resistance is also considered of 
importance in the development of platinum resistance as the main cytotoxic activity of 
cisplatin is mediated by a mitochondria-associated induction of apoptosis. There are 
conflicting opinions on the mitochondrial association with cisplatin sensitivity (usually 
involving mitochondrial changes in morphology and function). For example, in a study by 
Liang and Ullyatt on mitochondrial-DNA depleted U937 cells, where enhanced sensitivity in 
cisplatin was reported (Liang and Ullyatt 1998),  it was shown that cells continued to respond 
to cisplatin and undergo apoptosis. This could mean that mitochondrial DNA-expressed 
molecules may be important in altering cellular sensitivity to cisplatin-caused apoptosis, but 
may not be required for the actual apoptotic process itself. On the contrary, in a study by Park 
et al it was shown that SK-Hep1 hepatoma cells that had their mitochondrial DNA-depleted 
were resistant to cell death through oxidative stress or chemotherapeutic agents (Park, Chang 
et al. 2004). 
 
Mitochondrial pathway of apoptosis 
Generally, it‟s been known that cisplatin can induce apoptosis by Fas ligand induction on the 
surface of tumour cells, and killing the Fas-sensitive subpopulations, the direct activation of 
initiator protease, caspase-8 or cell stress signals via „activation‟ of mitochondria (Hirama, 
Isonishi et al. 2006). 
 
One crucial event in the apoptotic process is the release of cytochrome c from the 
mitochondria into the cytosol. Cytochrome c recruits the apoptotic protease-activating factor 
1 (Apaf-1) and procaspase-9 forming a complex which then activates the initiator caspase-9. 
Caspase-9 continues the cascading process with activation of caspase-3, leading to DNA 
fragmentation and, eventually, apoptosis (Cai, Yang et al. 1998);  (Shiozaki, Chai et al. 
2002). 
 
Figure 1.6 below illustrates the cisplatin-induced mitochondrial apoptotic pathway:  
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Figure 1.6 - Induction of the mitochondrial apoptotic pathway by cisplatin. A cartoon 
explaining how cisplatin activates the proapoptotic protein Bax resulting in the release 
of cytochrome c from the mitochondrial intermembrane space to the cytosol to induce 
the formation of the apoptosome (Apaf-1 cytochrome c complex); this step is being 
followed by binding and activation of procaspase-9 to the inner "hub" region of the 
apoptosome leading to activation of procaspase-3 (taken from “Molecular mechanisms 
of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a 
chemotherapy and antiangiogenesis drug” by T. Boulikas).  
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The role of mitochondria in healthy vs. cancer cells is discussed in more detail below: 
 
Mitochondria are important in maintaining normal function and homeostasis 
The role of mitochondria is fundamental in energy production, calcium homeostasis 
(Clapham 2007), apoptosis and ROS generation (Green and Reed 1998). Their main sources 
of fuel include glucose, fatty acids, and various amino acids, used for ATP generation 
through oxidative phosphorylation. The Krebs cycle which takes place in the mitochondria 
assists in NADH production, which, through the respiratory chain, is an important component 
of electron transportation and eventually creation of transmembrane potential (ΔΨ), 
subsequently used for production of ATP in complex V (Wang, Ogasawara et al. 2010). 
 
Impaired mitochondrial function in cancer 
Many cancer cells appear with changes in their mitochondrial structure and function 
compared to normal cells, including changes in size, shape and number, with fast growing 
tumour cells appearing to have fewer and smaller mitochondria (Fantin, Berardi et al. 2002); 
(Toogood 2008); (Modica-Napolitano and Singh 2004) or altered inner mitochondrial 
membrane proteins (Chang, Schnaitman et al. 1971); (Irwin, Malkin et al. 1978). 
Mitochondrial dysfunction in the form of altered ATP generation or abnormal increases in 
ROS has also been observed in cancer cells, as demonstrated by (Chen, Lu et al. 2007) and 
(Pelicano, Carney et al. 2004). Other examples of impaired mitochondrial function include 
decreased reparatory complex activities in the mitochondria of hepatoma cells (Chan and 
Barbour 1983); (Sun, Sepkowitz et al. 1981) and reduced ATPase activity (Pedersen and 
Morris 1974). Even though mitochondria possess an adequate base excision repair (BER), 
mutations in the mitochondrial DNA (mtDNA) or decreased activities in the DNA mismatch 
repair (MMR) system genes, such as Mlh1, can also lead to microsatellite instability, and 
subsequently cancer (Chen, Lu et al. 2007). Increased mitochondrial transmembrane potential 
(Bernal, Lampidis et al. 1982); (Johnson, Walsh et al. 1981) has also been observed in cancer 
cells. Since mitochondria are major sources of ROS, increased levels in cancer might mean 
increased leakage of electrons from the respiratory chain (complexes I & III). This electron 
leakage may lead to reaction with oxygen molecules forming superoxides and then hydrogen 
peroxides. Thus, increased ROS in cancer may be a sign of mitochondrial dysfunction - even 
though other non-mitochondrial sources may also be considered (Pelicano, Lu et al. 2009); 
(Wang, Ogasawara et al. 2010). 
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Targeting mitochondria as a cancer treatment 
It is possible that the differences in mitochondrial structure and function of cancerous cells 
may render them susceptible to drug-induced damage. For example, targeting Bcl-2 proteins 
may force the increase of mitochondrial permeability and release of apoptotic factors. Also, 
the increased dependence of the cancer cells on glycolysis (due to impaired mitochondrial 
function) may lead to preferential cell death through the use of glycolytic inhibitors (i.e. 3-
bromopyruvate (3-BrPA) or lonidamine) (Chen, Lu et al. 2007) (Armstrong 2006); (Dias and 
Bailly 2005); (Galluzzi, Larochette et al. 2006); (Morrison, Andera et al. 2009); (Ralph and 
Neuzil 2009).  
However, it should be noted that not all mitochondrial alterations should be generalized for 
all cancer cells. The alterations may vary depending on the type, origin, stage, metastatic state 
of the cancer cells, and even specific tumour microenvironments such as hypoxia (Wang, 
Ogasawara et al. 2010). 
 
1.2 Metabolism of cancer & the Warburg effect 
Metabolism is an important aspect of the carcinogenetic process as cancer cells show 
increased metabolic rates and an extreme demand for energy (Coloff and Rathmell 2006). 
Cancer cells also exhibit enhanced glucose uptake, which is known as the Warburg effect 
(Gatenby and Gillies 2004). Paradoxically, glucose is mostly anaerobically metabolized to 
lactate, providing much less ATP and energy than aerobic respiration; however, cancer cells 
have selectively developed adaptations to hypoxic conditions (Brahimi-Horn, Chiche et al. 
2007). In normal cells apoptosis can occur when the cells are found in an acidic environment. 
However, cancer cells are able to survive or even thrive in a low pH environment and 
unfavourable conditions (De Milito and Fais 2005). It has also been reported that the higher 
the glycolysis rate, the more aggressive the cancer is in terms of invasion and metastasis 
(Pelicano, Martin et al. 2006). Other metabolic changes in cancer, including ovarian cancer, 
involve switching from high glycerphosphocholine (GPC) and low phosphocholine (PC) to 
low GPC and high PC concentrations (Iorio, Mezzanzanica et al. 2005). So, metabolic 
differences between cancerous and non-cancerous cells could serve as biomarkers of cancer 
detection (Griffin and Shockcor 2004).  
 
Figure 1.7 illustrates the differences between oxidative phosphorylation, anaerobic 
glycolysis, and aerobic glycolysis (Warburg effect). 
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Figure 1.7 - Schematic representation of the differences between oxidative 
phosphorylation, anaerobic glycolysis, and aerobic glycolysis (Warburg effect). In the 
presence of oxygen, nonproliferating (differentiated) tissues first metabolize glucose to 
pyruvate via glycolysis and then completely oxidize most of that pyruvate in the 
mitochondria to CO2 during the process of oxidative phosphorylation. Because oxygen 
is required as the final electron acceptor to completely oxidize the glucose, oxygen is 
essential for this process. When oxygen is limiting, cells can redirect the pyruvate 
generated by glycolysis away from mitochondrial oxidative phosphorylation by 
generating lactate (anaerobic glycolysis). This generation of lactate during anaerobic 
glycolysis allows glycolysis to continue (by cycling NADH back to NAD
+
), but results in 
minimal ATP production when compared with oxidative phosphorylation. Warburg 
observed that cancer cells tend to convert most glucose to lactate regardless of whether 
oxygen is present (aerobic glycolysis). This property is shared by normal proliferative 
tissues. Mitochondria remain functional and some oxidative phosphorylation continues 
in both cancer cells and normal proliferating cells. Nevertheless, aerobic glycolysis is 
less efficient than oxidative phosphorylation for generating ATP. In proliferating cells, 
~10% of the glucose is diverted into biosynthetic pathways upstream of pyruvate 
production (Vander Heiden, Cantley et al. 2009). 
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Tumours commonly undergo extreme reprogramming of their basic metabolism, but it is still 
not very clear if these changes are brought about by tumourigenesis or they are themselves 
the cause of cancer development. This metabolic switch or transformation can give selective 
growth advantages and even resistance to apoptosis (Jones and Thompson 2009).  
 
Figure 1.8 below shows a detailed representation of the overall metabolic processes that 
occur inside a cancer cell. 
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Figure 1.8 - Metabolic processes inside a cancer cell. In normal cells, aerobic glycolysis implies the 
conversion of glucose via pyruvate into acetyl-CoA and its complete oxidation (through the 
mitochondrion-localized tricarboxylic acid [TCA] cycle and oxidative phosphorylation) to CO2 and H2O 
(which generates 38 ATP molecules per molecule of glucose). In contrast, in tumour cells, glycolysis tends 
to be aborted at either of two steps. First, aerobic glycolysis in tumour cells implies conversion of glucose 
into pyruvate (which generates only two ATP molecules per molecule of glucose) and subsequently into 
the waste product lactic acid. Second, in tumour cells, acetyl-CoA tends to be introduced into a truncated 
TCA cycle, with the net result that acetyl-CoA is exported into the cytosol and serves as a building block 
for cell growth and proliferation. In this truncated TCA cycle, citrate is preferentially exported to the 
cytosol via the tricarboxylate transporter. Once in the cytosol, citrate is cleaved by ATP citrate lyase 
(ACL) to generate oxaloacetate and acetyl-CoA. Oxaloacetate is reduced to malate, then reimported into 
mitochondria and reconverted to oxaloacetate in the matrix (while generating NADH that represses the 
TCA cycle), and it reacts with acetyl-CoA to complete the substrate cycle. Small arrows pointing up or 
down indicate cancer-associated upregulation/activation or downregulation/inhibition of enzymes, 
respectively. Alterations indicated in red can be caused by the activation of HIF-1. CA9 and CA12, 
carbonic anhydrases 9 and 12; CPT, carnitine palmitoyltransferase; GLUT, glucose transporter; GSH, 
glutathione; HIF, hypoxia-inducible factor; IDO, indoleamine 2,3-dioxygenase; HK, hexokinase; 
OXPHOS, oxidative phosphorylation; LAT1, L-type amino acid transporter 1; LDHA, lactate 
dehydrogenase isoform A; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK, 
pyruvate dehydrogenase kinase; PFK, phosphofructokinase; PI3K, phosphatidylinositol 3-kinase; PGM, 
phosphoglycerate mutase; PKM2, pyruvate kinase isoform M2; PPP, pentose phosphate pathway; SCO2, 
synthesis of cytochrome c oxidase 2; TLK, transketolase; VDAC, voltage-dependent anion channel. 
(Figure & text taken from “Tumor Cell Metabolism: Cancer's Achilles' Heel” by (Kroemer and 
Pouyssegur 2008). 
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1.3 Metabonomics and metabolic footprints 
Metabolic profiling includes metabonomics and metabolomics focusing on the analysis of 
metabolites in entire systems and helping in the understanding of biological mechanisms, 
including cancer. Metabonomics is the study of metabolic responses to various stimuli such 
as drugs, environmental changes and diseases (Nicholson, Lindon et al. 1999). Metabonomics 
is complementary to genomics, which studies the genome, and proteomics, which is the study 
of the proteins of an organism, and it involves the study of an organism‟s metabolome 
(Lindon, Nicholson et al. 2000). Metabolomic analysis is often conducted on biofluids, which 
can be obtained relatively non-invasively and without much discomfort, as with the collection 
of samples of urine or blood serum. Other fluids can also be used such as cerebrospinal or 
seminal fluid. It is also possible to use cell culture supernatants or tissue extracts (Lindon, 
Nicholson et al. 2000). 
 
As cells secrete a large number of metabolites into their external environment, this may 
reflect metabolic activity in the cells and also the level of transcription and translation of 
various genes (Kell, Brown et al. 2005). Therefore, a universal measurement of secreted 
metabolites might be used to analytical advantage. Metabolic footprinting is a recently-
developed method for the functional analysis and characterization of cells by defining the 
extracellular metabolome (Kell, Brown et al. 2005). It is a strategy for the analysis of cells 
and tissues by studying, in a high-throughput manner, the metabolites that they excrete, take 
or fail to take from their environment. 
 
1.4 Tools and techniques in metabolic analysis 
One of the most useful tools in metabolomics and in the study of cancer metabolism is the 
phenomenon of nuclear magnetic resonance (NMR), which is exploited in research through 
NMR spectroscopy. Advantages of NMR-based metabonomics include a relatively quick and 
easy sample preparation, the use of small sample size (usually less than 0.5 ml of fluid or 20 
g of tissue). Also, the fact that it is relatively non-destructive and that the data collection can 
yield results within a few minutes make NMR-based metabonomics extremely advantageous 
(Nicholson, Lindon et al. 1999; Lindon, Nicholson et al. 2000). NMR is also employed in the 
study of intact tissues in magic angle spinning (MAS) NMR spectroscopy. 
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1.5 The need for metabolic biomarkers 
No screening test has yet been shown to effectively reduce the risk of fatality in ovarian 
cancer and is one of the main reasons that ovarian cancers are not detected early in 
development. The generation of a routine screen test for the early-stage detection of ovarian 
cancer could be invaluable in decreasing mortality. Additionally, the likelihood of relapse or 
developing resistance may also be pre-empted through such screening following successful 
treatment as well as during treatment to monitor successful response to drugs.  
 
Biomarkers could be a means of allowing clinicians to recognize and detect ovarian cancer at 
an early stage. That‟s why the development of new biomarkers for ovarian cancer is needed 
for the improved detection and monitoring of the disease. Furthermore, metabolic biomarkers 
have an extra advantage; that of being easy to measure in the clinic by using non-invasive in 
vivo tools such as, for example, PET or MRI.  
 
In addition, platinum biomarkers are essential in optimizing the value of administering a 
platinum drug to patients by tailoring these to individual patient needs. Biomarkers could 
help in determining which patients can be managed by such treatment and if the treatment 
and its continuation are suitable for them, thus, preventing the patients from unnecessary 
discomfort and distress. 
 
It is not however possible that a single biomarker would be capable of producing sufficient 
prognostic value, as the intrinsic biology of the tumour and the host response may influence 
the results. This is where examination of baseline cancer profiles and their metabolic 
signatures become useful as they can look at the whole cancer metabolome from an elevated 
point of view, with the ability to get closer looks at specific metabolites that seem to be 
important in the carcinogenetic process.  
 
1.6 NMR-detectable metabolites 
A big variety of metabolites can be identified and quantified with NMR spectroscopy. Key 
metabolites that may have some kind of association with cancer include the following 
presented in table 1.2: 
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NMR-detectable metabolites 
alanine 
acetate 
aspartate  
choline 
creatine 
formate  
glucose  
glutamate  
glutathione 
glycerophosphocholine 
glycine 
isoleucine  
histidine 
lactate 
leucine 
myo-inositol 
phenylananine 
phosphocholine 
pyruvate 
succinate 
taurine 
valine 
Table 1.2 - list of NMR-detectable metabolites 
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1.7 General aims of this study 
In this thesis, the main theme of investigation will involve the metabolic examination of 
platinum resistance in ovarian cancer chemotherapy through the employment of a number of 
different analytical techniques and platforms, such as NMR, molecular biology and 
bioinformatics-based approaches, with the aim to generate a much-needed phenotype of 
platinum resistance. 
 
In the first part of the investigation (chapter 3), this study will deal with the metabolic 
examination of two in vitro-derived cell models of platinum resistance: a) a cell model that 
consists of kidney cell lines of common genetic background involving selective 
mitochondrial depletion for examining the association of Mlh1 to mitochondria and platinum 
resistance, and b) a model of platinum resistance that consists of well-established ovarian cell 
lines that are sensitive or resistant to platinum drugs.  
 
The following chapter (chapter 4) will follow a bioinformatics-based approach to compare 
the metabolic findings of the 3
rd
 chapter to the microarray gene expression data of the 
publicly available NCI-60 panel which consists of a variety of different cancer cell lines. This 
approach will take advantage of a newly-developed method by this lab, involving over-
representation analysis (ORA) and neighbourhood-based entities (NESTs).   
 
Finally, the examination presented in chapter 5 will focus on the study of a clinically-derived 
cell model of platinum resistance which will involve the use of isogenic ovarian cancer cells 
that are either sensitive or resistant to the platinum drug cisplatin after the application of 
chemotherapy. This examination will involve exposure of the cells to normoxic and hypoxic 
conditions in order to study the generated intracellular and extracellular metabolic 
concentration changes and possibly link them to platinum resistance. 
 
Overall, this pre-clinical metabolic-based investigation may assist in the goal towards 
biomarker identification that has a diagnostic and predictive value in the clinical environment 
in terms of patient chemotherapy response, and, thus, at times avoid unnecessary side-effect 
producing treatment. 
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Chapter 2 
 
Methods 
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2.1 Molecular biology methods  
2.1.1 Cell culture  
i)  Isogenic ovarian cancer cell lines 
All cell lines used in these experiments were grown in sterile tissue culture flasks 
(Corning
®,
,UK) and maintained in complete RPMI-1640 (Sigma-Aldrich, UK; cat no: 
R5886), growth medium with 10% fetal bovine serum (Sigma-Aldrich, UK; cat no: F6178) 
and 1% L-glutamine, penicillin, streptomycin solution (including 10,000 units of penicillin, 
10,000 µg of streptomycin, and 29.2 mg of L-glutamine/ml in 0.85% saline)  by Sigma-
Aldrich, UK; cat no: G6784. All cells were grown at 37 ºC in a SANYO MCO-18M 
humidified incubator in sterile standard cell culture conditions (5% CO2 and 21% O2). For the 
hypoxic experiments the cell culture incubation conditions were set at 1% O2, 5% CO2 at 37 
o
C, with hypoxia being achieved after approximately 20 minutes from the start of the 
experiment.    
Establishment of the isogenic ovarian cancer cell lines 
Two pairs of cell lines were used during the main study, originally established by Langdon 
and his colleagues (Langdon, Lawrie et al. 1988): PEA1 & PEA2 and PEO1 & PEO4 while 
an additional pair (PEO14 & PEO23) was used during pilot experiments.  
 
Each pair of cell lines was derived from the ascites or pleural diffusion of patients suffering 
from ovarian adenocarcinoma before and after the clinical appearance of cisplatin resistance 
(Langdon, Lawrie et al. 1988). According to Langdon, each set of cell lines was found to be 
morphologically distinct. Details of their clinical characteristics are given in table 2.1. 
 
Cell line Morphology Site IC50 (µM) 
PEA1 Poorly differentiated 
adenocarcinoma 
PE 7.07 
PEA2 PA 10.23 
PEO1 Poorly differentiated 
serous adenocarcinoma 
PA 1.33 
PEO4 PA 11.60 
PEO14 Well-differentiated 
serous adenocarcinoma 
PA 1.84 
PEO23 PA 10.77 
Table 2.1 – in vivo and in vitro characteristics of patients from whom the isogenic 
ovarian cancer cell lines were derived. (PE = Pleural Effusion, PA = Peritoneal Ascites)  
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All isogenic ovarian cancer cell lines used in this study and their corresponding cisplatin 
IC50 average values were kindly provided by Dr Euan Stronach & Professor Hani Gabra 
from the Department of Oncology, Faculty of Medicine, Imperial College, London.  
 
ii) Ovarian and kidney cancer cells used in the MLh1 study 
The cells used for the metabolic examination of Mlh1 involved the following cancer cell lines 
of ovarian (platinum resistance model) and kidney (HEK-293T model) origin (Table 2.2). All 
cells in this study were kindly provided by Prof Bob Brown and Dr Vincent O‟Brien of 
Imperial College, London, and Sistemic Scotland Limited, Glascow, respectively. 
 
HEK-293T Model (Kidney) 
HEK-293T MutLα+  
HEK-293T MutLα-  
HEK-293T MutLα+ ρ0 
HEK-293T MutLα- ρ0  
Platinum Resistance Model (Ovarian) 
A2780 
CP70 
CP70 E1  
CP70 A2  
Table 2.2 – list of cancer cell lines of the models used in the Mlh1 study  
 
The ovarian cancer cells were cultured in standard conditions as described earlier, and grown 
in RPMI-1640 media (Gibco, UK; cat no: 31870-025), while the kidney cancer cells were 
grown in DMEM media (Gibco, UK; cat no: 11960-044). Both media were supplemented 
with glutamine (Gibco, UK; cat no: 16000-036) and 10% FBS (Autogen Bioclear, UK; cat 
no: 7.01). All cells were placed in culture for 48 hours before harvesting and counting (5 
million cells for each cell line sample). All drug selection exposures imposed on the cells 
were removed 48 hours before cell harvesting. A detailed description on these cell lines and 
their characteristics can be found in the methodology section of chapter 3.   
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2.1.1.2 Cell harvesting 
 
Harvesting of cells using trypsinisation method 
Under sterile conditions, and at approximately 70% confluence, cells were detached from 
their T75 flasks first by removing the media, washing with 5 ml of phosphate buffer saline 
(PBS) (Sigma-Aldrich, UK; 56064C) and then by adding 5 ml of warmed 10% trypsin in 
EDTA (Sigma-Aldrich, UK; cat no: 59429C). This reaction was left to continue at 37
ο
C, 5% 
CO2 for 5 minutes or until all the cells were detached, and then stopped by the addition of 
5ml of fresh culture media. The resulting cell mixture was transferred into sterilized tubes 
(BD Falcon™, UK) and centrifuged for 5 minutes at 125g in a Beckman C5-6R centrifuge, 
after which the supernatant was aspirated off. The cell pellet was washed twice by adding 5 
ml of cold PBS, followed by resuspension and centrifugation at 125g for 5 minutes. The PBS 
was suctioned off again and the cells were resuspended in media (15 ml per T75 flask).   
 
Harvesting cells by direct methanol extraction method 
For the direct methanol extraction method, the media in the culture vessels were transferred 
into sterilised tubes. The media samples were then centrifuged (4 oC, 150g, 4 min) to pellet 
any dead cells and transferred into new sterilised tubes. They were stored at -40 oC until 
further use. The cells in the flasks were washed twice using 3 ml of cold (4 ⁰C) PBS. The 
cells were then quenched by adding 3 ml of cold methanol (kept at 4 ⁰C) and allowed to lyse 
for 2 minutes at room temperature. The cellular material was detached from the culture vessel 
using a cell scraper. The resulting suspension of cellular material was then transferred from 
the culture vessels to Eppendorf tubes. The suspensions were dried down overnight using a 
rotary speedvac at room temperature (RT) and then stored in the -40oC freezer until use. 
 
2.1.1.3 Cell storage 
For possible future use, stocks of the cells were frozen down by following the trypsinisation 
method, except that 1ml of freeze media consisting of 90% FBS and 10% dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich, UK; cat no: D2650) was used for their resuspension at the final 
step before their transfer into appropriate cryogenic tubes. The cryogenic tubes containing the 
cells were immediately transferred to a -80°C freezer inside a polystyrene box in order to 
prevent a fast rate of freezing and thus reducing cryogenic related cell damage. Within 24 
hours, the cells were subsequently transferred into liquid nitrogen for long term storage.  
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When more cells were needed for growth, the cryogenic vials were removed from the freezer 
and quickly defrosted in a 37°C water bath. This was followed by centrifugation of the cell 
solution for 125g for 5 minutes and transfer into a small T25 culture flask with 7 ml of cell 
culture media. The flasks with the cells were then transferred into the incubator (21% O2, 5% 
CO2 at 37
ο
C). 
 
2.1.1.4 Cell counting 
 
Cell counts using an automatic cell counter 
After cell detachment, 0.5 ml of cell suspension was transferred into Beckman-Coulter 
Accuvette vials containing 9.5 ml of Isoton (1:20 dilution) and counted using a Beckman-
Coulter Z2 series cell counter giving the number of cells per ml, which was then adjusted to 
give the total number of the cells in the suspension.  
 
Cell counts using a haemocytometer 
Alternatively, 20 µl of cell suspension was mixed with an equal amount of 0.4% Trypan Blue 
dye (Sigma-Aldrich, UK; cat no: T8154) in an Eppendorf. 10 µl of this mixture was pipetted 
onto both sides of the haemocytometer after having placed an appropriate glass cover slip on 
top of the cell counting chamber. Cells were counted using the middle 25 squares of the cell 
counting chamber, starting the counting from the top and left of each square. Cells were 
measured from both sides of the haemocytometer before the procedure was repeated 4 times 
in total for increased accuracy, while washing the haemocytometer with ethanol in between 
counts. 
 
The number of cells was calculated by using the following equation:  
 
Total No. of cells in suspension = No. of cells x 2 x 10
4
 x total volume of cell suspension 
 
2.1.1.5 Drug treatments and cell proliferation assays  
For the cytotoxicity experiments and confirmation of their IC50 values, a freshly-prepared 
cisplatin solution (Sigma-Aldrich, UK; cat no: P4394) was added in 96 well plates 
(Corning
®
,UK) in concentrations ranging from 0.1 to 1000 µM over a period of 72 hours and 
tested at frequent time intervals. Other treatments (data not shown) included cell exposure to 
(50 µM of L-Buthionine-sulfoximine (L-BSO) (Sigma-Aldrich, UK; cat no: B2515) which is 
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a glutathione-depleting agent, for confirmation purposes when examining glutathione 
concentrations during NMR-based experiments (used as a proof of principle). Control wells 
were treated in the same way using the corresponding vehicle agents.   
 
A number of different assays were performed in both pilot and subsequent experiments for 
optimisation and cross-confirmation purposes and included the following assay kits:  
 
(i) alamarBlue
®
 assay  
For the study and measurement of cell growth (or inhibition of cell growth) during drug 
treatments, cells were plated in 96-well plates, and, where necessary, 100 μl of cell culture 
media were added with 50 µM of L-BSO and / or varying doses of cisplatin as mentioned 
above. The alamarBlue® dye (AbD Serotec, UK; cat no: BUF012B) was added after another 
24 hours and the absorbance at 570 nm and 600 nm was measured using a Tecan Sunrise™ 
absorbance reader, after prior calibration of the appropriate incubation time and cell density. 
The percentage of reduced alamarBlue
®
, which is linearly correlated to cell number, could 
then be calculated.   
 
According to manufacturer, to calculate the percent difference in reduction between treated 
and control cells in cytotoxicity and proliferation assays the following equation was used: 
 
Percent difference between treated & control cells = (O2 x A1) - (O1 x A2) x100                        
                                                                                          (O2 x P1) - (O1 x P2) 
 
Where: O1 = molar extinction coefficient (E) of oxidized alamarBlue
®
 at 570 nm 
 
 O2= E of oxidized alamarBlue® at 600 nm 
 A1 = absorbance of test wells at 570 nm 
 A2 = absorbance of test wells at 600 nm 
 P1 = absorbance of positive growth control well (cells plus alamarBlue® but no test 
agent) at 570 nm 
 
 P2 = absorbance of positive growth control well (cells plus alamarBlue® but no test 
agent at 600 nm 
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Wavelength  Reduced (R)  Oxidized (O)  
540 nm  104395  47619  
570 nm  155677  80586  
600 nm  14652  117216  
630 nm  5494  34798  
Table 2.3 - Molar extinction coefficients for alamarBlue® at different wavelengths 
 
(ii) Sulforhodamine B-based (SRB) assay 
The SRB assay (Sigma-Aldrich, UK; cat no: TOX6) originally developed by Skehan et al. 
was used for cell density determination of cisplatin cytotoxicity in a 96-well based format, in 
terms of cellular protein content measurement of viable and non-viable cells. After a 24-hour 
attachment and the appropriate drug incubation period, cell monolayers were fixed with 10% 
(wt/vol) trichloroacetic acid (TCA) and incubated for 60 minutes at 4
o
C, after which the 
cellular debris was removed by repeated washes with water. The cells were air-dried and 
stained in 0.4% Sulforhodamine B solution in a volume 50% of the original cell culture 
media volume. After a staining period of 30 minutes the excess dye was removed by a quick 
wash using 1% (vol/vol) acetic acid. The cells were air-dried and the protein-bound dye was 
dissolved in 10 mM Tris base solution for optical density determination at a wavelength of 
490 nm using a Tecan Sunrise™ microplate reader after room temperature incubation on a 
Stuart® Scientific Gyro rocker at 30 rpm for enhanced mixing.  
 
The cell assay data were analysed using the plate-supplied Maggelan software.  
 
2.2 NMR Spectroscopy 
 
2.2.1 Basic theory  
 
2.2.1.1 The phenomenon of nuclear magnetic resonance  
Nuclear magnetic resonance, or NMR, is a phenomenon occurring when the nuclei of 
particular atoms are positioned in a static magnetic field and then exposed to an oscillating 
magnetic field. Not all nuclei experience this phenomenon as this depends on whether these 
nuclei possess a property called spin (Figure 2.1) (Claridge 2004). 
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Figure 2.1 - A charged spinning particle (i.e. a proton) generates a magnetic moment. 
The direction of the generated magnetic moment depends on the particle‟s rotational 
direction (taken from Magnetised Nuclear Spin Systems. Last accessed 26 July 2010).  
 
2.2.1.2 NMR spectroscopy 
NMR spectroscopy is a technique employed to obtain physical, chemical, electronic and 
structural information about molecules. There are various types of NMR spectroscopy, such 
as 
31
P NMR, 
19
F NMR, 
15
N NMR and 
3
He NMR, but the most commonly used is 
1
H NMR – 
which also constituted the main technique used in this study (Claridge 2004). 
 
1
H NMR spectroscopy 
High resolution 
1
H NMR spectroscopy is the application of nuclear magnetic resonance in 
spectroscopy with respect to hydrogen-1 protons found in the molecules of a sample 
(Silverstein 2005). It has been shown to be one of the best techniques for the analysis of 
biofluids and for determining the structure of molecules, due to the fact that hydrogen is very 
abundant in biological systems and its nucleus is very sensitive to NMR signals (Claridge 
2004). 
 
NMR spectrometers 
A typical 
1
H NMR spectrometer (NMR magnet) is seen in Figure 2.2 while figure 2.3 
illustrates its main internal parts, as well as the instruments used for spectral detection and 
acquisition.  
 
Magnetic moment 
Spinning charged 
particle 
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Figure 2.2 - A typical NMR spectrometer operating at 600 MHz (taken from Bruker 
BioSpin, UltraShield Plus Magnets Delivering Ultimate Shielding Performance. Last 
accessed 15 August 2010).  
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Figure 2.3 - A typical illustration of an NMR spectrometer‟s internal parts and 
auxiliary instruments used in detection and acquisition of NMR spectra (text and figure 
taken from Lakehead University Instrumentation Laboratory, NMR Theory of 
Operations. Last accessed 04 September 2010).  
 
Nuclear spin and resonance 
The property of spin is fundamental in NMR. All atoms have nuclei with a characteristic 
nuclear spin quantum number, I, with values multiples of ½ that can be positive or negative. 
The nuclei that have an „I‟ value of zero (I = 0) do not possess a nuclear spin and, thus, 
cannot exhibit a nuclear magnetic resonance (NMR-silent) (Claridge 2004).  Some elements 
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like carbon-12 do not have a nuclear spin as their atomic mass and number are even; however 
the majority of isotops possess a nuclear spin that can in principle be observed by NMR 
(Claridge 2004). The spinning nucleus carries charge and while spinning it possesses a 
magnetic moment, μ.  The magnetic moment can be calculated by the formula:  
 
μ = γP, 
 
where γ is the magnetogyric ratio (which is constant for any nuclide and is an indication of 
how magnetically strong a nucleus is) and P is the angular momentum (caused by a non-zero 
I number). Both of the magnetic moment and angular momentum have magnitude and 
direction and can be represented as vectors (Claridge 2004).  
 
  
Figure 2.4 – precessing magnetic moments of nuclei on the x-y-z plane, inside an 
external static magnetic field (B0). The field is conventially applied along the z- axis of 
the Cartesian co-ordinate frame. The nuclei motions are represented as vectors moving 
across the surface of a cone (figure and text taken from John C. Edwards, Principles of 
NMR. Last accessed 23 July 2010).   
 
Inside an external static magnetic field (B0) all the microscopic magnetic moments align 
themselves in the direction of the field as their energy states become quantised. The nuclei 
are able to take 2I+1 possible orientation inside the magnetic field. The half-spin nuclei can 
take two possible orientations with respect to the static magnetic field, α and β (Figure 2.5). 
The α state has a component of the magnetic momenr parallel to the field and is of lower 
energy, while in the β state is anti-parallel to it. This difference in energy is termed as ΔE, 
α state 
β state 
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and is dependent on the strength of the interaction between the magnetic field and the nucleus 
(Claridge 2004). It is calculated by the formula: 
 
ΔE = hv = hγB0/2π, 
 
where v is the frequency of the absorbed radiation and h is Plank‟s constant (Claridge 2004).  
 
 
Figure 2.5 - A rotating nucleus can take up either of two orientations in an applied 
electromagnetic field. The energy separation between the α and β spin states is 
determined by measuring the frequency of electromagnetic radiation needed to induce 
an α→β transition (figure and text taken from Bios Scientific Publishers, Assembly of 
the Transcription Initiation Complex. Last accessed 18 August 2010). 
 
 
When the nucleus is placed inside a static magnetic field it is forced to precess. This 
precession depends on the strength of the field and the magnetogyric ratio of the spin and is 
referred to as the Larmor precession. Related to the Larmor precession is the Larmor 
frequency of the nucleus, which is the resonant frequency of its spin. Irradiation at the 
Larmor frequency can cause a ΔE transition in the spin state of the nuclei. When irradiating 
the nuclei at the Larmor frequency they interchange between the lower energy and the higher 
energy state. When this is achieved, they nuclei are said to be „in resonance‟ with the applied 
radiation (Claridge 2004). 
 
Modern NMR spectrometers employ very strong field strengths with operating frequencies as 
high as 800 MHz or more, which, for protons, correspond to their resonant frequencies. The 
intensity of the NMR signal is measured by integrating the area under the generated peak‟s 
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resonance line and is proportional to the number of nuclei that give rise to that signal 
(Claridge 2004). 
 
The vector model of NMR 
In order for the nuclear magnetic resonance to occur by inducing transitions between energy 
states, the application of a time-dependent oscillating magnetic field at the Larmor frequency 
of the spin is necessary.  This field is designated B1 to distinguish it from the static B0 field. 
When the field is static (B0), nuclei will precess at a random distribution of orientations, with 
only a small excess being in the lower energy state (parallel to the applied field). This results 
in the creation of various magnetic moment vectors (Claridge 2004). When an oscillating 
magnetic field (B1) is applied through a short intense pulse of radiofrequency (passed around 
a coil placed around the sample in the magnet), the nuclei in the sample become excited. This 
way, transitions between spin states are brought about and phase coherence is imposed on the 
randomly distributed molecular magnetic moment vectors. For example, following a typical 
90° pulse, the individual spin vectors cluster together along the y-axis of the x-y plane, and 
are said to be in phase coherence (Claridge 2004). To simplify the representation of all the 
magnetic vectors, the bulk magnetisation vector, Mz or M0, term is used, which is the sum of 
all the individual vectors together (Figure 2.6).   
 
 
Figure 2.6 - Application of a radiofrequency pulse in an oscillating magnetic field B1 on 
the bulk magnetisation vector M0, drives it from its equilibrium position toward the x-y 
plane from the z- axis, causing its rotation around the x- and y- axes, before returning 
back to equilibrium (taken from John C. Edwards, Principles of NMR. Last accessed 23 
July 2010).  
 
B1 B1 
90
o
 Pulse 
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Chemical shifts and couplings 
Nuclei are surrounded by circulating electrons whose movements are induced by the 
externally-applied magnetic field. These moving electrons create their own magnetic field, 
which in turn results in the “shielding” of the various nuclei from the external magnetic B0 
field. As a result, nuclei found in different chemical environments give rise to signals of 
different resonance frequencies. The highly-shielded nuclei will emit at lower frequencies, 
whereas the nuclei with less electron-generated shielding will give rise to higher frequencies 
(Claridge 2004). The term “chemical shift” is given to the shift in resonance frequency 
caused by the chemical environment in which the nucleus is found and is denoted as δ. Its 
position is not absolute but measured relatively to standard compounds, one of which is 
trimethylsilylpropionate (TSP). It is measured in parts per million (ppm) by the following 
formula:   
 
δ = (ν - ν ref)/ νref x 10
6
,  
 
where δ is the chemical shift, ν is the frequency of the signal of interest, and νref is the 
frequency of the standard (Claridge 2004).    
 
Chemical shift is a very important parameter in NMR as it allows observation of nuclei either 
on their own or in groups and it very helpful in drawing conclusions about their chemical 
environment and even molecule structure. In a molecule, it‟s not uncommon for magnetic 
interactions to occur between nuclei of neighbouring atoms, thus, giving rise to NMR signals 
which provide useful information on their structural anatomy.  It is also important to note that 
individual signals may be split into several more lines in the spectra, as a result of the 
interaction with neighbouring nuclei. This phenomenon is known as spin-spin or scalar 
coupling (Claridge 2004).  
 
Free induction decay (FID) & Fourier transformation (FT) 
A free induction decay (FID) is generated as irradiated excited nuclei relax (Figure 2.7). The 
signal amplitude of the FID decreases over time as the net magnetization returns back to 
equilibrium. The generated decaying signal is the free induction decay and contains the sum 
of all the frequencies from the targeted nuclei. Due to its high frequency, the signal cannot be 
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recorded directly but is mixed with a lower frequency signal to produce a digitised 
interferogram of low frequency, the FID (Claridge 2004).  
 
 
 
Figure 2.7 – Example of an FID signal and its transformation from a time domain to a 
frequency domain signal through Fourier Transformation (taken from John C. 
Edwards, Principles of NMR. Last accessed 23 July 2010).   
 
 
Because in NMR the intensity of the FID signal is presented as a function of frequency, 
Fourier Transformation (FT) of the FID is applied in order to yield a frequency domain 
spectrum (Claridge 2004).  
 
Pulse sequences 
The pulse sequences used in this study included the following: 
 
Water presaturation 
Before the application of a 90° pulse, the sample is irradiated with a long pulse of low energy 
using the exact frequency at which the protons of water precess. This results in the saturation 
of the typically highly increased water signal leading to its removal from the resulting NMR 
spectrum. This is very helpful in the observation of the smaller signals in the spectrum 
coming from the less abundant molecules in the sample or the ones with relatively low 
concentrations (Claridge 2004).  
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The main pulse sequences used in this study were the “NOESY” and “CPMG” pulses both of 
them including presaturation pulses applied during the relaxation delay, D, for the removal of 
water proton signals from the spectra. 
 
NOESY presaturation pulse: D-90
°
-t1-90°-tm-90°-acquire 
NOESY stands for Nuclear Overhauser Effect Spectroscopy and the Nuclear Overhauser 
Effect (NOE) between nuclear spins is used for establishing the corresponding correlations. It 
can be used either in 1-dimensional (1D) or 2-dimensional (2D) experiments. In the 1D 
experiments of this study, the NOESY pulse sequence (Figure 2.8) involved the radiation of 
the sample with three separate radiofrequency pulses, which resulted in the magnetisation 
vector to move into the x-y plane, then into the z axis, and eventually back to the x-y plane. 
This generally leads to suppression of all the signals not currently in the 90° orientation right 
before the acquisition of the FID. As previously mentioned, the water presaturation pulse was 
applied in between the 90° pulses (Claridge 2004).  
 
The pattern followed was D-90°-t1-90°-tm-90°-acquire.  
 
 
Figure 2.8 - Schematic of a typical Nuclear Overhauser Effect (NOE) pulse sequence 
(supplied from author‟s own schematic diagrams). 
 
Usually the applied magnetic field (B1) exhibits some heterogeneity, with the edges of the 
sample volume not experiencing the field fully and, thus, not experiencing the full 90° pulses. 
There is a strong correlation between those regions and the residual solvent and therefore, the 
suppression of these regions leads to a better suppression of solvent signals coming from the 
water resonance (Claridge 2004).    
 
 
 
τ1 τm 
90° 90° 90° 
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Carr-Purcell-Meiboom-Gill (CPMG) pulse: D-90
°
-{-180°-}n-acquire 
The CPMG pulse comprises of a single initial 90° pulse followed by a repeated 180° pulse. 
This results in the rotation of the magnetisation vector into the x-y plane causing phase 
coherence in all the magnetisation vectors within the sample. This is followed by a 180° 
pulse, which re-phases the magnetisation vectors into coherence but permits a T2 relaxation to 
occur. The effect that is achieved by using this particular pulse sequence is an elimination of 
the larger molecular weight compounds that have shorter T2 relaxation times due to the delay 
in the FID acquisition. This pulse sequence also helps in eliminating resonances that have 
been broadened by chemical exchanges (Claridge 2004). 
 
 
Figure 2.9 – Schematic of a typical Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence 
(taken from Basic Concepts T2 - Relaxation time. Last accessed 25 July 2010). 
 
2.3 Sample preparation 
 
2.3.1 NMR sample generation  
Prior to NMR analysis, the sample replicates were harvested from their culture flasks and the 
cells were detached from the surface either with the standard trypsinisation method (Mlh1 
study) or the optimised direct methanol extraction method (isogenic study) as previously 
mentioned on page 64.  
 
i)  Preparation of extracellular media for 
1
H NMR  
The culture media samples were defrosted at room temperature and 550 μl of each was mixed 
with 50μl of 0.2% (w/v) Trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP) in deuterium 
oxide (D2O) (GOSS Scientific Instruments Ltd, UK)  in D2O and added into 5 mm NMR 
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tubes before analysis by
 1
H NMR. Prior to NMR analysis, tubes were inverted twice to ensure 
samples were adequately mixed.  
 
(ii) Preparation of intracellular cell extracts for 
1
H NMR 
The cells were extracted using the methanol-chloroform-water extraction method as 
previously recommended elsewhere  (Le Belle, Harris et al. 2002). The cells were placed on 
ice and a mixture of 200 μl of CHCl3 and 100μl of methanol was added. The cells were 
vortexed and an additional 300μl H2O of HPLC-grade was then added. The cells were 
vortexed again to create a uniform suspension and then centrifuged for 10 minutes at 16000g. 
After carefully removing the Eppendorfs from the centrifuge, the resulting upper aqueous 
layers were removed and placed into new Eppendorfs, while the lower organic layers were 
transferred into glass vials. The whole procedure of extracting the cells was repeated on the 
remaining sample in order to enhance metabolic recovery. The layers were placed in the fume 
hood overnight for evaporation of methanol. The aqueous cell extracts were subsequently 
freeze-dried and reconstituted in 600 μl of phosphate buffer (0.2 M Na2HPO4, 0.043 M 
NaH2PO4, 100 μM TSP, 3 mM NaN3, 100% D2O). They were then vortexed and 550μl of the 
aqueous extract solution was transferred into a 5 mm NMR tube for NMR analysis. 
  
2.4 NMR parameters  
The intracellular aqueous extracts and media samples from repeat experiments were analyzed 
using 
1
H NMR spectroscopy and involved the following general parameters using minor 
modifications where necessary: NMR spectral data were acquired on a Bruker DRX600 
spectrometer which was operating at 600.13 MHz 
1
H NMR frequency and 300 K. Prior to the 
spectral acquisition gradient shimming was applied. 
1
H NMR spectra of the samples were 
acquired using a 1D NOESY pulse sequence (RD-90

-t1-90

-tm-90

-acquire) and a Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence (RD-90

-{-180-}n-acquire). The CPMG 
sequence generated spectra edited by T2 relaxation times, i.e. with reduced signals from high 
molecular weight species or systems in intermediate chemical exchange. The 1D NOESY 
experiment generated a corresponding unedited spectrum with improved solvent peak 
suppression. For all spectra 128 free induction decays (FIDs) were collected into 32K 
complex data points, using a spectral width of 12,019 Hz (20 ppm), with a 2 s relaxation 
delay between pulses. A water presaturation pulse was applied throughout the relaxation 
delay.  For the 1D NOESY experiment an additional presaturation pulse was applied during 
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the mixing time (tm, 100 ms) and t1 was held constant at 3 s. For the CPMG experiment n = 
300 and  = 400 s, for a total T2 relaxation time of 240 ms. The CPMG spectral editing 
method was used for helping in decreasing the content generated by high molecular weight 
entities in the spectra.  
 
2.5 NMR Spectral data processing 
The spectral data were zero-filled by a factor of 2 and the FIDs were multiplied by an 
exponential weighting function that was equivalent to a line broadening of 1 Hz prior to 
Fourier transformation (FT) using XWin-NMR (Bruker Biospin Ltd.) software. Further data 
processing & analysis, unless otherwise stated, was achieved using NMRProc in-house 
software (used in baseline corrections and referencing spectra) & MetaSpectra (used in the 
import of NMR data into Matlab), written by Dr T.M.D. Ebbels, Dr. H C. Keun, Mr 
J.T.Pearce, Dr Rachel Cavill & Dr. Olivier Cloarec (Cloarec, Dumas et al. 2005); (Pearce, 
Athersuch et al. 2008). The acquired NMR spectra for both intracellular extracts and media 
samples were phased and baseline-corrected before being referenced to an internal TSP 
standard at δ 0.0. All spectra were scaled to TSP and the intracellular aqueous extract 
additionally normalized by the median fold change (MFC) to the median spectrum; i.e. 
during MFC normalization each of the spectra was divided by a reference spectrum which 
was the median of all the samples in the NMR dataset providing a fold change for each 
spectral point (Dieterle, Ross et al. 2006). Only analysis of the 1D CPMG spectra was 
conducted, as the signals from residual protein in the sample were suppressed. Metabolites 
that were clearly resolved and appeared to alter concentration by either visual inspection of 
the spectra or after multivariate analysis were selected for quantitative analysis. Metabolic 
peaks were, thus, subsequently integrated for semi-quantitative evaluation comparison; this 
was achieved by computing the area under each desired resonance peak of each spectrum 
using Matlab-based code in Matlab version 7.6.0.324 R2008a (MathWorks, UK) written and 
compiled by Dr Rachel Cavill and Dr Hector Keun. The data were then imported into 
SIMCA-P+ version 11.5 (Umetrics, UK) for comparative analysis.  
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2.6 Structural assignments 
The various
1
H NMR metabolic assignments were achieved as follows:  
- by consulting pre-existing knowledge of metabolic spectra in the databases of online 
NMR libraries, such as BioMagResBank (BMRB) (Ulrich, Akutsu et al. 2008) and the 
Human Metabolome Project (HMDB) (Wishart, Knox et al. 2009), 
- by comparing the generated chemical shifts with known published compound values of 
similar pH (Fan, Higashi et al. 1986); (Nicholson, Foxall et al. 1995), 
- by using the Chenomx® NMR Suite software including Chenomx® Processor and 
Chenomx
®
 Profiler (Chenomx Inc, Canada) with its supplemented 600 MHz internal 
metabolite library at neutral or near-neutral pH, 
- by applying STOCSY: On the occasions where metabolic assignments could not be 
positively confirmed, the substrate identities were confirmed using computational spectral 
correlation analysis such as STOCSY (Cloarec, Dumas et al. 2005), 
- by spiking samples with known standards for further confirmation of specific metabolic 
assignments using an in-house spike calculator. 1D 
1
H NMR spectra were recorded using 
the same parameters as previously mentioned. If the newly-recorded resonance of the 
standard compound matched the frequency of the unknown metabolite, a positive 
identification was made. Some of the compounds that were spiked into NMR samples 
included creatine, phosphocreatine, pyruvate and acetate.      
 
2.7 Data analysis 
 
2.7.1 Chemometrics and Pattern Recognition for Statistical Analysis 
Once the NMR spectra are acquired, there are various chemometric methods and tools in 
existence for facilitating and simplifying extraction of information from the complex datasets, 
which usually deal with large amounts of data, making it difficult to identify meaningful 
differences. Such tools include multivariate statistical analysis, or pattern recognition (PR), 
which are able to identify and interpret concealed patterns of observations and variables in 
the spectral data (Lindon, Holmes et al. 2001). 
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2.7.2 Pattern recognition theory 
Pattern recognition can be divided into two categories, supervised and unsupervised. An 
example of unsupervised PR is Principal Component Analysis (PCA) (Figure 2.10). Principal 
component 1 (PC1) is a combination of variables that explains the greatest variation. The 
second principal component (PC2) defines the next largest amount of variation. There is no 
limit to the number of possible principal components. Supervised methods include soft 
independent modelling of class analogy (SIMCA) and Partial Least Squares (PLS) methods. 
Supervised methods use the class information given for a set of sample data to optimise the 
separation between two or more sample classes. Supervised methods need a second 
independent data set to test class predictions made using the training set (Lindon, Holmes et 
al. 2001); (Spencer, Bonnin et al. 2009). 
 
 
 
 
 
 
 
 
Figure 2.10 - Representation of a typical PCA method - a multivariate procedure which 
rotates the data such that maximum variabilities can be projected onto the axes x, y, 
and z and, thus, be reduced (figure courtesy of Dr. H. Keun, Imperial College, London). 
 
Principal component analysis   
PCA is multivariate method of analysis used widely when dealing with large datasets. Its use 
enables the large numbers of variables in the multivariate and multidimensional datasets to be 
reduced into a small amount of dimensional axes while at the same time managing to retain 
the variations in the data. This reduction in dimensionality is achieved through the use of p 
variables X1, X2,…, Xn by finding their combinations to generate uncorrelated principal 
components (PCs) PC1, PC2,…, Pn, also termed eigenvectors. PCs separate the samples 
according to the greatest variation in the dataset and are ordered in a way so that PC1 exhibits 
the highest amount of the variation, PC2 exhibits the second greatest amount of variation, 
PC3 exhibits the third greatest amount of the variation, and so on:  
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(PC1) ≥ (PC2) ≥ (PC3) ≥… ≥ (PCn) 
 
Visually, this results in the generation of a scores plot and a loadings plot allowing easy 
visualization of trends in the data. The scores plot represents the position of each sample in 
the new co-ordinate space. It helps in correlating spectral regions to specific metabolites 
responsible for the observed trends, as well as identifying metabolic outliers.  Each point on a 
scores plot represents one sample from its corresponding NMR spectra. Points close to each 
other have similar metabolic profiles while the further away they are located from each other 
they more dissimilar their profiles are. The loadings plots complement the scores plots and 
visualise the contribution of the spectral regions to the calculation of the scores. Each 
loadings plot point represents a specific region of the NMR spectra and thus a potential 
metabolite. Points found at the circumference of the plot are the most significant in the 
calculating process of the scores (Maltese and Verpoorte 2009).  
 
Data reduction („binning‟ or “bucketing”) for PCA 
During pattern recognition analysis the NMR spectra were divided and the signal integrals 
calculated in  0.04 intervals across the chemical shift range ( 0 to 9.96). The water regions 
( 4.5 to  5) were excluded to remove variation in the pre-saturation coming from the water 
resonance. The TSP regions were also removed from the data prior to further analysis. The 
integrated NMR spectral regions were divided by the total spectral intensities for 
normalization purposes. The resulting reduced and normalized NMR spectral data were then 
imported into an Excel sheet and were mean-centered prior to PCA analysis using the 
SIMCA-P software. SIMCA-P was used for the generation of all the models of PCA loadings 
and scores plots in this study.  During this process, Matlab was also used for visualization of 
the spectra. 
 
Statistical Total Correlation Spectroscopy (STOCSY) 
STOCSY stands for statistical total correlation spectroscopy and helps in identifying peak 
intensities that are highly correlated leading in turn to identification of peaks belonging to the 
same molecule and, thus, aiding in spectral assignment (Cloarec, Dumas et al. 2005). The 
usefulness of this method is not limited in peaks from the same entity but can also lead to 
identification of molecules that are interdependent on each other but belong to the same 
metabolic pathway. Graphical representation of the correlation matrix in the sample dataset 
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can be done in Matlab providing an easy visualisation of the correlated resonances potentially 
belonging to the same molecule. Maintaining the spectrometer conditions constant, the 
resonance intensities from a specific molecule always have the same ratio and they should be 
fully correlated between samples (correlation coefficient r=1). In practice, though r is usually 
less than 1 due to the various peak overlaps and the spectral noise, which are almost always 
present in the 
1
H NMR of bio-samples. Despite that however, very high correlations are 
usually achieved between the corresponding resonances of the variables in the same 
molecule. 
 
2.8 Bioinformatics and statistical tests 
Statistical tests that were used in this study included the following:  
 
Student‟s t-test  
Student‟s t-test can be used to determine if the average values for each set of groups is 
significantly different by comparing the actual difference between two means in relation to 
the variation in the data and producing a „p‟ (probability) value. There are two versions of the 
t-test. The one-sample Student's t-test tests a hypothesis by comparing a sample mean with a 
hypothesized true mean, and the two-sample Student's t-test which uses a similar technique to 
compare a two sample mean using standard error of the difference. 
 
Bioinformatics (ORA and NEST-based approach)  
This thesis also included some bioinformatics analysis involving over-representation analysis 
(ORA) and neighbourhood-based entities (NESTs). For this part of the study (chapter 4) the 
detailed methodology as well as the statistical tests that were used during this analysis a 
presented in the relevant section of chapter 4 (section 4.2).  
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Chapter 3 
 
Metabolic examination of platinum resistance in cancer cells using in vitro 
cell models of platinum resistance. 
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3.1 Introduction & Aims 
The Mlh1 gene (MutL gene of E. coli or MutL homolog) is a member of the Mismatch Repair 
(MMR) gene family (Cooper, Kohonen-Corish et al. 2008) and is critical in maintaining 
genomic stability. hMlh1 is the human homolog of the gene which usually forms active 
complexes with another protein, PMS2 (Schafmayer, Buch et al. 2007).  
 
Cells that lack Mlh1 are thought to have a reduced capacity of transmitting nuclear DNA 
damage signals to the apoptotic machinery. Mlh1 loss has also been associated with Lynch 
syndrome (hereditary nonpolyposis colon cancer) (Balmana, Stockwell et al. 2006) and Muir-
Torre syndrome (Ponti, Losi et al. 2006). Lack of Mlh1 expression also leads to microsatellite 
instability, which is found to be crucial in the mechanism of cancer development, as 
experiments in Mlh1-deficient mice demonstrate (Prolla, Baker et al. 1998). Attempts on re-
introducing the gene in Mlh1-null mice however have been found to increase sensitivity 
(Buermeyer, Wilson-Van Patten et al. 1999). Reduced Mlh1 expression has been found to be 
implicated in contributing to increased resistance to DNA-damaging compounds (Hardman, 
Afshari et al. 2001) and decreased sensitivity of various cancer cell lines to platinum-based 
drugs such as cisplatin (Balch, Huang et al. 2004). Since MMR-deficient cells are much less 
sensitive to cisplatin (Papouli, Cejka et al. 2004) than those with fully functional MMR gene 
mechanisms, this has been argued to play a role in the development of platinum resistance 
after chemotherapy (Plumb, Strathdee et al. 2000). 
 
The precise way that loss of Mlh1 expression directly affects response to DNA damage 
caused by platinum cytotoxic drugs remains unclear. However, further insight on the role of 
Mlh1 loss and its relationship with cancer has been shown by a recent study by Tessem et al, 
where a metabolic signature associated with Mlh1in the gut tissue was produced. According 
to this study, a type of genetic instability involving MSI-H (high-frequency microsatellite 
instabilities) in a large percentage of patients with hereditary nonpolyposis colorectal cancer 
frequently occurs, and stems from epigenetic silencing of Mlh1 through methylation of its 
promoter sequences. This study managed to produce an MLh1 metabolic signature which 
included metabolites such as glucose, lactate, phosphocholine and myo-inositol (Tessem, 
Selnæs et al. 2010). On a separate note, other studies examining Mlh1 have additionally 
reported alterations in the mitochondrial membrane potential and mitochondrial distribution 
within cancerous cells (Isonishi, Saitou et al. 2001). 
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Most importantly, it has also been suggested that platinum resistance in cancer chemotherapy 
also involves mitochondria. For example, it was found that mitochondrial DNA-depleted 
U937 cells exhibited increased cisplatin sensitivity, demonstrating that these cells continued 
to respond to death by cisplatin through apoptosis (Liang and Ullyatt 1998). Other 
experiments with mitochondrial DNA-depleted SK-Hep1 hepatoma cells, have shown that 
carrying mitochondrial DNA mutations confers resistant to various forms of cell death, such 
as oxidative stress and chemotherapeutic agents like cisplatin (Park, Chang et al. 2004). 
These findings suggest that an important cisplatin-resistance mechanism lies in the protection 
of mitochondria from DNA damaging agents. 
 
Here, we further investigate this association by the study of Mlh1-specific metabolic 
signatures in vitro models: a transient Mlh1 expression cell model in the kidney epithelial cell 
line HEK-293T, in which the effect of mitochondrial depletion was also examined, and a 
Platinum Resistance Model (PRM) with ovarian cell lines (A2780 & CP70) of well-
established Mlh1 status.  
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3.2 Methods 
Spectra were acquired and analysed for intracellular aqueous extracts from four groups of 
kidney cell lines and four groups of ovarian cell lines. These cell lines represent different 
models of Mlh1-controlled states with differences in their origin, genetic background and 
selective process. All cell samples were kindly provided by Dr Vincent O‟Brien (formerly of 
the Beatson Inst. Glascow) & Prof Bob Brown (Imperial College London / Royal Marsden 
Hospital) and his group.  
 
The HEK-293T MutLα cells are derived from human embryonic kidney HEK 293T cells 
lacking MLh1, after transfection with an hMLH1 cDNA vector. More specifically, HEK-293T 
cells are a derivative of HEK-293 kidney cells that stably express the large T-antigen of 
SV40, and are more easily transfectable. Furthermore, the HEK-293T MutLα cell lines are 
under the control of the inducible Tet-Off expression
 
system (Cejka, Stojic et al. 2003). The 
MutLα- ρ0 cell lines were selected for depletion of mitochondrial DNA after exposing them 
in 50 ng/ml ethidium bromide and 50 ng/ml uridine. 
 
The two ovarian cancer cell lines, A2780 and CP70, are well-characterized models for 
cisplatin sensitive and cisplatin-resistant lines, respectively, and have been originally 
described by Behrens and his team as useful tools in studying platinum resistance 
mechanisms (Behrens, Hamilton et al. 1987). CP70 is a sub-line of A2780 derived by 
prolonged in vitro exposure to cisplatin that lacks Mlh1 expression. Clonal sub-populations of 
CP70 expressing Mlh1 (CP70 E1) or not (CP70 A2) after chromosome 3 microcell transfer 
were also used in this study to allow more specific examination of the Mlh1 to phenotypic 
variation in this model. 
 
Table 3.1 summarises the cell lines and their relevant characteristics. 
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Cell Lines Mlh1 Expression Details 
HEK-293T Model (Kidney) 
HEK-293T MutLα+  + Mlh1 restored by plasmid 
transfection – Mlh1 is expressed. 
HEK-293T MutLα-  - Mlh1 restored by plasmid 
transfection – Mlh1 expression 
switched OFF by Doxocycline 
exposure 
HEK-293T MutLα+ ρ0 + Mlh1 restored by plasmid 
transfection – Mlh1 is expressed - 
Mitochondrial DNA depletion by 
ethidium bromide and uridine  
exposure   
HEK-293T MutLα- ρ0  - Mlh1 restored by plasmid 
transfection – Mlh1 expression 
switched off by Doxocycline 
exposure - Mitochondrial DNA 
depletion by ethidium bromide and 
uridine exposure  
Platinum Resistance Model (Ovarian) 
A2780 + Cisplatin-sensitive 
CP70 - Cisplatin-resistant 
CP70 E1  + Mlh1 restored by chromosome 3 
microcell transfer   
CP70 A2  - Only contains chromosome 3 regions 
without Mlh1 expression 
Table 3.1 – Mlh1 status and characteristics of the cell lines used in this study. 
 
 
Harvested cells were extracted and 
1
H NMR spectra were obtained as described in chapter 2. 
The data were also processed and normalized as previously described and then visually 
inspected to characterize metabolic effects of Mlh1 status. Their mean intracellular metabolic 
profiles were compared within the same model as well as across both models.  
 
Multivariate analysis in the form of Principal Component Analysis (PCA) was performed as 
described in chapter 2, to visualize patterns and differences between the cell groups as well as 
the variables (metabolites) that contributed to these differences.  
 
Intensities of positively assigned metabolites which have been previously associated with 
cancer in the literature (i.e. alanine, phosphocholine) or contribution to development of 
elevated platinum resistance (i.e. glutathione) were chosen for further quantitative analysis 
using in-house software as described in chapter 2.  
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For the relative quantification of each of the selected metabolites the area under the spectral 
peak was calculated using the ppm regions presented in Table 3.2. Their relative metabolite 
intensities were then compared and tested for significance. 
 
Aqueous Cell Extracts 
Metabolites 
Start  (ppm) End (ppm) 
Alanine 1.47 1.5 
Choline 3.205 3.2134 
Phosphocholine 3.2134 3.2335 
Glycerophosphocholine 3.2335 3.2435 
Glutathione 2.485 2.61 
Lactate (1) 1.32 1.35 
Lactate (2) 4.095 4.142 
Myo-inositol 4.065 4.085 
Table 3.2 – Spectral regions integrated for a selection of metabolites that exhibited the 
biggest changes according to PCA analysis. 
 
 
 
The data normalization factor (such as cellular protein content) was shown to have some 
impact on the statistical and quantitative results indicating the need to carefully consider 
how to best normalize the data within the study [see].  
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3.3 Results 
In this study, the two different cell models were examined both individually (sections 3.3.1 & 
3.3.2 for the HEK-293T and PRM, respectively) and together as a pair (section 3.3.3). 
 
3.3.1 Metabolic effects of Mlh1 expression in HEK-293T cells 
Figure 3.1  shows full resolution  mean 
1
H NMR spectra of intracellular aqueous extracts for 
the cell lines constituting the HEK-293T model, referenced to TSP and normalized by 
Median Fold Change:  MutLα+ (green), MutLα- (cyan), MutLα+ ρ0 (blue), MutLα- ρ0 (red). 
Metabolites were visually examined across the aliphatic spectral region (δ0 - δ4.1) and the 
aromatic spectral region (δ6 - δ9.5) region. The metabolic changes included differences in 
intracellular alanine, choline, phosphocholine, glycerophosphocholine, glutathione myo-
inositol, and lactate intensities as well as branched-chain amino acids (valine, leucine, 
isoleucine). However, consistent changes across the cell lines on the basis of Mlh1 expression 
were observed mostly on the levels of intracellular choline, phosphocholine and glutathione.  
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Figure 3.1 - Full resolution 
1
H NMR mean spectra of the HEK-293T model, normalized 
to TSP & Median Fold Change. MutLα+ (green),  MutLα- (cyan), Mutlα+ ρ0 (blue), 
MutLα- ρ0 (red) 
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In order to systematically and more objectively define a metabolic signature associated with 
Mlh1 status, the bucketed CPMG spectral data were imported into SIMCA, and pattern 
recognition was used to identify discriminatory metabolites between the groups as described 
in chapter 2.  We then investigated the global metabolic differences in an unsupervised 
approach by performing principal component analysis (PCA). This approach was chosen 
because PCA methods can help in reducing the dimensionality of the data, so the original 
variables were reduced to a smaller number of variables termed principal components (PCs). 
Before multivariate statistical analysis was performed all spectral data were bucketed 
followed by the use of “Pareto scaling”, which is defined as the mean-centered data divided 
by the square root of the standard deviation. This type of scaling is able to provide a 
reasonable balance of contributions from high and low signals 
For the HEK-293T cell model data, PCA extracted three principal components (PC1, PC2, 
and PC3) which corresponded to three dimensions of greatest variance in the data. This 
approach identified the NMR spectra-derived metabolic differences across all three 
components. In particular, the first principal component (PC1) did not appear to separate the 
cell lines into distinct groups (Figure 3.2); PC2 however specifically identified differences 
between intracellular aqueous extracts of groups of cells with functional mitochondria and 
cells which had their mitochondrial DNA depleted (Figures 3.2 & 3.3). In addition, PC3 was 
able to differentiate between the two groups of cells that possess functional mitochondria into 
two separate clusters on the basis of Mlh1 expression status (Figure 3.3). A separation on the 
basis of Mlh1 expression was not observed for mtDNA depleted cells. Since the HEK-293T 
model acted as a model of transient Mlh1 gene expression, the observed cell group 
clusterings may indicate that the metabolic effects of Mlh1 were mediated by mitochondria.  
 
For the HEK-293T PCA scores plots (Figures 3.2 A and 3.3 A) there are corresponding 
loadings plots (Figures 3.2B and 3.3B) representing metabolites at specific NMR spectral 
regions, where peaks that may contribute extensively to the variance between the different 
cell groups can be visualized.  
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For example, some of the metabolic resonances that were found to differentiate samples into 
groups across PC2 are seen at  1.5, 2.46, 3.22, 3.78 and 5.22 for the mitochondrial-DNA 
depleted cells (MutLα + ρ0 and MutLα - ρ0), whereas resonances exhibiting the opposite 
trend for non-mitochondrial-DNA cels across PC2 can be seen at  1.34, 1.54 3.54 and 3.62 
(Figure 3.2 B).    
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Figure 3.2 - PC1 & PC2: Scores (A) and corresponding loadings plot (B) of 
principal component analysis on 
1
H NMR CPMG one-dimensional spectra for 
aqueous intracellular extracts of HEK-293T cells normalized by the Median 
Fold Change. Each point in A represents an individual cell sample of MutLα+ 
(black), MutLα- (red), MutLα+ ρ0 (blue) and MutLα- ρ0 (green). The ellipse 
in A represents the Hotelling with 95% confidence. Numbers beside data point 
on the loadings plot in B correspond to specific bins used in the analysis.  
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Figure 3.3 - PC2 & PC3: Scores (A) and corresponding loadings plot (B) of principal 
component analysis on 
1
H NMR CPMG one-dimensional spectra for aqueous 
intracellular extracts of HEK-293T cells normalized by the Median Fold Change. 
Each point in A represents an individual cell sample of MutLα+ (black), MutLα- 
(red), MutLα+ ρ0 (blue) and MutLα- ρ0 (green). The ellipse in A represents the 
Hotelling with 95% confidence. Numbers beside data point on the loadings plot in B 
correspond to specific bins used in the analysis. 
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The third component (PC3) was the component that showed a clear Mlh1 expression status 
separation between the cell groups (Table 3.3) in this model. The metabolites, the resonances 
of which constitute approximately 20% of the spectra, are presented below in descending 
ppm value order.  
 
The PCA-derived data combined with full spectral resolution of the one-dimensional spectra 
and reported data from the literature allowed identification and assignment of specific 
metabolites for both components. The metabolite assignments along with their corresponding 
ppm and loading values are presented in table 3.3.   
 
PC3 
ppm Loading Value Metabolite  
7.7 - 0.21058 Unassigned (1) 
5.42 + 0.101489 Unassigned (2) 
4.18 - 0.12893 Phosphocholine  
3.94 + 0.16842 Creatine 
3.78 + 0.172373 Glutathione/Glutamate 
3.58 + 0.196177 Myo-inositol 
3.34 + 0.10211 Glycerophosphocholine 
3.22 - 0.291832 Choline/Phosphocholine 
3.06 - 0.144356 Unassigned (3) 
3.02 + 0.195801 Creatine 
2.34 + 0.130972 Glutamate  
2.18 + 0.120939 Glutathione/glutamine/glutamate 
2.14 + 0.153524 Glutathione/glutamine/glutamate 
2.1 + 0.136284 Glutathione/glutamine/glutamate 
2.06 + 0.149316 Glutamate  
2.02 + 0.134372 Glutamate  
1.5 + 0.146588 Alanine  
1.34 + 0.283922 Lactate (1) 
1.06 + 0.126024 Amino acids (isoleucine, leucine, valine) 
1.02 + 0.138837 Amino acids (isoleucine, leucine, valine) 
Table 3.3 – Table showing the metabolites with the biggest changes across the binned 
spectral kidney metabolome across the 3
rd
 PCA component (PC3)   
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Integration data of some of the most notable metabolites observed after NMR and PCA 
analyses in the HEK-293T cells are presented below (with all intracellular aqueous extracts 
normalized to the median spectrum).  These metabolites include glutathione, alanine and 
phosphocholine as a representation of the most meaningful changes observed in the spectral 
data.  
 
In this particular model, intracellular glutathione levels were higher in the Mlh1-negative 
lines as Figure 3.4 A illustrates. However, the difference was not significant in the 
mitochondrial DNA-depleted cells (Figure 3.4 B and C). A similar situation was observed 
with alanine (Figure 3.5 A), whose levels were also increased in the Mlh1-negative cells 
(MutLα-). However, the difference was negligible (Figure 3.5 B) between Mlh1 positive 
(MutLα+ ρ0) and Mlh1-negative cells (MutLα- ρ0) whose mitochondrial DNA was depleted. 
Phosphocholine levels were significantly decreased in the Mlh1-negative cells (MutLα-) and 
slightly decreased in the MutLα- ρ0 cells compared to their Mlh1-positive parent cell lines 
(Figure 3.6 A); similarly to alanine though, the difference in the phosphocholine levels 
between Mlh1-positive and Mlh1-negative cells was much less pronounced in the 
mitochondrial DNA-depleted cell lines (Figure 3.6 B).   
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Figure 3.4 - The effect of Mlh1 expression on intracellular glutathione  
A) Median normalized spectra 
B) Integrated metabolite intensity 
C) Intensity difference between cell lines of differing Mlh1 status  
n = 3. * p<0.05, ** p<0.01, *** p<0.001 
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Figure 3.5 - The effect of Mlh1 expression on intracellular alanine 
A) Median normalized spectra 
B) Integrated metabolite intensity 
C) Intensity difference between cell lines of differing Mlh1 status  
n = 3. * p<0.05, ** p<0.01, *** p<0.001 
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Figure 3.6 - The effect of Mlh1 expression on intracellular phosphocholine  
A) Median normalized spectra 
B) Integrated metabolite intensity 
C) Intensity difference between cell lines of differing Mlh1 status  
n = 3. * p<0.05, ** p<0.01, *** p<0.001 
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3.3.2 Metabolic effects of Mlh1 expression in ovarian cells of Platinum Resistance Model 
Representative full resolution CPMG 
1
H NMR mean spectra of the ovarian cells of the 
Platinum Resistance Model, referenced to TSP and normalized to Median Fold Change are 
presented below in Figure 3.7 and revealed changes in the intracellular levels of lactate, myo-
inositol, glutathione, alanine, phosphocholine and branched chain amino acids. Spectra of 
A2780, CP70, CP70 E1, and CP70 A2 cells are represented in black, red, green and blue, 
respectively.  
 
Inspection of the scores and loadings plots (Figures 3.8 and 3.9) from a PCA analysis model 
of these spectra identified a more specific panel of metabolites that were altered in response 
to Mlh1 expression status. Metabolites that were significantly altered on the presence or 
absence of Mlh1, across the different cell conditions, are described further below. The 
integral intensities for the selected metabolites were calculated as previously described in 
chapter 2. 
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Figure 3.7 – Full resolution 1H NMR mean spectra of the Platinum Resistance model, 
normalized to TSP & Median Fold Change. A2780 (black), CP70 (red), CP70 E1 
(magenta), CP70 A2 (blue) 
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Similarly to the HEK-293T cell model, PCA scores plots of the reduced ovarian spectra 
showed a trend toward separation of the Mlh1-negative and Mlh1-positive cell groups 
(Figures 3.8 A and 3.9 A).  
  
Of the four principal components for the Platinum Resistance model, PC1 separated the cell 
lines into two groups: one consisting of the platinum resistant lines A2780 and CP70, and one 
consisting of the clonal sub-population cells of the CP70 E1 and CP70 A2 lines. PC2 did not 
achieve to separate any of the lines into clear and distinct groups. The third (PC3) as well as 
the fourth (PC4) turned out to produce the clearest separation between ovarian cells of 
different Mlh1 status and genetic background. In particular, each of the four ovarian cell 
groups was clustered into a separate quadrant created by both PC3 and PC4. This denotes a 
separation based not only on their Mlh1 status but possibly other independent factors. Those 
may be determined by the genetic background of those cells as well as their subsequent 
genetic manipulation as in the occasion of CP70 E1 and CP70 A2 where specific targeting of 
Mlh1 occurred, using complete or partial chromosomal transfer. The Mlh1 gene expression 
effect can still be seen across PC4 where Mlh1-negative cells are located in the top two 
quadrants whereas the Mlh1-positive cells are clustered in the bottom two quadrants of the 
ellipse.  
 
Figures 3.8 B and 3.9 B of the corresponding PCA loadings plot show the specific NMR 
spectral regions of various metabolites responsible for the variation in PC1 & PC2 and PC3 
& PC4 of the Platinum Resistance model. 
 
Resonances that separated the Mlh1-positive from the Mlh1-negative cell lines across PC4 
can be seen in Figure 3.9 B. Higher resonances for the Mlh1-negative cells were seen at  
1.34, 1.5, 2.18, 2.54, 3.54, 3.78 and 7.7, while lower ones could be seen at   2.34, 2.7, 3.22, 
3.62, 3.86 and 4.18. The opposite was true for the Mlh1-positive cells. 
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Figure 3.8 – PC1 & PC2: Scores (A) and corresponding loadings plot (B) of principal 
component analysis (PCA) on 
1
H NMR CPMG one-dimensional spectra for aqueous 
intracellular extracts of ovarian cells normalized by the Median Fold Change. Each 
point in A represents an individual cell sample of A2780 (blue), CP70 (green), CP70 E1 
(black) and CP70 A2 (red). The ellipse in A represents the Hotelling with 95% 
confidence. Numbers beside data point on the loadings plot in B correspond to specific 
bins used in the analysis. 
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Figure 3.9 – PC3 & PC4: Scores (A) and corresponding loadings plot (B) of principal 
component analysis (PCA) on 
1
H NMR CPMG one-dimensional spectra for aqueous 
intracellular extracts of ovarian cells normalized by the Median Fold Change. Each 
point in A represents an individual cell sample of A2780 (blue), CP70 (green), CP70 E1 
(black) and CP70 A2 (red). The ellipse in A represents the Hotelling with 95% 
confidence. Numbers beside data point on the loadings plot in B correspond to specific 
bins used in the analysis. 
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In this model, the component that showed a clear separation between the cell groups, based 
on Mlh1 expression status, was the fourth component (PC4). After analysis of the PC3 and 
PC4 components in the loadings column plots, the ovarian metabolites that showed the 
biggest changes across the fourth component (PC4) and which constituted approximately 
20% of the total spectral features are presented in Table 3.4 in descending ppm value order. 
PC4 shows separation of the cell groups on their Mlh1 basis alone.  
 
PC4 
ppm  Loading Value Metabolite 
7.7 + 0.138482 Unassigned (1)  
4.18 - 0.182966 Phosphocholine 
3.94 + 0.154029 Creatine 
3.86 - 0.106708 Methionine 
3.78 + 0.235156 Alanine 
3.62 - 0.133823 Ethanol 
3.34 + 0.096839 Glycerophosphocholine 
3.3 + 0.152956 Myo-inositol 
3.22 - 0.258136 Choline/  Phosphocholine 
3.06 + 0.234367 Unassigned (2) 
3.02 + 0.205264 Creatine 
2.98 + 0.124512 Unassigned (3) 
2.74 - 0.110324 Unassigned (4) 
2.54 + 0.212563 Glutathione 
2.5 + 0.101446 Glutamate/ Glutamine 
2.34 - 0.172459 Glutamate  
2.22 - 0.124986 Glutamate 
2.18 + 0.197899 Glutamate 
2.06 - 0.206247 Glycoprotein‟s 
1.94 - 0.094926 Acetate / Argentine 
1.78 - 0.121272 Unassigned (5) 
1.5 + 0.237684 Alanine 
1.3 + 0.096177 Lactate / Heroine 
Table 3.4 – Table showing metabolites with the biggest changes across the binned 
spectral ovarian metabolome across the 4
th
 PCA component (PC4) 
 
It is important to note that some bins can contain more than one metabolite, meaning that the 
metabolite directly responsible for the observed variance cannot be clearly defined without 
compound-specific profiling. However, the clear separation PCA results that were obtained 
indicate a high potential value of metabolic profiles reflecting important biochemical 
differences between the different cell groups.  
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Some of the most notable metabolic differences observed after NMR and PCA analyses in the 
Platinum Resistance model are presented below in a semi-quantitative manner and, as with 
the HEK-293T cell model, also include glutathione, alanine and phosphocholine.  
 
All intracellular aqueous extracts were normalized to Median Fold Change. The 
1
H NMR 
spectra of the selected intracellular metabolites were quantified by integrating the peak areas 
between their corresponding ppm ranges (Table 3.2). After integration, their metabolic 
relative intensities were generated by subtracting the quantified intensity values of the Mlh1-
positive cells from those of the Mlh1-negative cells. 
 
As it would be expected intracellular glutathione levels were again higher in the Mlh1-
negative cell lines (Figure 3.10). The difference was less pronounced between the plasmid-
transfixed cells CP70 E1 and CP70 A2 cell lines as illustrated more clearly by Figure 3.10 B. 
Intracellular alanine levels were higher in the Mlh1-negative cells (Figure 3.11 A) and the 
relative difference was more pronounced between the A2780 and CP70 cells (Figure 3.11 B). 
Phosphocholine levels (Figure 3.12 A) were decreased in the Mlh1-negative cells. The 
relative difference in phosphocholine is similar between each cell pair in the ovarian 
Platinum Resistance Model.  
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Figure 3.10 - The effect of Mlh1 expression on intracellular glutathione 
A) Median normalsed spectra 
B) Integrated metabolite intensity 
C) Intensity difference between cell lines of differing Mlh1 status  
n = 3. * p<0.05, ** p<0.01, *** p<0.001 
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Figure 3.11 - The effect of Mlh1 expression on intracellular alanine 
A) Median normalsed spectra 
B) Integrated metabolite intensity 
C) Intensity difference between cell lines of differing Mlh1 status  
n = 3. * p<0.05, ** p<0.01, *** p<0.001 
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Figure 3.12 - The effect of Mlh1 expression on intracellular phosphocholine 
A) Median normalsed spectra 
B) Integrated metabolite intensity 
C) Intensity difference between cell lines of differing Mlh1 status (shown in negative scale) 
n = 3. * p<0.05, ** p<0.01, *** p<0.001 
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3.3.3 Model Comparison & Metabolic Signature of Mlh1 
Comparison of the different cell models allowed us to specifically identify a putative 
metabolic signature unique to the expression of the Mlh1 gene. Metabolites that were 
consistently altered across the different conditions are described further below for all models 
and an explanation is given on why this identification was possible.  
 
Table 3.5 describes the alterations in the panel of the most important metabolites identified 
from analysis of Mlh1 expression across all cell lines in both the HEK-293T and Platinum 
Resistance models in terms of metabolic percentage change. The values for the intracellular 
aqueous extracts were based upon the average metabolite changes (n=3) with the Mlh1-
negative cells referenced to their corresponding parental Mlh1-positive cell lines. 
 
Ratios 
(% change) 
CP70:A2780 CP70 A2:CP70 E1 Muttα-:MutLα+ MutLα- ρ0:MutLα+ ρ0 
alanine +57 *** +26 ** +28  ** 0 
GSH +54 * +04 +07 * +05 
lactate (2) -15 -01 +06 -10 
myo-inositol -03 +65 *** +17 * -02 
choline +72 * +11 ** +07 * +04 
PC -29 * -22 -10 -01 
GPC +47 -07 -06 -04 
creatine +05 +52 +21 -07 
unknown B +08 +25 * -10 +07 
unknown A +19 +24 +28 +12 
glycine -16 +48 +34 +5 
PC (2) -30* -20* -10* -2 
Table 3.5 - Percentage change in intracellular aqueous extracts of average metabolite 
integrals (n=3). Welch‟s two-sample unequal variance t-test with a two-tailed 
distribution. * p<0.05, ** p<0.01, *** p<0.001  
 
 
The results showed that two models of different genetic origin exhibited similar metabolic 
behaviour. More specifically, the majority of the metabolic alterations, as displayed by the 
CP70 A2:CP70 E1 and MutLα-:MutLα+ ratio comparisons, showed similar trends in terms of 
both directionality and levels of change. This was made apparent despite the obvious 
differences in cellular origin between the two models, where the HEK-293T consists of 
kidney cell lines whereas the Platinum Resistance model consists of ovarian cell lines. A 
conclusion that could be extracted after seeing these metabolic similarities, is the fact that the 
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metabolic changes observed in this instance could only be originating from the Mlh1 gene 
and its subsequent protein expression.  
 
The reason for reaching this conclusion stands behind the actual genetic constitution of the 
different cell models employed in this study. On this particular experiment, the ovarian lines 
CP70 E1 and CP70 A2 differed only in terms of Mlh1 possession; the CP70 E1 cell line is 
Mlh1-positive after Mlh1 gene restoration, while CP70 A2 is Mlh1-negative. Both of these 
cell lines have chromosome 3 fragments (after the transfection procedure as described earlier) 
and both originate from CP70 cells, which constitute their parental cell line, and are Mlh1-
negative. This model system was important in helping with the elucidation of the Mlh1 
metabolic signature as it acts in a very specific way, i.e. it allowed us to observe the effect of 
Mlh1 in isolation from other genetic factors that might affect the resulting metabolic 
phenotype. In turn, the CP70 cell line was itself compared to a known standard cell line of 
known Mlh1 status (A2780, which is Mlh1-positive). The CP70 and A2780 sub-model 
comparison was initially able to give us an indication of the metabolic levels of change within 
the Platinum Resistance model as both lines could act as controls of Platinum Resistance 
behaviour. In the same way, comparison of the MutLα- and MutLα+ sub-model within the 
HEK-293T model (a system which allows transient Mlh1 expression through doxocycline 
exposure by acting as an on/off Mlh1 switch), could more accurately pinpoint metabolic 
changes in response to Mlh1 expression being turned on or off.  
 
By comparing these models and sub-models it was possible to draw a general picture of the 
possible metabolic effects attributed to Mlh1 only. Figure 3.13 below assists in the 
comparative visualization of the directionality of the metabolic percent-change ratios between 
the different cell models and sub-models. A metabolic directionality was observed when 
comparing CP70 A2:A2780 vs. CP70 A2:CP70 E1 (Figure 3.13 A) and CP70:A2780 vs. 
MutLα-:MutLα+  (Figure 3.13 B) sub-models, with metabolites such as GSH and alanine 
both showing increasing levels. The CP70 A2:CP70 E1 vs. MutLα- :MutLα (Figure 3.13 C) 
comparison though also produced a directionality (observed for the majority of metabolites, 
n=10) despite the fact that the sub-models belonged in different cell models. Some 
metabolites in particular such as alanine, GPC, and choline) showed close similarities not 
only in directionality but also on the level of metabolic change. 
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Metabolic signature of MLH1 (model and sub-model percentage change comparison) 
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Figure 3.13 – Visual comparative representation of percentage change in intracellular 
aqueous extracts of average metabolite integrals in different cell models (n=3). 
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3.3.3.1 Metabolic ratios   
Calculating metabolic ratios is a good way of examining relationships between metabolites, 
in this particular case, PC & GPC since changes in such a ratio could be associated with cell 
growth, cell cycling and, thus, cancer. 
 
The ratio of PC to GPC can be important in terms of cell proliferation and cancer 
aggressiveness. The significance of the [PC]:[GPC] ratio in cell transformation and 
malignancy has been confirmed by various studies on tumour cell lines. In particular, it has 
been found that increased [PC]:[GPC] values may serve as indicators of malignancy in NMR 
tumour investigations (Bhakoo et al., 1996). 
 
Interestingly, there was a consistent decrease in the [PC]:[GPC] ratios in the Mlh1-negative 
cell lines (Figure 3.14) in this study, with the difference more apparent in the Mlh1 cell lines 
of the platinum resistance model. In addition, the mitochondrial DNA-depleted cells exhibit 
the smallest change in ratio concentration.  
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Figure 3.14 - PC:GPC ratios of average integrated metabolic intensities. Asterisk (*) 
denotes p<0.05.  
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3.4 Discussion 
In this study, pairs of kidney (HEK-293T derived) and ovarian cancer (A2780-derived) cell 
lines, either positive or negative for the MMR protein Mlh1, were assessed for metabolic 
changes correlating to loss of Mlh1, platinum resistance and mitochondrial status and 
function. Here, the association of loss of Mlh1 with impaired mitochondria and platinum 
resistance within a metabolic context between two models of different cell origin in vitro was 
investigated.   
 
3.4.1 Loss of Mlh1 and its association with platinum resistance 
Earlier reports from the clinical and preclinical setting regarding alterations in MMR proteins 
such as Mlh1 suggested that they play a role in platinum chemotherapy resistance, and that 
the effect of the loss of Mlh1 could be apparent even in cell lines of different origin (ovarian, 
lung, breast or colorectal). In vitro studies (Aebi, Kurdi-Haidar et al. 1996); (Brown, Hirst et 
al. 1997); (Fink, Aebi et al. 1998); (O'Brien and Brown 2006) have indeed reported a 
relationship between MMR loss and platinum resistance. Furthermore, clinical studies have 
linked MMR deficiency with decreased response to platinum-based chemotherapy (Fink, 
Nebel et al. 1998); (Strathdee, Appleton et al. 2001); (Gifford, Paul et al. 2004). 
 
3.4.2 In Vitro Metabolic Signature of Mlh1 Expression 
In this study, the availability of two different cell models (HEK-293T & PRM) with 
differential Mlh1 expression provided an ideal opportunity to study platinum drug resistance 
within a metabolic context. Here, the NMR-generated metabolic signature of Mlh1 and its 
likely contribution to platinum resistance and impaired mitochondrial status is discussed: 
 
The main metabolic changes in the NMR spectral data included changes in metabolites 
known to be important in cancer progression (i.e. phosphocholine) and increased platinum 
resistance (i.e. glutathione). These NMR-observed metabolites were found to be part of the 
overall Mlh1 metabolic signature (described in section 3.3.3). A more comprehensive 
description of these metabolites is presented below and intends to discuss the meaning of 
these findings in more detail: 
 
Glutathione (GSH) 
GSH levels were consistently higher for all Mlh1-negative cells. This increase is interesting 
since reduced expression of Mlh1 is associated with increased resistance to platinum (Ding, 
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Mohd et al. 2009) and at the same time, resistance to platinum has been linked to increased 
detoxification by thiol containing groups (Doz, Roosen et al. 1993). These results are indeed 
consistent with the changes observed here. The greatest percent-change increase was 
observed in the CP70 cells when compared to the A2780 cells, (suggesting the possibility that 
Mlh1 is not the only relevant gene causing these changes between the cell groups). The rest 
of the cells showed a small-scale increase in GSH in both the PRM and the HEK-293T cell 
models. Since mitochondria are responsible for oxidative phosphorylation and the 
mitochondrial respiratory chain can be an important source of increased reactive oxygen 
species (ROS) in cancer (Pelicano, Carney et al. 2004), increases in GSH may be a 
compensation mechanism for the higher levels of oxidative stress resulting from improper 
metabolism of oxygen in the mitochondria. This is relevant to one of this study‟s main 
hypotheses, which theorised that Mlh1is somehow responsible for regulating mitochondrial 
function. 
 
Alanine, Lactate and Branched Chain Amino Acids 
There was a significant increase in intracellular alanine in all cells with Mlh1 loss except in 
the case of the mitochondrial DNA-depleted cells (both MutLα+ ρ0 and MutLα- ρ0) where 
the change was 0%. More specifically, alanine was found to be increased in CP70 (Mlh1-
negative) cells as well as in CP70 A2 cells, which are also Mlh1-negative. Significantly 
higher alanine levels have been observed in other cancers like prostate cancer, consistent with 
a need for increased protein synthesis in tumour cells (Tessem, Swanson et al. 2008). Of 
course, increases in alanine could also be attributed to catabolism of proteins within the 
cancer cell. Another explanation could be the metabolism of lactate. As lactate is also known 
to be converted to alanine via pyruvate by ALT (alanine transaminase) and lactate 
dehydrogenase (LDH), this may be a possible source of the significant increase in alanine. In 
our study however, the levels of intracellular lactate appear to be slightly decreased in all 
Mlh1-negative cells across both models with the exception of MutLα- which shows a slight 
increase in the HEK-293T model. These decreases are mostly in contrast to the generally 
accepted idea of increased glycolysis and enhanced lactate production in cancerous cells as 
compared to non-cancerous ones - a typical feature of tumour cell metabolism – thus, at this 
instance lactate does not seem to follow the expected glycolytic pattern or be directly linked 
to the alanine increases. Interestingly though, reports regarding alanine formation had shown 
that it can also be produced through the oxidation and catabolism of branched-chain amino 
acids, namely valine, leucine, and isoleucine  (Odessey, Khairallah et al. 1974). Along with 
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alanine, all three of these amino acids were identified as some of the biggest separators of 
Mlh1 status in the HEK-293T model. Such an observation was not made in the PRM though, 
possibly due to additional genetic factors coming into play. Cells use leucine, isoleucine, and 
valine for protein synthesis or alternatively these amino acids are catabolized into sources for 
glucose and lipid
 
generation (Doering and Danner 2000). Preservation of these amino acids is 
important in cell survival. It may be possible that the HEK-293T cell model revealed some 
increased need of the cancer cells for amino acids for the production of alanine. 
 
Choline-related metabolites 
Choline and its metabolites are generally needed for maintaining the structural integrity
 
and 
signalling functions of cellular membranes. However, choline-related metabolism has been 
previously identified to be altered in tumour cells and tissues (Podo 1999); (Glunde, Jacobs et 
al. 2006) - with emphasis given on three main molecules: choline, phosphocholine (PC) and 
glycerosphosphocholine (GPC).  
 
In our study, intracellular PC levels were seen to decrease in all the Mlh1-negative cells. 
However the decrease in the mitochondrial DNA-depleted cells was miniscule at just 1%. 
Changes in GPC levels were not consistent across the Mlh1-negative cells, with a great 
increase observed in the ovarian Mlh1-negative CP70 cell line at 47%. The rest of the Mlh1 
negative cells exhibited a small decrease in their GPC concentration levels. Increased PC 
levels have been observed in tumours (Eliyahu, Kreizman et al. 2007) and in cells with loss 
of tumour suppressor genes such as p53 (Mori, Delsite et al. 2004), as well as in cells with 
higher growth rates and increasing tumorigenic potential in general. Increases in PC have also 
been observed in ovarian cell lines (Iorio, Mezzanzanica et al. 2005). In our study such an 
observation could not be made, and thus, it was not currently possible to associate Mlh1 loss 
and PC with increased cancer aggressiveness or metastasis. The reason why PC changed in 
the non mitochondrial DNA-depleted cells but remained stable in the Mlh1-negative ones 
who had their mitochondrial DNA depleted could be perhaps explained by the fact that PC is 
involved in cell membrane synthesis by acting as a precursor of phosphatidylcholine in 
phospholipid membranes (Attard, Jean et al. 1999). The decrease in PC levels observed in our 
study for the Mlh1-negative cells could be consistent with decreased utilization for cell 
membrane synthesis implying some possible defect in membrane structure. The other 
possibility is an increased hydrolysis of PC into choline, hence its increased levels (see 
below). In addition, the fact that mitochondria-depleted cells in the HEK-293T kidney cell 
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model show only a very small difference in PC levels may also support a connection between 
Mlh1 and mitochondria, since in the absence of mitochondria, PC would not be utilized any 
further. Since PC is catalysed by choline kinase converting ATP + choline into PC and ADP, 
the stable PC levels in the mitochondria-depleted cells may reflect a type of oxidative 
phosphorylation dysfunction in the mitochondria.   
 
Choline levels were increased intracellularly in all Mlh1-negative cells. The greatest percent-
change increase was observed in the CP70 cells at 72% followed by CP70 A2. The 
differences in the HEK-293T model were less pronounced compared to the ovarian cells, and 
were increased by 7% for the MutlLα- cells and 4% for the MutLα- ρ0 cells. The increased 
choline levels could perhaps be explained in association with the PC findings discussed 
above; it might be possible that at the specific time point of the experiment, phosphorylation 
and convesrsion of choline into phosphocholine by choline kinase had not occurred yet, 
hence the decreased PC but increased choline concentrations in the Mlh1-negative cells. This 
could be confirmed in future experiments through monitoring the enzyme activity of choline 
kinase.  
 
Myo-inositol 
Myo-inositol increased the most in the Mlh1-negative CP70 A2 cells from the PRM model 
and the MutLα- cells from the HEK-293T cell model. It also decreased slightly for both CP70 
and MutLα- ρ0 cells, however this difference was minuscule. These changes are probably 
mostly indicative of the background genetic variability in the tested cell lines. The increases 
observed in some of the Mlh1-negative cells, may also reflect differences caused by the 
genetic manipulation (transfection/microcell transfer) that was part of the experimental 
process. It might also be possible that, with myo-inositol being an osmolyte, increased levels 
were needed to accommodate for a possible increase in osmotic stress for these particular cell 
lines - which is usually achieved through downregulation of intracellular sodium and 
potassium (Kultz and Csonka 1999).  
 
3.4.3 Concluding remarks 
Our findings offer a range of possible explanations on the role of specific metabolites and 
their association with the Mlh1 gene, platinum resistance and mitochondria. It has been found 
that cells exposed to cisplatin exhibit certain degrees of inhibition in  respiration (Tacka, 
Dabrowiak et al. 2004) possibly due to direct conjugation to DNA and proteins of 
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mitochondria (Cullen, Yang et al. 2007). It is possible that cells lacking Mlh1 are more 
capable in maintaining their homeostasis and energy balance than cells possessing the fully 
functional copy of the gene, thus rendering them more resistant to chemotherapeutic 
treatments. Overall, this study has managed to isolate and identify a unique Mlh1 metabolic 
signature, which includes metabolites with an important role in cancer development, as well 
as to connect mitochondrial metabolism to Mlh1 loss of expression.  
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Chapter 4 
 
Over-representation analysis of pathways significant with genes and 
metabolites selected by correlation to Mlh1 
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4.1 Introduction 
As a continuation of the Mlh1 study presented in chapter 3, a novel bioinformatics approach, 
which is described in section 4.2, was applied in order to compare our previous metabolic 
findings with specific published NCI-60 cell line microarray gene expression profiles and 
check for any possible associations between them.  
 
The NCI-60 is a gene expression panel consisting of 60 cancer cell lines displaying patterns 
according to their tissue of origin. The tissues involved include types of hematopoietic, 
epithelial, mesenchymal and melanocytic origin (Ross et al. 2000). It was developed by the 
US National Cancer Institute (NCI) as a drug discovery tool and cellular mechanics 
information source and was eventually developed to serve as an anticancer drug screen 
support (Shoemaker, 2006). 
 
Table 4.1 lists the cell lines included in the NCI-60 panel and whose publicly-available gene 
expression profiles were used in this study. 
 
The analysis presented later in this chapter was made possible through the use of a 
continually updated online database system, called ConsensusPathDB: 
 
ConsensusPathDB is a database focusing on interactions between entities such as genes, 
RNA proteins, metabolites and various types of complexes in humans. This can make 
possible the study of heterogeneous interactions through their comprehensive integration into 
the system, and thus, increase the chances of the analysis being closer to the biological 
reality. More specifically, the analysis of biological systems and their functions through 
interaction networks has been steadily increasing over recent years, facilitating the generation 
of knowledge and understanding of biological processes either in a molecular or a wider 
systemic level. However, a considerable amount of these interactions are interspersed in a 
variety of different databases, which either focus on different sets of reactions, or face 
problems with incomplete overlaps and differing information and formatting details, even 
between similar databases. Thus, a question arises about the ability of such interaction 
networks to represent the “biological truth” in a more wholesome way.  For the time being, 
ConsensusPathDB seems to be one of the best answers in addressing this issue.  
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NCI-60 Cell Lines 
    
Cell Line Name                  Panel Name Cell Line Name Panel Name 
CCRF-CEM   Leukemia   M14  Melanoma  
HL-60(TB)  Leukemia  MDA-MB-435  Melanoma  
K-562  Leukemia  SK-MEL-28  Melanoma  
MOLT-4  Leukemia  SK-MEL-5  Melanoma  
RPMI-8226  Leukemia  UACC-257  Melanoma  
SR  Leukemia  UACC-62  Melanoma  
A549/ATCC  Non-Small Cell Lung  IGR-OV1  Ovarian  
EKVX  Non-Small Cell Lung  OVCAR-3  Ovarian  
HOP-62  Non-Small Cell Lung  OVCAR-4  Ovarian  
HOP-92  Non-Small Cell Lung  OVCAR-5  Ovarian  
NCI-H226  Non-Small Cell Lung  OVCAR-8  Ovarian  
NCI-H23  Non-Small Cell Lung  NCI/ADR-RES  Ovarian  
NCI-H322M  Non-Small Cell Lung  SK-OV-3  Ovarian  
NCI-H460  Non-Small Cell Lung  786-0  Renal  
NCI-H522  Non-Small Cell Lung  A498  Renal  
COLO 205  Colon  ACHN  Renal  
HCC-2998  Colon  CAKI-1  Renal  
HCT-116  Colon  RXF 393  Renal  
HCT-15  Colon  SN12C  Renal  
HT29  Colon  TK-10  Renal  
KM12  Colon  UO-31  Renal  
SW-620  Colon  PC-3  Prostate  
SF-268  CNS  DU-145  Prostate  
SF-295  CNS  MCF7  Breast  
SF-539  CNS  MDA-MB-231/ATCC  Breast  
SNB-19  CNS  HS 578T  Breast  
SNB-75  CNS  BT-549   Breast   
U251  CNS  T-47D  Breast  
LOX IMVI  Melanoma    
MALME-3M  Melanoma    
Table 4.1 – List of the NCI-60 cell lines and their corresponding tissues of origin used in 
this study (sourced from NCI <http://dtp.cancer.gov/mtargets/mt_index.html> Accessed 
24 June 2010). 
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So far the whole ConsensusPathDB database includes interactions from 12 separate databases 
(Table 4.2) at the time of writing. Because not all of these databases have the same name for 
their housed interactions, the way all these different entities are linked to each other is 
through the use of common identifiers such as UniProt in the case of proteins (Uniprot 
Consortium, 2010), Ensembl in the case of genes or transcripts (Flicek et al., 2008) and 
KEGG/ChEBI in the case of metabolites (Degtyarenko et al., 2008).  
 
Integrated Databases in ConsensusPathDB. 
BioCarta (signalling) 
BioGRID (protein) 
DIP (protein) 
HPRD (protein) 
HumanCyc (metabolic) 
IntAct (protein) 
KEGG (metabolic) 
MINT (protein) 
Netpath (signalling) 
PID - Pathway Interaction Database (signalling) 
PIG - Pathogen Interaction Gateway (host-pathogenic & host-host protein) 
Reactome (metabolic and signalling) 
SPIKE (protein interactions, signalling) 
Table 4.2 – Databases and pathways included in the ConsensusPathDB online database 
(data supplied by (Kamburov, Wierling et al. 2009). 
 
The general methodology and results of this chapter‟s analysis are presented in the following 
sections: 
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4.2 Methods 
One of the biggest problems with traditional biochemical pathway networks is that the 
construction and “packaging” of these molecular interactions are arbitrary, and at times it can 
be based on the personal choices of the map-constructing individuals. As previously 
mentioned, this can sometimes lead to a biased network representation of the biological 
reality. It can also lead to various biochemical interactions being overlooked. This study has 
tried to overcome this problem by employing a novel bioinformatics-based methodology, 
explained in more detail below, while looking at the same time for Mlh1-based associations 
with the results of the previous chapter. 
 
In particular, a novel method involving the microarray gene expression profiles of the NCI-60 
panel using the ConsensusPathDB database was tested for the first time, focusing on the 
search for gene and metabolic pathway associations involving Mlh1. This procedure, aimed at 
overcoming the problem posed by the traditional biochemical pathway networks, by 
employing the use of Over-Representation Analysis (ORA) and Neighbourhood-based entity 
sets (NESTs).  
 
Over-representation analysis is an effective way of addressing the challenge of interpreting 
gene lists generated from microarray data. It uses a cumulative hypergeometric test to define 
whether a set of genes in a list is statistically represented more than what would be expected 
by chance (Leong, 2009).  
 
The NEST-based approach was also chosen because of the fact that it can overcome single-
database boundaries, as it can continue even further beyond and display cross-talking 
between pathways.  
 
Figure 4.1 illustrates the general principle in the neighbourhood-based approach. The NESTs 
form sub-networks that contain all the physical entities around a central sub-network, which 
has a “radius”. This is defined as the number of interactions from the centre.  When there is a 
single interaction the radius is said to be a radius of one (radius 1), whilst with two 
interactions, the radius is two (radius 2). The area including the metabolite and the genes for 
each radius will be referred to as a “module”.  
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 In general, the genes in the NCI-60 panel can be measured for significant correlations with 
another gene (such as Mlh1 in this study), by searching for physical entities (i.e. metabolites) 
that have a predefined number of genes surrounding them. For example, in this chapter, the 
number of surrounding genes was set to 2, for reasons explained later on in this section.  
 
 
Figure 4.1 – Example map of NEST network interactions between metabolites and 
related genes one step (radius of 1) or two steps away (radius of 2) from a metabolite 
located at the centre of the network. 
 
 
 
 
 
NEST INTERACTION NETWORK 
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The basic steps that were taken during the NEST-based approach in this study are presented 
below: 
 
1) Firstly, the publicly available microarray gene expression data from the NCI-60 cancer 
cell line were downloaded (Bussey, 2006) and, subsequently, the total number of the 
genes present in the NCI-60 panel was translated into Uniprot protein identifiers for use 
with the ConsensusPathDB database.  
 
NOTE: From this point onwards, the term “proteins” will be used to refer to the 
corresponding genes, as each of the genes is now considered to be linked to the Uniprot 
label of the protein it codes for. 
 
2) This was followed by the generation of a panel with 241 protein names significantly 
correlated with Mlh1. This was generated through specific statistical tests involving the 
Pearson correlation and the subsequent application of a False Discovery Rate (FDR) 
using a 20% cut-off, which was applied to the set of p values on the total panel of proteins 
to determine the level of false positives.   
 
3) As a separate step, the input lists consisting of the list of genes measured in the 
transcriptomic data on the NCI-60 panel (31,122 proteins with 15,506 unique IDs) and 
the generated gene panel of the Mlh1-associated proteins (241 proteins with 225 unique 
IDs) were entered into in-house software written in Python (by Rachel Cavill, 2009) for 
comparison with the modules (NESTs) present in the ConsensusPath DB database. 
Subsequently, the total number of proteins in the NCI-60 panel was compared with the 
ConsensusPathDB data, and the effective size of modules (including any identifier 
repeats) was calculated. This effective size was in turn compared to the Mlh1-associated 
panel of 241 proteins, which counted the number of selected proteins in each module. The 
probability (p-values) of this amount of overlap was then calculated through the 
application of a hypergeometric distribution test, as mentioned earlier. The above 
procedure focused on a unique module each time before moving on to the next one in 
line. Thus, for the “radius 1” analysis a total of 2,021 modules were examined, while for 
the “radius 2” one, 1973 modules were examined in total. Finally, a filtering process was 
also applied, where NESTs were selected based on if they had more than 1 protein around 
a metabolite (>1), as well as a probability value less than 0.05 (p<0.05). This filtering 
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tried to achieve a strengthening of the significance of the resulting data and, thus, increase 
the confidence on the results. (As already explained, the p-values reflected how 
significant the overlap between the input list and the members of the pathways were as 
compared to random, with small p-values indicating that the input list contained more 
members than as expected by chance). 
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4.3 Results 
The results of the NEST-based analysis are presented in this section of the chapter: 
 
The list of the 241 protein names generated at the beginning of the analysis, which were 
found to be associated with Mlh1, can be seen in the appendix section at the end of this thesis, 
while the results of the NEST analysis are summarised in Table 4.4. The following table 
(Table 4.3) lists some of the metabolic pathways associated with each metabolite:  
Table 4.3 – Metabolic pathways associated with each metabolite according to 
CosensusPath database 
 
Metabolic Pathways 
oleic acid palmitate stearate sialyl-3-paragloboside 
fatty acid amide 
hydrolase 
 
Oleoyl-[acyl-
carrier protein] 
hydrolase  
 
Oleoyl-[acyl-
carrier protein] 
+ H2O <=> 
Acyl-carrier 
protein + (9Z)-
Octadecenoic 
acid  
 
Interaction of 
Oleoyl-[acyl-
carrier protein] 
and H2O 
  
Interaction of 
H2O and 
Oleoyl-CoA 
 
RXN-9644 
 
Oleoyl-CoA + 
H2O <=> CoA + 
(9Z)-
Octadecenoic 
acid 
Interaction of 
Hexadecanoic acid  
 
Interaction of 
Hexadecanoic acid 
and Protein 
Palmitoyl-CoA 
hydrolase 
depalmitoylation of 
eNOS  
 
ATP + 
Hexadecanoic acid + 
CoA <=> AMP + 
Palmitoyl-CoA + 
Diphosphate 
 
Interaction of 
Palmitoyl-CoA and 
H2O 
1-
palmitoylglycerone 
phosphate + 
hexadecanol => O-
hexadecylglycerone 
phosphate + 
palmitate  
 
Interaction of 
Hexadecanoyl-[acp] 
and H2O 
 
Stearoyl-CoA 
hydrolase 
Octadecanoyl-
[acyl-carrier 
protein] + H2O <=> 
Acyl-carrier protein 
+ Octadecanoic 
acid  
 
ceramide + H2O 
<=> stearate + 
sphingosine 
[endoplasmic 
reticulum] 
 
Stearoyl-CoA + 
H2O <=> CoA + 
Octadecanoic acid 
Interaction of H2O 
and Stearoyl-CoA 
 
Interaction of 
Octadecanoic acid  
 
phytoceramide + 
H2O => stearate + 
phytosphingosine  
 
ceramide + H2O => 
stearate + 
sphingosine [Golgi]  
GDP-L-fucose + Sialyl-3-
paragloboside <=> GDP + 
IV3NeuAc,III3Fuc-
nLc4Cer  
 
CMP-N-
acetylneuraminate + 
Paragloboside <=> CMP 
+ Sialyl-3-paragloboside 
 
CMP-N-
acetylneuraminate + 
Sialyl-3-paragloboside 
<=> CMP + 3`,8`-LD1  
 
Interaction of GDP-L-
fucose and alpha-N- 
 
Acetylneuraminyl-2,3-
beta-D-galactosyl-1,4-N-
acetyl-beta-D- 
 
Interaction of CMP-N-
acetylneuraminate and 
beta-D-Galactosyl-1,4-N-
acetyl-beta-D- 
 
glucosaminyl-1,3-beta-D- 
Neolactotetraosylceramide 
α-2,3-sialyltransferase 
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As already mentioned, a part of this procedure involved ignoring those pathways that had 
only a single picked entity (since the p-value on these occasions may be misleading) and 
focusing on metabolites that had at least two significant proteins around them in each 
module. By looking at the generated table (Table 4.4) with the results of the analysis, there 
were only four metabolites which were found at the centres of the modules, and which had 
more proteins from the Mlh1 20% FDR cut-off list, than one would expect at random. 
 
Looking at all the proteins one step away from the metabolites, there are 9 proteins one step 
(one radius) away from oleic acid with two of them associated with Mlh1 (p = 0.00207). 
There are also 37 proteins one step away from palmitate (palmic acid), with two of them 
associated with Mlh1 (p = 0.03330). 
 
Looking out further, i.e. two steps away from the metabolite (radius of two), two more 
significant modules can be found; those for sialyl-3-paragloboside (2 out of 38 proteins, p = 
0.03497) and stearate (2 out of 40 proteins, p = 0.03841). 
The table below (Table 4.4) displays the list of the top significant metabolites for each radius, 
respectively. As already mentioned, those metabolites consisted of oleic acid, palmitate, 
sialyl-3-paragloboside and stearate.  
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Metabolites Number 
of 
modules 
 
 Proteins 
in 
pathway 
Proteins 
selected 
Protein 
P-value 
      
Radius 1 2021     
 
Oleic acid   9 2 0.00207 
 
Palmitate   37 2 0.0333 
 
  
   
 
  
   Radius 2 1973  
      
sialyl-3-
paragloboside 
  38 2 0.03497 
 
 
stearate   40 2 0.03841 
 
Table 4.4 - List of significant metabolite pathways using a radius of one (Radius 1) and 
a radius of two (Radius 2) distance from the metabolic nest after applying a threshold of 
>1 and p< 0.05 in the number of selected proteins. 
 
 
After these metabolites were identified, it was also possible to cross-check which proteins 
from each of these modules were in the Mlh1-correlated list of 241 proteins. The cross-
examination generated the results seen in table 4.5.  
These protein names included ACOT4_HUMAN and FAS_HUMAN in the case of oleic 
acid, palmitate and stearate, and FUT9_HUMAN and NCAM1_HUMAN in the case of 
sialyl-3-paragloboside.  
 
The online-generated ConsensusPathDB network map of oleic acid in Figure 4.2 is a 
visualisation example of these interactions. 
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Oleic acid (radius 1) 
ACOT1_HUMAN, ACOT2_HUMAN, ACOT4_HUMAN, BAAT_HUMAN, BACH_HUMAN, 
FAS_HUMAN, FFAR1_HUMAN, SAST_HUMAN  
 
Palmitate (radius 1) 
A8K2J7_HUMAN, ACOT1_HUMAN, ACOT2_HUMAN, ACOT4_HUMAN, ACOT8_HUMAN, 
ACSL1_HUMAN, ACSL3_HUMAN, ACSL4_HUMAN, ACSL5_HUMAN, ACSL6_HUMAN, BAAT_HUMAN, 
BACH_HUMAN, FAS_HUMAN, FFAR1_HUMAN, PPARA_HUMAN, PPT1_HUMAN, PPT2_HUMAN,   
RXRA_HUMAN, SAST_HUMAN, TBL1R_HUMAN, TBL1X_HUMAN 
 
Stearate (radius 2) 
ABCBB_HUMAN, ACOT1_HUMAN, ACOT2_HUMAN, ACOT4_HUMAN, ACOT8_HUMAN, 
APHC_HUMAN, ASA2C_HUMAN, ASA3L_HUMAN, ASAH2_HUMAN, ASAH1_HUMAN, ASAH3_HUMAN, 
ATX1_HUMAN, BAAT_HUMAN, BACH_HUMAN, FAS_HUMAN, LAT2_HUMAN, NLTP_HUMAN, 
PPT1_HUMAN, PPT2_HUMAN, Q96EA2_HUMAN, S27A5_HUMAN, SAST_HUMAN, XCT_HUMAN, ZN277_ 
HUMAN  
 
Sialyl-3-paragloboside (radius 2) 
CF015_HUMAN, FUT4_HUMAN, FUT5_HUMAN, FUT6_HUMAN, FUT7_HUMAN, FUT9_HUMAN, 
FUT10_HUMAN, NCAM1_HUMAN, SIA8A_HUMAN, SIA8B_HUMAN, SIA8C_HUMAN, 
SIA8D_HUMAN, SIA8E_HUMAN, SIA8F_HUMAN, SIA10_HUMAN  
Table 4.5 - Proteins found to be correlated to metabolites associated with Mlh1 in the 
tested protein list. Protein names highlighted in red colour represent the proteins found 
in the Mlh1-correlated NCI-60 20% cut-off list.  
 
During the ConsensusPathDB analysis, proteins not present in the list of the tested proteins, 
can still be seen in the network map (Figure 4.2) around each metabolite mentioned. This is 
due to a name-spacing mapping problem, so no test could be applied to check for their 
significance. For example in the case of oleic acid (Figure 4.2) some genes, 
namelyACBG1_HUMAN, ACBG2_HUMAN, FAAH1_HUMAN and FAAH2_HUMAN, were 
absent from the total protein list.  
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Figure 4.2 - Example of a ConsensusPathDB-generated network map of physical entities and complexes related to a metabolite (oleic 
acid in this instance) which has been previously significantly associated with Mlh1. Related proteins (in blue/green colour) correspond to 
the tested NCI-60 proteins. Out of the 14 proteins appearing in the map, two of them (circled in red) are present in the Mlh1-associated 
panel of 241 proteins. 
Present in NCI-60 20% FDR list 
Absent from list of total proteins 
tested 
 
 
 
ddd 
 
 
132 
 
4.3 Discussion  
 
4.3.1. Mlh1-correlated genes and metabolites  
The Mlh1-associated genes that were identified as significant using the bioinformatics-based 
methodology described in this chapter were ACOT4, FAS, FUT9 and NCAM1 while their related 
metabolites were oleic acid, palmitate, stearate and sialyl-3-paragloboside. Here, we take a more 
detailed look at these entities as a way of confirming a possible connection with platinum 
resistance in cancer and, wherever possible, an association with the metabolic findings of the 
previous chapter (chapter 3). 
 
One of the genes that came up as significant in this study was ACOT4. ACOT4 encodes for Acyl-
coenzyme A thioesterase 4. These thioesterases are enzymes responsible for the hydrolysis of 
acyl-CoAs to the free fatty acid and coenzyme A (CoASH), thus, being able to regulate 
intracellular concentrations of acyl-CoAs, free fatty acids and CoASH (Hunt and Alexson 2002). 
In particular, according to GeneRIF, ACOT4 is responsible for the termination of beta-oxidation 
of medium-chain dicarboxylic acids releasing the corresponding free acids (Westin, Hunt et al. 
2005). The significant metabolites associated with ACOT4 were three closely related metabolites, 
namely oleic acid, palmitate and stearate.  
 
Palmitate (hexadecanoate) is a typical fatty acid the anionic form of saturated palmitic acid. It is 
involved in various metabolic pathways including beta-oxidation, Krebs cycle and the respiratory 
chain for the production of energy in many tissues, including muscle tissues. It is formed from 
tripalmitin and its subsequent oxidation reactions involve catalysis of palmitoyl CoA by a long 
chain acyl CoA synthetase. Palmitate oxidation for the production of energy is impressive as it can 
provide a net yield of 129 ATP molecules per molecule (Salway 2004). At the moment however, 
there is insufficient data to provide a link between palmitate, cancer or platinum resistance; there 
have been reports however that have linked its retinyl form (retinyl palmitate) to genotoxicity and 
photo-clastogenicity in mouse lymphoma cells and in Jurkat T-cells (Dufour, Whitwell et al. 
2009). 
 
The other ACOT4 associated metabolite that appeared important in the correlation with Mlh1 was 
oleic acid. In animals, oleic acid is generated by the dehydrogenation of stearate (Annison, Linzell 
et al. 1967), which was also associated with ACOT4 in this study. Past reports have shown that in 
breast cancer cells, oleic acid induced migration and proliferation of the cells as well as increased 
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survival and invasion. It also involved activation of MEK1/2, ERK1/2, FAK and Src, which also 
have been associated with cancer (Soto-Guzman et al., 2009). 
 
Fas was another important gene identified in this study, which according to published data in the 
literature, is one of the strongest candidates for conferring platinum drug resistance in cancer cells. 
Fas is a 45 KDa transmembrane polypeptide found on the cell membranes of normal and 
cancerous cells (Watanabe-Fukunaga et al., 1992; Nagata, 1994). Together with its ligand, FasL, 
the Fas/FasL system can regulate the process of apoptosis.  Cancer cells can avoid apoptosis by 
down-regulating the expression of Fas. For example, lung cancer cells that were cisplatin-resistant 
showed low Fas protein levels with a significant decrease in apoptosis. Additional reports showed 
that Fas over-expression could reverse drug resistance in H446/CDDP cells. The Fas mechanisms 
by which cisplatin resistance is regulated still remain unclear though. Perhaps, Fas-resistant cells 
can be resistant to chemotherapy, due to the disruption of pathways involved in the apoptotic 
induction by chemotherapeutic drugs (Los, Herr et al. 1997); (Wu, Wang et al. 2010). 
 
FUT9 and NCAM1 were also Mlh1-related genes that were identified as significant, while their 
related metabolite was Sialyl-3-paragloboside. FUT9 is one of the genes encoding for a group of 
enzymes called alpha-3-fucosyltransferases which can catalyze the reaction  in the synthesis of 
Lewis antigens (Hittelet, Camby et al. 2003). FUT9 also synthesizes the LeX oligosaccharide, a 
sugar expressed in organ buds during human embryogenesis. This antigen has been mentioned to 
be aberrantly
 
expressed in association with various malignant tissues (Cailleau-Thomas, Coullin et 
al. 2000); (Hakomori 1998); (Orntoft and Vestergaard 1999) and perhaps may give some validity 
in the association between FUT9 and platinum resistance; however, for the time being, knowledge 
regarding this connection is very limited. NCAMs (neural cell adhesion molecules) are antigens 
expressed in normal tissues but also in cancers such as neuroblastomas, myelomas and acute 
myeloid leukaemias. Current experimental regimens involve anti-NCAM target therapy (Jensen 
and Berthold 2007) in cancer patients but there are no data presently available regarding its 
association with resistance to platinum drugs, especially in ovarian cancer. However, recent 
studies have connected various immunoglobulin-like cell adhesion molecules with ovarian cancer 
and receptor tyrosine kinases. In addition, proteolytic processing of these molecules produces 
fragments whose activities that can support ovarian cancer development (Bombardelli and 
Cavallaro 2010). Overall, it would be prudent that some consideration was given to these genes 
and their associated metabolites for possible implications with platinum resistance in the future. 
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4.3.2 Correlation with previous findings 
Apart from the above correlations of the aforementioned Mlh1-associated genes and metabolites 
with cancer and/or platinum resistance, the previous metabolic findings in Chapter 3 were also 
compared with the findings presented in the current chapter. 
 
In the previous chapter, the metabolites whose levels showed significant changes and that were 
found to be correlated with Mlh1 expression and platinum resistance included glutathione, alanine, 
lactate, branched chain amino acids, myo-inositol and choline-related metabolites such as 
phosphocholine.  
 
It was not currently possible to find a direct connection between the findings in the two chapters 
(chapters 3 and 4), as none of the metabolites in the bioinformatics study and the cell-cultured 
based study appear to be associated at a first glance. However, while looking for indirect 
relationships an interesting fact seemed to appear in the case of phosphocholine. In the previous 
chapter it was mentioned that phosphocholine is involved in cell membrane synthesis by acting as 
a precursor of phosphatidylcholine in phospholipid membranes (Attard, Jean et al. 1999). In the 
past, there was a study on the mechanism through which certain fatty acids could enhance the 
biosynthesis of phosphatidylcholine in rat hepatocytes in culture. In particular, long-chained fatty 
acids increased incorporation of [methyl-(3)H] choline from phosphocholine into 
phosphatidylcholine, while oleate and palmitate supplementation enhanced phosphatidylcholine 
production by 3- and 2.2-fold, respectively (Pelech, Pritchard et al. 1983). The mechanism by 
which these events occurred is still unclear but it could for example, involve the utilisation of 
ACOT4 as a means of driving these events forward, perhaps by indirectly promoting 
phosphocholine utilisation in the cells.  
 
4.3.3 Concluding Remarks 
In conclusion, this study successfully tested in practice a novel way for a NEST-based 
examination of complex pathways involving genes and metabolites, using Mlh1 as a 
representative example to showcase its effectiveness. It also managed to identify candidate genes 
that, through their relation to Mlh1 as well as various cancers, may make them a good starting 
point for basing platinum resistance-related experiments in the future. 
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Chapter 5 
 
Metabolic examination of platinum resistance in cancer cells using in vivo cell 
models of platinum resistance. 
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5.1 Introduction  
 
Ovarian cancer is a devastating disease affecting millions of women worldwide (Tsigkou, Marrelli 
et al. 2007). Despite successful initial therapy with platinum drugs in women with advanced 
ovarian cancer, a relapse often follows, after which platinum therapy is mostly ineffective 
resulting in a poor outcome (Hartmann, Lu et al. 2005). This is due to the fact that like many other 
cancers, ovarian cancer cells can exhibit increased platinum resistance – which can be either 
intrinsic or acquired – caused by a variety of different factors, such as, for example, increased 
DNA repair (Parker, Eastman et al. 1991). However, platinum anti-cancer drugs, such as cisplatin, 
are still some of the most important and effective chemotherapy agents in the treatment of 
malignancies (Boulikas 2004) and despite the advent of less toxic and less side effect-producing 
drugs, they are still very widely used.  
 
It has been postulated that one of the many possible reasons adding to the appearance of resistance 
to platinum drugs, is the effect of hypoxia. It is well known that oxygen concentrations in solid 
tumours can reach very low levels compared to normal tissues, making the tumour area quite 
heterogeneous in terms of oxygenation status. In general, hypoxic environments are commonly 
seen in many human cancers and are often associated with poor prognosis (Brown and Wilson 
2004). These hostile microenvironments are usually created due to tumours having a distant and 
inadequate blood-vessel supply (Tannock 1998), thus, leading to ineffective drug exposure. Other 
reasons accounting for the increased hindering of cytotoxic drugs in hypoxic tumours include: a 
decreased cell proliferation rate, which is conversely analogous to the distance from the blood 
vessels, as well as a decrease of sensitivity to apoptosis i.e. mediated by p53 through hypoxic 
selection of cells with p53 loss (Brown and Wilson 2004). In addition, some anticancer agents 
require increased oxygen conditions in order to bring about a significant cytotoxic effect 
(Batchelder, Wilson et al. 1996). Lastly, upregulation of genes (i.e. p-glycoprotein) known to be 
involved in drug resistance has also been associated with an increased resistance in hypoxia 
(Wartenberg, Ling et al. 2003). 
 
Additionally, there is growing evidence that not only hypoxia contributes to resistance in standard 
drug regimes, but it is also associated with a more aggressive phenotype, increased angiogenesis 
(Harris 2002), high number of mutations (Yuan and Glazer 1998), invasion (Pennacchietti, 
Michieli et al. 2003) and metastasis (Subarsky and Hill 2003). 
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Current strategies aiming at increasing the efficacy of cancer treatments involve hypoxia-activated 
prodrugs, hypoxia-selective gene therapy, HIF-1 targeting, and even recruitment of specifically 
recombinant anaerobic bacteria (Brown and Wilson 2004). However, not enough focus has been 
given in the study of the metabolic profile of cancer cells, either in vivo or in vitro, that are 
resistant to platinum under either normoxic or hypoxic conditions.  
 
5.1.1 Objectives  
 
Taking into account the above considerations, the main goals of the experiments presented in this 
chapter were to: 
 
 Attempt to use an in vivo platinum resistance metabolic model of cancer in vitro, by 
observing and comparing the metabolic behaviour of isogenic ovarian cancer cell line pairs, 
namely PEA1 & PEA2, and PEO1 & PEO4. The metabolic baseline differences between 
platinum-sensitive (PEA1 and PEO1) and platinum-resistant cells (PEA2 and PEO4) were 
measured under both conditions of high (normoxia) and low (hypoxia) oxygen levels, in order to 
achieve in vivo conditions that would most resemble real-life situations. 
 
 Possibly identify platinum drug resistance phenotype biomarkers of cancer metabolism 
with the help of NMR spectroscopy. 
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5.2 Materials & Methods 
Spectral metabolic profiles of the selected PEA1 & PEA2, and PEO1 & PEO4 isogenic ovarian 
cancer cells under both normoxic (21 % O2) and hypoxic (1% O2) conditions were measured using 
1
H NMR spectroscopy and then analysed using pattern recognition tools.  
 
The main methodology is summarised below, while more details on the methods employed in this 
study have been presented in chapter 2. Normoxic cells are identified by an „N‟ suffix (i.e. PEA1 
N) while hypoxic cells with an „H‟ (i.e. PEA1 H). 
 
5.2.1 Cell work  
A more detailed description of the methodology is presented in chapter 2, but in summary for the 
NMR-based work, the isogenic pairs of the ovarian cancer cells were split 48 hours before seeding 
equal numbers into T25 flasks (approx. 1.3 million cells each). They were then left to attach for at 
least 24 hours under standard normoxic conditions (21 % O2 and 5% CO2 at 37 
o
C) followed by 
exposure to hypoxic conditions (1% O2 and 5% CO2 at 37 
o
C) for 24 or 48 hours. Immediately 
prior to cell harvesting, media aliquots were collected, centrifuged and transferred to tubes for 
removal of pelleted dead cells. The cell monolayers in the flasks were then washed twice with cold 
PBS before lysing with cold methanol (MeOH). The resulting cell suspensions were transferred to 
new tubes and dried down using a rotary speedvac machine overnight. The aqueous metabolites of 
the cell extracts were prepared for NMR analysis using the CHCl3:MeOH extraction method. 
Eventually, the media and aqueous cell extract samples were transferred into NMR tubes for 
1
H 
NMR spectral acquisition using CPMG pulse programme sequences. For the cell assay-based 
work, the SRB assay was used on the cells in a 96-well plate format to test for cytotoxicity effects 
after 24 or 48 hour cisplatin exposure (5 µM). More details for the above can be seen in 
methodology chapter 2.  
 
5.2.2 Data analysis  
As a first step, intracellular aqueous extracts and extracellular media were examined and 
compared under either or both normoxic and hypoxic conditions using pattern recognition (PCA) 
analysis (Simca-P software) and comparative signal integration of the data (Matlab and Excel 
software).  
 
In preparation for the PCA analysis, the CPMG NMR spectra of the intracellular aqueous data 
were referenced to TSP and normalized to median fold change, and divided into 0.04 bins, 
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excluding the TSP and water regions (as previously described in chapter 2). Similarly, the data 
from the media samples were processed in the same way but were only scaled to TSP. 
 
5.2.3 Visual inspection, metabolic assignments and peak integration 
Firstly, the NMR spectra were visually inspected and an example full resolution spectrum from 
the intracellular extracts of the isogenic pairs under normoxia and hypoxia can be seen in Figure 
5.1. Metabolic assignments were then conducted as previously described in chapter 2 and achieved 
using published literature data, online metabolic databases, spiking experiments and use of 
appropriate software (i.e. ChenomX). The areas between the chemical shift ppm values (noted as 
„Start‟ and „End‟) located underneath the spectral peaks of the various metabolic resonances were 
used for peak integration and subsequent relative quantification of their intra- and extracellular 
concentrations.   
 
The positively confirmed spectral regions and their corresponding metabolic assignments for the 
intracellular extracts and the media can be seen in Tables 5.1 and 5.2, respectively.  
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Figure 5.1  - Full resolution 
1
H NMR spectra showing various metabolic assignments for the 
intracellular aqueous extracts in the isogenic ovarian cancer cells under normoxia (PEA1 N, 
PEA2N, PEO1 N, PEO4 N) and hypoxia (PEA1 H, PEA2 H, PEO1 H, PEO4 H). 
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Metabolic assignments (intracellular aqueous extracts) 
Start (ppm) End (ppm) Metabolites 
0.9 0.95 isoleucine 
0.95 0.96 isoleucine + leucine 
0.96 0.985 leucine 
0.985 1.005 valine 
1.005 1.03 isoleucine 
1.03 1.07 valine 
1.31 1.355 lactate 
1.47 1.51 alanine 
2.01 2.09 glutamate 
2.09 2.2 glutamate 
2.33 2.375 glutamate 
2.4 2.415 succinate 
2.43 2.485 glutamine/glutamate 
2.485 2.6 glutathione 
2.661 2.695 aspartate 
2.695 2.73 aspartate 
2.785 2.815 aspartate 
3.03 3.045 creatine 
3.205 3.2125 choline 
3.215 3.23 phosphocholine 
3.23 3.241 glycerophosphocholine 
3.241 3.295 taurine + myo-inositol + glucose 
3.295 3.331 taurine + myo-inositol + glucose 
3.335 3.365 methanol 
3.45 3.51 glucose 
3.51 3.56 myo-inositol 
3.56 3.575 glycine 
3.7 3.8 glutathione + glutamate + glutamine 
3.92 3.95 creatine 
4.06 4.09 myo-inositol 
4.09 4.14 lactate 
4.145 4.21 phosphocholine 
4.62 4.63 glucose 
5.23 5.26 glucose  
8.4 8.42 formate 
Table 5.1 - Spectral regions of the positively confirmed metabolites of the intracellular 
aqueous extracts samples as observed by NMR. 
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Metabolic assignments (extracellular media) 
Start (ppm) End (ppm) Metabolites 
0.92 0.948 isoleucine 
0.948 0.9595 isoleucine + leucine 
0.9595 0.9815 leucine 
0.9815 1.002 valine 
1.002 1.028 isoleucine 
1.028 1.06 valine 
1.16 1.21 ethanol 
1.3 1.36 lactate + threonine 
1.468 1.4935 alanine 
1.6 1.78 leucine 
1.9 1.94 acetate 
2 2.08 glutamate 
2.08 2.2 glutamine 
2.371 2.384 pyruvate 
2.4 2.416 succinate 
3.64 3.692 ethanol 
3.805 3.88 glucose 
3.88 3.94 glucose 
4.05 4.09 myo-inositol 
4.08 4.16 lactate 
4.62 4.68 glucose 
5.2 5.27 glucose 
6.8 6.94 tyrosine 
7.02 7.12 histidine 
7.13 7.26 tyrosine 
7.3 7.5 phenylananine 
7.7 7.9 histidine 
8.45 8.47 formate 
Table 5.2 - Spectral regions of the positively confirmed metabolites of the 
extracellular media samples as observed by NMR.  
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5.3 Results 
The main results from the metabolic investigation in platinum resistance in the selected isogenic 
ovarian cancer cell pairs under two different oxygen conditions are presented in the following 
sections. 
 
As a first step, cytotoxicity-based cellular assays were conducted, whilst the intracellular and 
extracellular content of the isogenic ovarian cancer cell lines was subsequently inspected using 
both spectral and multivariate analysis. This analysis led to the generation of a specific cellular 
baseline metabolic profile and the identification of several known and unknown metabolites. The 
positively confirmed metabolites that showed the most meaningful changes were then selected to 
undergo further analysis.  
 
5.3.1 Testing cisplatin cytotoxicity in hypoxic & normoxic isogenic ovarian cancer cells 
Before commencing the NMR analysis, preliminary in vitro cytotoxicity assays were repeatedly 
performed to test whether hypoxia had any effects a) on the growth of the selected isogenic cell 
lines and b) in platinum (cisplatin) resistance.   
 
The generated plots (Figure 4.1) from the results of the cytotoxicity assay (SRB) performed on 
one of the cell pairs (PEO1 & PEO4) revealed that: 
 
Hypoxia hindered growth of both sensitive and resistant cells compared to normoxia-exposed 
cells. In addition, cisplatin-treated cells in hypoxia showed greater survival than similarly treated 
cells in normoxia, with the effect more pronounced in the hypoxic resistant lines (PEA2 H and 
PEO4 H); whilst especially for the PEO4 cells the difference between treated and untreated cells 
was minimal. 
 
The PEO1 and PEO4 cell pair was chosen for testing the above, as it was the one previously 
shown to have a bigger difference in LD50 values (see chapter 2) between the isogenic cell lines, 
compared to the PEA1 and PEA2 cell pair.  
 
These results give more support to the theory of hypoxia playing a role in the resistance against 
platinum drugs like cisplatin, and also prepared the ground for the subsequent NMR-based 
analysis of the selected isogenic pairs.  
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Figure 5.2 – Plots showing the effects of cisplatin treatment (5 µM) on the ovarian cancer isogenic lines PEO1 
(cisplatin-sensitive) & PEO4 (cisplatin-resistant) in normoxia (21 % O2) and hypoxia (1% O2), as measured by 
the Sulforhodamine B-based proliferation assay after 48 hours of exposure. Error bars indicate standard 
deviation of the mean (SEM) (n = 16). Asterisk denotes p<0.05 (student‟s t-test). 
* * 
* * 
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5.3.2 NMR-based analysis of isogenic ovarian cancer cells 
The baseline NMR investigation that followed immediately after the cell proliferation assays, 
revealed a variety of changes in the metabolic phenotype of all the cell lines examined. The results 
on the intracellular and extracellular content of the cells are presented below: 
 
5.3.2.1 Examination of intracellular aqueous extracts of isogenic ovarian cancer cells 
While looking at the intracellular extracts for clues on their behaviour in regards to platinum 
resistance, it was obvious that their metabolic phenotype was affected by hypoxia. 
 
A straight-forward visualisation of these effects was achieved through pattern recognition 
analysis, and is presented in the next section: 
 
5.3.2.1.1 Examination through pattern recognition analysis 
In order to make the relationship between the cell lines visually clearer, a specific method of 
pattern recognition (PCA analysis) was performed in all of the cell pairs together, under both 
normoxia and hypoxia.  
 
Visual inspection through PCA seemed to reveal two distinct effects induced by exposure of the 
cells to the two oxygen conditions. These included movement of the cell clusters in the PCA plots 
(Figures 5.3 and 5.4) for both sensitive and resistant cells towards a hypoxic metabolic phenotype, 
as well as an additional effect, which seemed to be based on the background genetic differences 
between the cell lines.  
 
These results are presented in more detail below: 
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5.3.2.1.2 PEA1 vs. PEA2 vs. PEO1 vs. PEO4 isogenic ovarian cancer cells under normoxia or 
hypoxia 
Multivariate analysis on the NMR-generated data of the two cell pairs revealed the following: 
 
When the isogenic cell lines were examined together under both normoxia and hypoxia, the 
principal components that were able to produce the clearest separation between the profiles of the 
intracellular extracts in all cell lines were PC2 and PC3. In particular, PC2 accounted for about 
19% of the variance, whereas PC3 accounted for approximately 14%. 
 
The general idea that was deduced after PCA analysis (Figure 5.3) was that the normoxic 
phenotype seemed to shift across the PC2 axis, i.e. towards the right side of the plot, where most 
of the hypoxia-exposed lines were located. The corresponding loadings plot (Figure 5.4) revealed 
a shift towards glycolytic compounds (such as lactate at δ 1.34), under hypoxia for all cells (both 
sensitive and resistant) regardless of their resistance status. 
 
The loadings plot in Figure 5.4 shows the bins responsible for the metabolic movements of the 
sensitive cells and resistant cells in these normoxic and hypoxic conditions. For example, the 
metabolic bin belonging to lactate (δ 1.34) seemed to be increased in hypoxic cells (PEO1 H and 
PEO4 H), whilst resonances such as those found at δ1.5, 2.18, 2.34, 2.54, 3.58, and 3.78 seemed to 
be increased in normoxic cells mostly. On the other hand, examples of metabolic resonances 
differentiating resistant from sensitive cells could be found at 1.5 and 3.58 (PEA2 N cells) as well 
as 2.34 and 3.78 (PEA1 N cells).  
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Figure 5.3 - Scores plot of principal component analysis (PC2 & PC3) on 
1
H NMR CPMG one-dimensional spectra for aqueous 
intracellular extracts of isogenic ovarian cancer cells normalized to TSP and Median Fold Change. Plot is showing metabolic movements 
through effect of hypoxia and genetic background of the cells. Each point represents an individual cell sample. The ellipse represents the 
Hotelling with 95% confidence.  
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Figure 5.4- Loadings plot of principal component analysis (PC2 & PC3) on 
1
H NMR CPMG one-dimensional spectra for aqueous 
intracellular extracts of isogenic ovarian cancer cells normalized to TSP and Median Fold Change. Numbers beside data point 
correspond to specific bins used in the analysis. 
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5.3.2.1.3 Pattern of change of metabolites under normoxia or hypoxia in intracellular 
aqueous extracts  
At this stage, it is important to note that in order to understand how hypoxia may affect 
resistance to platinum, at least in these particular cell models, it is also necessary to observe 
the relative changes in intensity levels between them. This is presented in more detail in a 
later section of the chapter (section 5.3.2.1.5) where a closer and more individual look is 
taken; however, the general pattern as well as the levels of the various intracellular metabolic 
changes between all of the cell lines can still be seen in Table 5.3 and the bar chart in Figure 
5.5, where a percent-change based comparison was conducted and is presented here for 
illustrative and comparative purposes.        
 
i) Sensitivity vs. resistance 
As a first step, a percent-change comparison was made between intracellular intensities of 
isogenic cell lines in either normoxia or hypoxia. This meant comparing the cell lines in the 
following ratio-based way: 
 
- PEA2 N vs. PEA1 N (normoxia) 
- PEO4 N vs. PEO1 N  (normoxia) 
 
and 
 
- PEA2 H vs. PEA1 H (hypoxia) 
- PEO4 H vs. PEO1 H (hypoxia) 
 
The percent-change calculations of the metabolic ratios (Table 5.3 and Figure 5.5) revealed 
the following intracellular events between isogenic cell lines in normoxia or hypoxia, in 
terms of directionality (i.e. increased or decreased levels as compared to their isogenically-
paired cell line in the same oxygen condition).  
 
(Significant differences are marked with the relevant asterisks).  
 
 
 
150 
 
INTRACELLULAR AQUEOUS EXTRACTS 
METABOLITES PEA2 N/PEA1 N PEO4 N/PEO1 N PEA2 H/PEA1 H PEO4 H/PEO1 H 
GPC  55*** -14* 136** 38* 
Glucose -18 4 -26 -21 
Myo-inositol (2) 11 6 -14** -15 
Isoleucine   -5 -9 7 1 
Aspartate (2) 137*** -5 -13 -38 
Glutamate  6 -19** -2 9 
Glutathione  19* -19*** 8 -7 
Glycine  267*** -15*** 106*** 3 
Leucine   51* -13* 11 5 
Valine  42 -15 9* 11 
PC  37* 30** 82*** 10 
Taurine  -17 -11 -26* -3 
Choline -13 19 18 0 
Alanine  171*** -45*** 16* 12 
Creatine  17* -38** 11 29 
Lactate (2) -2 -57*** -8 16 
Succinate  20 -24** 44* 0 
Table 5.3 – Average metabolic ratios (percent-change) in sensitive vs. resistant ovarian 
cancer isogenic cells in normoxia (21% O2) & hypoxia (21% O2) of intracellular aqueous 
extracts. * p<0.05, ** p<0.01, *** p<0.001 (unpaired student‟s t-test using two-tail 
distribution). 
 
More specifically the concentrations of the metabolites were altered as follows: 
 
Lactate decreased in all resistant cell lines except in the case of PEO4 H, where it increased. 
Creatine, alanine, valine, leucine, glycine and glycerophosphocholine increased in all 
resistant cell lines except in the case of PEO4 N where they decreased. Phosphocholine 
increased in all resistant cell lines. Taurine decreased in all resistant cell lines whilst 
glutathione increased in PEA2 but decreased in PEO4 cell lines. Glucose increased in all 
resistant cells except in the case of PEO4 N, where it showed a slight increase. Glutamate 
increased in PEO4 H and PEA2 N but decreased in PEO4 N and PEA2 H cell lines. 
Isoleucine decreased in normoxic resistant cells but increased in the hypoxic resistant cell 
lines while myo-inositol increased in the normoxic resistant cells but decreased in the hypoxic 
resistant ones. Aspartate decreased in all resistant cells but increased in PEA2 N cell lines. 
Succinate increased in PEA2 cells but decreased in PEO4 N, while it showed no significant 
changes between PEO4 H and PEO1 H. Finally, choline increased in PEO4 N and PEA2 H 
but decreased in PEA2 N. It also showed no significant changes between PEO4 H and PEO1 
H.  
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From the above, it could be gathered that some of the most interesting changes metabolites, 
involved phosphocholine and taurine, which increased and decreased, respectively, in all 
resistant cell lines regardless of oxygen exposure, as well as isoleucine and myo-inositol 
which respectively increased and decreased consistently but only in the hypoxia-exposed 
resistant cell lines. Again, it‟s important to note that genetic variability between the particular 
cell lines seems to come into play each time the intracellular metabolic intensities are 
examined and compared. 
Figure 5.5 below visualises all these patterns:  
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Figure 5.5 - Bar chart showing the metabolic intensities pattern for the intracellular aqueous extracts of PEA1 & PEO1 (cisplatin-
sensitive) and PEA2 & PEO4 (cisplatin-resistant) ovarian cancer isogenic cell lines in normoxia (21% O2) and hypoxia (1% O2). 
Changes are expressed in terms of percent-change (n=3).
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ii) Normoxia vs. Hypoxia 
The cell lines were also individually compared in terms of normoxic effect vs. hypoxic effect 
since changes in the metabolic phenotype can also affect the way the cells respond to 
platinum. In this instance, cell lines were compared in the following ratio-based way in order 
to individually, and more effectively, isolate the hypoxia-induced changes: 
 
PEA1 N vs. PEA1 H 
PEA2 N vs. PEA2 H 
PEO1 N vs. PEO1 H 
PEO4 N vs. PEO4 H 
 
Table 5.4 below provides the actual percentage change values for the intracellular aqueous 
extracts in normoxia- vs. hypoxia-exposed cell lines. Each normoxic cell line was compared 
to its hypoxic equivalent, in order to assess the level of metabolic change in response to 
hypoxia. The pattern and levels of change are presented below (Table 5.4 and Figure 5.6). 
 
INTRACELLULAR AQUEOUS EXTRACTS 
METABOLITES PEA1 N/PEA1 H  PEA2 N/PEA2 H PEO1 N/PEO1 H PEO4 N/PEO4 H 
GPC  5 -31* 10 -32** 
Glucose 22 36* 5 37* 
Myo-inositol (2) 4 34*** 1 26* 
Isoleucine   9 -3 -8 -17 
Aspartate  36 271*** 125*** 247** 
Glutamate  22 32** 48** 10* 
Glutathione  46** 61** 68** 46** 
Glycine  16 107*** 71*** 42** 
Leucine   -29 -4 -5 -21** 
Valine  -29 -8 -8 -29 
PC  38 5 9 29** 
Taurine  4 16* 12 3 
Choline 5 -23* -2 16 
Alanine  -3 125*** 74*** -15* 
Creatine  12* 18* 68* -19** 
Lactate (2) -39* -34*** 29 -52*** 
Succinate  -25 -37** 23 -7 
Table 5.4 – Average metabolic ratios (percent-change) between normoxic (21% O2) and 
hypoxic (5% O2) ovarian cancer isogenic cells (intracellular aqueous extracts). * p<0.05, 
** p<0.01, *** p<0.001 (unpaired student‟s t-test using two-tail distribution). 
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More specifically, the metabolic changes that were observed involved the following: 
 
Taurine, phosphocholine, glycine, glutathione, glutamate, aspartate, myo-inositol and glucose 
decreased in all hypoxia-exposed cell lines. Valine and leucine increased in all hypoxic cells 
compared to their corresponding normoxic ones while succinate and lactate increased only in 
the case of PEO1 N. Creatine decreased only in the case of PEO4 N and alanine decreased in 
the PEA1 N and PEO4 N cell lines. Choline decreased in PEA2 N and PEO1 N cell lines 
whilst isoleucine only increased in PEA1 N cells. Lactate decreased in all hypoxic cells 
except PEO1 H. Finally, glycerophosphocholine increased in the hypoxic resistant cell lines 
but not in the normoxic ones.  
 
Figure 5.6 helps in visualising these patterns and shows the metabolic changes of the 
intracellular extracts in response to hypoxia. 
155 
 
-100% -50% 0% 50% 100% 150% 200% 250% 300%
Glycerophosphocholine 
Glucose
Myo-inositol
Isoleucine  
Aspartate 
Glutamate 
Glutathione 
Glycine 
Leucine  
Valine 
Phosphocholine 
Taurine 
Choline
Alanine 
Creatine 
Lactate 
Succinate 
Intensity changes in intracellular aqueous extracts of ovarian cancer isogenic pairs in response to hypoxia 
PEO4 N/PEO4 H
PEO1 N/PEO1 H
PEA2 N/PEA2 H
PEA1 N/PEA1 H 
 
Figure 5.6 - Bar chart showing the metabolic intensities pattern for the intracellular aqueous extracts of PEA1 & PEO1 (cisplatin-
sensitive) and PEA2 & PEO4 (cisplatin-resistant) ovarian cancer isogenic cell lines in normoxia (21% O2) and hypoxia (1% O2). 
Changes are expressed in terms of percent-change (n=3).
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5.3.2.1.4 Focused comparative examination of metabolic intensities in the intracellular 
extracts 
A representative selection of the previously analysed and relatively quantified NMR-
observed intracellular metabolites, which exhibited the most consistent changes and/or had a 
more direct association with the Warburg effect (such as glucose and lactate) are presented in 
the following pages. This section aims at aiding in the visualisation of these particular 
metabolites and the discussion of the results in section 5.5. As previously mentioned, the 
intracellular aqueous extracts were relatively quantified (Figure 5.7) by integrating the peak 
areas between their corresponding ppm ranges (Table 5.1). The metabolic intensities were 
compared and tested for significance using the student‟s t-test, as described earlier. 
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A 
 
B 
C 
Figure 5.7 - Mean absolute values of Median Fold Change-normalized NMR intensities 
for the intracellular aqueous extracts of A) glucose, B) lactate and C) phosphocholine 
(PC) between platinum sensitive and resistant isogenic ovarian cancer cells. p<0.05, ** 
p<0.01, *** p<0.001 (unpaired student‟s t-test using two-tail distribution). Error bars 
indicate standard error of the mean (SEM). 
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The ratios of phosphocholine and glycerophosphocholine were also examined (Figure 5.8) in 
this study and appeared to have low intracellular PC:GPC values. 
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Figure 5.8 - PC:GPC ratios of mean absolute values of Median Fold Change-normalized 
NMR intensities for the intracellular aqueous extracts of PC and GPC between 
platinum sensitive and resistant isogenic ovarian cancer cells. * p<0.05, ** p<0.01, *** 
p<0.001 (unpaired student‟s t-test using two-tail distribution). Error bars indicate 
combined differential error of the mean. 
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5.3.2.1.5 Examination of extracellular media of isogenic ovarian cancer cells 
Similarly to the intracellular extracts, the extracellular media were also examined and 
compared under either or both normoxic and hypoxic conditions. PCA and percentage-
change examinations were also performed as previously described.  
 
As before, the hypoxic conditions seemed to have an effect on the metabolic phenotype in the 
media, as they had in the extracts, allowing the possibility of some kind of association with 
increased or decreased platinum resistance. 
 
5.3.2.1.6 Examination of metabolic trends in the media through pattern recognition 
(PCA) analysis 
While looking at the top principal components (i.e. PC1, PC2…) in the media, PCA analysis 
seemed to initially present a bigger challenge in finding clear metabolic clusters of separation 
for either sensitive or resistant lines in normoxia or hypoxia.  This could be due to the high 
abundance of nutrients already present in the cell culture media, “drowning” the important 
metabolic changes and, thus, rendering them more difficult to examine through PCA. 
Looking further down in the hierarchy of components (i.e. PC4 & PC5) though, a separation 
started to become a little clearer. The variance for PC4 is about 58% and for PC5 around 
47%. As shown in figure 5.9 below, some hypoxia-induced metabolic changes that were 
restricted to resistance status only became apparent: when examining all cell lines together 
under normoxia and hypoxia, the majority of the normoxic resistant cells (in green) seemed 
to show a very obvious separation from their hypoxic counterparts (in red), whereas, the 
sensitive cells (in gray) under the same conditions did not appear to show any separation but 
rather a much wider and more interspersed distribution throughout the plot area. The loadings 
plot in Figure 5.10 shows the resonances of the metabolic bins responsible for the scores in 
Figure 5.9. For example, resonances at δ 2.34 and 3.78 for the resistant cells seemed to 
separate them from the sensitive cells with resonances found at δ 2.46 and 4.1.  
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Figure 5.9 - Scores plots of principal component analysis  on 
1
H NMR CPMG one-dimensional spectra for extracellular media of 
isogenic ovarian cancer cells scaled to TSP. Plot is showing effect of hypoxia on resistant cells across PC4 & PC5. Each scores point 
represents an individual cell sample while the ellipse represents the Hotelling with 95% confidence.  
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Figure 5.10 - Loadings plots of principal component analysis (PC4 & PC5) on 
1
H NMR CPMG one-dimensional spectra for extracellular 
media of isogenic ovarian cancer cells scaled to TSP. Numbers beside each data point in the loadings plot correspond to specific bins 
used in the analysis. 
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5.3.2.1.7 Pattern of change of metabolites under normoxia or hypoxia in extracellular 
media 
The percent-change inspection of the metabolic ratios revealed the following extracellular 
events between sensitive and resistant isogenic cell lines in normoxia and hypoxia. The 
visualisation of the levels and patterns of the various metabolic changes between the cell lines 
can be seen in the tables and bar charts below (Table 5.5 & Figure 5.11 for „sensitivity vs. 
resistance‟, as well as Table 5.6 & Figure 5.12 for the „hypoxia vs. normoxia‟ comparisons).7 
 
i) Sensitivity vs. Resistance  
The table below (Table 5.5) provides the actual percentage change values for each metabolic 
comparison as well as the relevant statistical significance, marked with the relevant asterisks.   
 
MEDIA 
METABOLITES PEA2 N/PEA1 N PEO4 N/PEO1 N PEA2 H/PEA1 H PEO4 H/PEO1 H 
Acetate -34*** -51* -7 -2 
Glutamine -1* 23* 5* 15* 
Myo-inositol -6 0 7 26 
Pyruvate -32*** -30 6 2 
Glucose 13*** 58* 19* 86*** 
Glutamate 2 4 1 17* 
Isoleucine  5** 10 5* 12* 
Leucine  3* 19* 6* 19** 
Lactate (2) -17*** -43* -10* -32** 
Phenylananine 1 5 4* 10 
Succinate  7** 16* 8** 14* 
Valine 1* 19** 6* 19** 
Alanine 29*** -49** 13** -15* 
Histidine  2 7 21 -1 
Tyrosine  -3 11 10*** 9 
Table 5.5 - Average metabolic ratios (percent-change) in sensitive vs. resistant ovarian 
cancer isogenic cells in normoxia & hypoxia of extracellular media. * p<0.05, ** p<0.01, 
*** p<0.001 (unpaired student‟s t-test using two-tail distribution). 
 
 
By looking at the relevant tables and figures it could be deducted that: 
 
Tyrosine and glutamine increased in all resistant cells but decreased in PEA2 N. (The 
decrease in tyrosine and glutamine between PEA2 N and PEA2 H cells was negligent at 3% 
and 1%, respectively). Histidine increased in all resistant cells but decreased in PEO4 H. This 
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decrease was also minuscule at 1%. Alanine increased in PEA2 cells but decreased in PEO4 
cell lines. Valine, leucine, isoleucine, succinate, phenylananine, glutamate, and glucose 
increased in all resistant cell lines. Lactate and acetate decreased in all resistant cell lines. 
(The acetate decrease was less steep in the case of the hypoxic cells compared to the 
normoxic ones). Pyruvate increased in hypoxic resistant cells while it decreased in the 
normoxic resistant ones. This change was less pronounced for the hypoxic cells. Myo-inositol 
followed a similar pattern; however there was no significant change in the PEO4 N cell line 
as in the case of pyruvate when compared to PEO1 N.  
 
Summarising the above observations, the extracellular metabolites that showed consistent 
changes included valine, leucine, isoleucine, glutamate, succinate, phenylananine and glucose 
whose intensities were higher in all resistant cell lines, as well as acetate and lactate which 
were decreased in the same lines.  Interestingly, pyruvate and myo-inositol seemed to respond 
to the hypoxic conditions by showing an increasing trend in their concentrations in the 
hypoxic media but not in the normoxic. Another notable difference in behaviour was also 
observed in the case of acetate where the decreased observed in all resistant cells was less 
pronounced for the hypoxic pairs. 
 
Figure 5.11 below visualises these changes:
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Figure 5.11 - Bar chart showing the metabolic intensities pattern for the extracellular media of PEA1 & PEO1 (cisplatin-sensitive) and 
PEA2 & PEO4 (cisplatin-resistant) ovarian cancer isogenic cell lines in normoxia (21% O2) and hypoxia (1% O2). Changes are 
expressed in terms of percent-change (n=3). 
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ii) Normoxia vs. Hypoxia  
Similarly, the metabolic ratios between extracellular media samples of the same cell line 
when exposed to either normoxia or hypoxia revealed the following events. 
 
Table 5.6 below provides the actual percentage change values for the normoxic vs. hypoxic 
metabolic comparisons. 
 
MEDIA 
METABOLITES PEA1 N/PEA1 H  PEA2 N/PEA2 H PEO1 N/PEO1 H PEO4 N/PEO4 H 
Acetate 114*** 51** 190*** 45 
Glutamine -9* -15*** -3 3 
Myo-inositol -2 -14** 19 -5 
Pyruvate 191*** 87*** 192*** 100 
Glucose 43*** 36** 54*** 31 
Glutamate 6* 7** 18* 5 
Isoleucine  -1 -1 7 5 
Leucine  -2 -5* 6 7 
Lactate -41*** -45*** -31** -42* 
Phenylananine 0 -3** 8 3 
Succinate  2 0 4 6 
Valine -1 -6* 5 5* 
Alanine 84*** 110*** 107*** 23 
Histidine  3 -13* 0 8 
Tyrosine  1 -12** 2 3 
Table 5.6 - Average metabolic ratios (percent-change) between normoxic and hypoxic 
ovarian cancer isogenic cells (extracellular media). * p<0.05, ** p<0.01, ***p<0.001 
(unpaired student‟s t-test using two-tail distribution). 
 
 
Particular changes that could be observed from the corresponding tables and figures involved 
the following extracellular events in terms of concentration change: 
 
Acetate, pyruvate, glucose, glutamate and alanine decreased in all hypoxic cells. Acetate and 
pyruvate showed the biggest levels of change in the hypoxic sensitive cells compared to the 
hypoxic resistant ones. This pattern was also observed in the case of glucose. Succinate also 
decreased in all hypoxic cells, however there was 0% change in the case of resistant cell line 
PEA2. Lactate increased in all hypoxic cells, regardless of resistance status. (Also, its levels 
of change were mostly similar for the majority of cell pairs). Tyrosine, histidine and 
phenylananine increased in PEA2 H cells only, with the majority of the remaining hypoxic 
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cells decreasing. The changes for these, however, were miniscule. Valine, leucine and 
isoleucine showed an increase in PEA1 H and PEA2 H cells, whereas the rest of the resistant 
cells slightly increased. On this occasion, glutamine and myo-inositol followed a more 
random pattern  
 
Figure 5.12 below shows the visualised pattern of these changes. 
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Figure 5.12 – bar chart showing the metabolic intensities pattern for the extracellular media of PEA1 & PEO1 (cisplatin-sensitive) and 
PEA2 & PEO4 (cisplatin-resistant) ovarian cancer isogenic cell lines in normoxia (21% O2) and hypoxia (1% O2). Changes are 
expressed in terms of percent-change (n=3). 
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5.3.2.1.8 Focused comparative examination of metabolic intensities in the extracellular 
media 
Similarly to the intracellular extracts examinations, an individual look at the extracellular 
intensities of the media metabolites that appeared to be consistently-patterned and/or 
associated with glycolysis and the Warburg effect, helped in highlighting their behavioural 
similarities and differences in more detail.  
 
A few representative plots of these metabolites are presented below and discussed in more 
detail in section 5.5. They include glucose, lactate, pyruvate, acetate and myo-inositol.  
 
As previously mentioned, the extracellular media were scaled to TSP and the 
1
H NMR 
spectra of the selected intracellular metabolites were relatively quantified (Figures 5.15 and 
5.16) by integrating the peak areas between their corresponding ppm ranges (Table 5.2). 
Asterisks denote the relevant values of significance.  
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Figure 5.13 - Mean absolute values of TSP-scaled NMR intensities for the extracellular 
media of A) glucose and B) lactate between platinum sensitive and resistant isogenic 
ovarian cancer cells. * p<0.05, ** p<0.01, *** p<0.001 (unpaired student‟s t-test using 
two-tail distribution). Error bars indicate standard error of the mean (SEM). 
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Figure 5.14 - Mean absolute values of TSP-scaled NMR intensities for the extracellular 
media of A) pyruvate, B) acetate and C) myo-inositol between platinum sensitive and 
resistant isogenic ovarian cancer cells. * p<0.05, ** p<0.01, *** p<0.001 (unpaired 
student‟s t-test using two-tail distribution). Error bars indicate standard error of the 
mean (SEM). 
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5.5 Discussion 
Cancer cells exhibit increased glycolysis for generation of ATP
 
(the Warburg effect) (Christofk, 
Vander Heiden et al. 2008). Among the biggest factors considered to contribute to this effect 
are mitochondrial
 
respiration dysfunction and hypoxia, which are frequently linked to 
resistance to chemotherapeutic agents in the tumour
 
microenvironment (Xu, Pelicano et al. 
2005). However, it still remains unclear whether this increased glycolytic
 
activity in cancer 
cells is caused by intrinsic metabolic
 
changes or by the anaerobic conditions within the tumour 
(Zu and Guppy 2004). Our study focused on examining metabolic alterations both under 
standard oxygen conditions and in response to hypoxia.  
 
Taking into account the declining levels for a considerable amount of metabolites, hypoxia 
seemed to have a considerable effect on nutrient consumption. Cancer cell proliferation 
requires synthesis of various macromolecules such as lipids, proteins, and nucleotides 
(DeBerardinis, Mancuso et al. 2007). Under hypoxia this need for both growth and survival 
could lead to utilisation of additional sources for energy production apart than the first choice 
molecule, which is usually glucose. At the same time, decreased levels may also reflect 
impediments in cell growth. Based on the metabolic observations, nutrients like glucose, 
taurine, phosphocholine, glycine, glutathione, glutamate and aspartate in the intracellular 
extracts seemed to be declining for all hypoxic cells, regardless of their resistance status, with 
possibilities including either the cells‟ attempt to protect themselves against hypoxic injury 
and/or compensate for any possible energy deficits.  
 
5.4.1 Metabolic changes under normoxia and hypoxia 
 
Branch-chained amino acids 
Some exceptions occurred, though, in the case of the essential amino acids leucine, isoleucine 
and valine. Both valine and leucine increased intracellularly under hypoxia, regardless of their 
resistance status. The reason why this happens may be explained by a number of possibilities. 
First, it may be possible that hypoxia may promote the uptake of these essential amino acids 
from the media into the cell for various cellular functions including cytoprotection. A study by 
Nishimura and colleagues has shown that valine can contribute to the generation of high-energy 
phosphates in mitochondria and protect heart cells from hypoxia (Nishimura, Muragaki et al. 
1989). Additionally, leucine levels inside the cells may be higher under hypoxia, since it has 
been shown to play a role in HIF-1α-mediated transcription whose interaction with the 
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necessary p300 co-activator relies upon a hydrophobic interface that is leucine-rich (Gu, 
Milligan et al. 2001). Isoleucine also increased intracellularly under hypoxia, but interestingly 
only for the hypoxic resistant samples, indicating a possible contribution to the resistance effect 
in hypoxia with an as yet unknown mechanism. In vitro studies in the past, though, have 
speculated that leucine and isoleucine might promote carcinogenic activity in vivo in the 
bladder of rats (Kakizoe, Komatsu et al. 1982).Both of these amino acids were also later shown 
to cause bladder tumourogenicity in a rat model of carcinogenesis using the N-butyl-N-(4-
hydroxybuty) nitrosamine (BBN) initiator (Nishio, Kakizoe et al. 1986). 
 
Glucose  
Looking at some more metabolites in detail, intracellular glucose in resistant cells showed a 
declining tendency for most lines when compared to their isogenic sensitive lines which, 
according to our initial hypothesis, it was something to be expected for resistant cells. In 
addition, intracellular glucose exhibited declining concentration levels in all hypoxic samples 
when compared to normoxic ones; it is notable however that the decrease was only significant 
in the hypoxic cisplatin-resistant cells, which is on its own interesting as it may signify a 
tendency of the resistant cells to consume more glucose than the cisplatin-sensitive lines in 
hypoxia. In turn, extracellular glucose in the hypoxic media also exhibited lower concentrations 
when compared to the normoxic ones, whilst when compared to their isogenic sensitive lines, it 
was found to be higher in the resistant cells. First of all, the decreased glucose levels in the 
hypoxic samples could point towards a number of possibilities. One possibility could be that 
intracellular glucose was consumed universally by all cells; however, since this decrease was 
more significant in the resistant cells under hypoxia, this could support the theory for the 
existence of an exaggerated Warburg effect in such a low oxygen environment, leading, this 
way perhaps to increased resistance in hypoxic conditions. From another standpoint, since 
extracellular glucose was higher in the resistant cells, compared to the sensitive ones, this might 
also mean decreased glucose uptake in the resistant cells. In conjunction with the lactate 
observations discussed below, these findings might reveal a mechanism by which resistant cells 
behave under hypoxia, which is also related to the use of lactate as a substrate for energy 
production in hypoxia (see paragraph below).   
 
Lactate 
Lactate is a molecule closely associated to glucose. In this study, intracellular lactate levels 
increased for all hypoxic cells when compared to normoxic ones, with the exception of 
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cisplatin-sensitive cell line PEO1 H (The reason for the different behaviour in PEO1 H might 
lie in the actual genetic composition of the cell line or due to an experimental artefact). The 
above events may indicate that at least for the rest of cells there is a possible trend towards 
increased lactate production in hypoxia. The lactate production in cells is usually driven from 
glucose consumption. It is also known that in the absence of oxygen, glucose undergoes 
fermentation to lactate, indicating that the majority of cells increased their anaerobic respiration 
by converting more glucose to lactate. The situation became a little clearer while examining the 
media samples, as all of the cell lines followed a more consistent pattern. Extracellular lactate 
levels increased for all hypoxic cells compared to the normoxic samples, indicating lactate 
production in hypoxia (with the excess lactate being secreted out of the cell). Indeed, because 
the majority of cancer cells cannot store carbon as neither glycogen nor triglycerides, the 
excess carbon atoms generated from the glycolytic process are usually secreted as lactate (Bui 
and Thompson 2006). 
 
Glucose & lactate relationship 
The study and comparison of the metabolic behaviour of glucose and lactate under normoxia 
and hypoxia, seemed to reveal a possible mechanism for the resistant cells: since, all resistant 
cells (in both oxygen conditions) seemed to have lower lactate concentrations than their 
isogenic sensitive cells intracellularly, this could imply the possibility of lactate being used as 
an alternative means of energy production for these cells. This can also be supported by the 
glucose findings while examining the hypoxic resistant cells: there, significantly higher 
intracellular glucose consumption occurred, coupled with increased extracellular glucose 
levels. This may mean that hypoxia may have led to an increased lactate production as a 
preferential energy reserve for the cells under such conditions. This is also supported by the 
observation of increased glucose levels in the media of the resistant samples, possibly 
indicating less glucose (but higher lactate) uptake.  
 
Summarising the above, three conclusions can be reached so far:  
 
- Hypoxia affects the levels of glycolytic entities such glucose and lactate. For the 
majority of cell lines, concentrations were lower for glucose (both intra- and 
extracellularly) and higher for lactate (both intra- and extracellularly, compared to 
normoxic. 
 
174 
 
- Resistant cells seemed to consume more glucose (with the effect exaggerated in 
hypoxia) as demonstrated by their decreased intracellular glucose levels in the resistant 
cells.  
 
- Since extracellular glucose levels in the media were higher in resistant cells whilst their 
intracellular glucose levels were declining (or remained relatively stable) this might 
mean that resistant cells may also prefer lactate as an additional energy source after 
lactate becomes available through the glycolytic process. Indeed, intracellular and 
extracellular lactate levels in resistant cells are declining (with the difference more 
apparent in the PEO1/PEO4 pair). On some occasions, hypoxic conditions seemed to 
make these changes more apparent. 
 
Pyruvate 
Pyruvate is another candidate molecule associated with the development of platinum resistance. 
Pyruvate is usually produced from glucose (glycolysis), supplying energy to living cells during 
the citric acid cycle (Alberts, Johnson et al. 2002). Examining the pyruvate levels in the media, 
sensitive and resistant cells showed decreased levels in all hypoxic lines, regardless of 
resistance status. However, under hypoxic conditions, pyruvate levels showed very similar 
concentrations between resistant and sensitive cells whereas under normoxia, the resistant lines 
exhibited a much greater difference in their levels compared to the sensitive ones. As in the 
case of acetate, the concentration gap between hypoxic sensitive and resistant cells was 
minimal. There are various possibilities for this behaviour in hypoxic pyruvate levels.  
 
First of all, if the increased levels of lactate were compared with the very low pyruvate levels in 
the hypoxic media (for both resistant and sensitive cells) this could indicate increased 
consumption of pyruvate for the formation of lactate. Indeed, it has been found that when there 
is insufficient delivery of oxygen to the cells, there can be a shift towards lactate production as 
an alternative way for energy production (Andrews, Chen et al. 1999). Metabolic alterations 
involving pyruvate have been previously observed in cancer (i.e. increased glycolysis and 
glutaminolysis) which are known to increase lactate in tumour cells (Sonveaux, Vegran et al. 
2008); (DeBerardinis, Mancuso et al. 2007) which are consistent with the increased lactate 
production/secretion discussed earlier. 
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It is also possible that pyruvate plays a part in protecting the cancer cell during hypoxia; 
pyruvate can stabilize HIF-1α and inhibit the pyruvate dehydrogenase complex. This has been 
shown to promote malignancy (McFate, Mohyeldin et al. 2008). Also, by allowing this HIF 
stabilization, pyruvate could promote resistance to oxidative stress and anti-cancer therapy 
(Martinive, Defresne et al. 2006); (Dewhirst, Cao et al. 2008). Additionally, it is known that 
pyruvate can reduce the ability of chemotherapeutic agents to induce apoptosis. For example, it 
has been shown to reduce the cytotoxicity of cisplatin in renal proximal tubular epithelial cells 
(Baek, Kwon et al. 2003) and, in general, of apoptosis-inducing drugs, working through 
oxidative stress (Frederiksen, Siemens et al. 2003); (Sanna and Rofstad 1994); (Song, Liu et al. 
2006). Besides its metabolic role, pyruvate can act as a strong anti-oxidant (O'Donnell-Tormey, 
Nathan et al. 1987); (Andrae, Singh et al. 1985); (Lee, Kang et al. 2003); (Martin 1996), 
interfering with ROS-induced intracellular signals, necessary for cellular functions such as cell 
proliferation or apoptosis (Dewhirst, Cao et al. 2008); (Pelicano, Carney et al. 2004) and, thus, 
protecting the cancer cells from oxidative stress. Additionally, pyruvate has been shown to 
decrease hypoxia-induced DNA damage and increase DNA repair in liver tumours (Roudier, 
Bachelet et al. 2007) possibly by maintaining PARP activity, in hypoxic cancer cells (Roudier 
and Perrin 2009). 
 
Acetate 
In the case of acetate there seemed to be a difference in behaviour between normoxic and 
hypoxic lines (see tables 5.5 and 5.6). Looking closer at its extracellular levels, all hypoxic cell 
lines had decreased acetate in the media (possibly due to effects in growth). However, this 
decline might also reveal an intrinsic metabolic mechanism, which only becomes apparent in 
hypoxia, and implicates the regulation of concentration of compounds like acetic acid. For 
example, acetate uptake in tumour cells is
 
thought to be mediated by acetyl-CoA synthetase 
(ACSS). Studies have shown that ACSS
 
expression is upregulated in hypoxia, suggesting that 
this may play an important role in controlling the metabolism of acetate in cancer cells (Yoshii, 
Furukawa et al. 2007). In addition to that, the acetate levels in all resistant cell lines appeared to 
have significantly decreased concentration levels compared to their sensitive counterparts. 
However, under hypoxia, the difference between resistant and sensitive cell lines was relatively 
minimal. It is not entirely clear why this behaviour was observed. Normally, though, the 
concentration of acetate in cells is kept at low levels so as to avoid disrupting the physiological 
pH. Since on this occasion the overall change in acetate levels was smaller for the resistant 
cells but bigger for the sensitive cells, one could theorise that for some reason resistant cells did 
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not need to alter greatly their pH in hypoxia compared to sensitive cells, and have in general a 
better-adapted ability to withstand low pH-inflicted pressure, contributing, thus, to the overall 
effect of resistance.  
 
Myo-inositol 
In the case of myo-inositol a unique pattern was observed. As with other molecules, 
intracellular myo-inositol decreased in all hypoxic cell lines. However, this decrease was much 
more pronounced in the case of the resistant cells (Table 5.4). This might indicate either 
enhanced myo-inositol consumption or less production from glucose in hypoxia. This also 
became more apparent when comparing changes between the isogenic pairs; intracellular myo-
inositol decreased in all hypoxia-exposed resistant cell lines but not in the normoxia-exposed 
ones (Table 5.3). Conversely, extracellular myo-inositol exhibited increases in the hypoxic 
resistant cells, while the normoxic resistant either exhibited a small decrease or remained 
stable. This might indicate reduced uptake of myo-inositol from the extracellular media in the 
case of hypoxic resistant cells. Reports on myo-inositol in ovarian cancer cells have showed 
increased levels under standard culture conditions and since it has been speculated that myo-
inositol may act as a kind of anti-oxidant (Muraoka and Miura 2004) it could be assumed 
possible to confer resistance against drugs. In our study, if there is indeed decreased myo-
inositol utilisation in hypoxic resistant cells, this may mean that resistant cells in hypoxia have 
different ways of dealing with chemotherapeutic drugs, by-passing the need for increased myo-
inositol and, thus, stimulating the interest of further investigating its role. 
 
Choline-related compounds 
The phospholipid glycerophosphocholine (GPC) is another intracellular metabolite that showed 
a notable response regarding its hypoxic concentration levels when compared to the normoxic 
ones. Under hypoxia, GPC levels increased for the resistant cells but decreased for the sensitive 
cells. The pattern was more random when comparing sensitive vs. resistant cells.  A previous 
study had shown that GPC in hypoxia had declined to non-detectable levels (following an 
initial increase), while genes that encoded related phosphatidylcholine enzymes were 
downregulated (Ackerstaff, Pflug et al. 2001). It was speculated that such processes could have 
an effect on the changes observed in GPC levels under hypoxia. However, how this is linked to 
phosphatidylcholine metabolism and their expression levels, especially under hypoxia, still 
remains relatively unexplored (Glunde, Jie et al. 2004). Phosphocholine decreased in all 
hypoxic cells but also increased in all resistant cells. This may indicate that this particular 
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metabolite is not greatly affected by the presence of oxygen. However, just the fact that 
phosphocholine was increased in the resistant cells compared to their isogenic sensitive ones, 
gives some support to existing data that link its increased levels to cancer. For example, 
previous studies have demonstrated that loss of p53 lead to increased phosphocholine in colon 
cancer cells and may suggest that on this occasion at least, the observed increased malignancy 
may be partly mediated through choline-related pathways (Mori, Delsite et al. 2004). Other 
studies have also shown that phosphocholine can act as a biomarker in breast cancer expressing 
upregulation in various choline transporters or choline kinase genes (Eliyahu, Kreizman et al. 
2007). 
 
5.4.2 Correlation with previous NMR-based metabolic findings 
While trying to compare the metabolic lab findings of this chapter with those presented in 
chapter 3, it quickly became obvious that a metabolic comparison between cancer cell lines of 
different genetic orientation and, thus, different phenotypic behaviour, can be challenging at 
times.  
 
The first part of the study involved pairs of kidney (HEK-293T derived) and ovarian cancer 
(A2780-derived) cell lines, either positive or negative for the MMR protein Mlh1. The 
metabolic changes correlating to platinum resistance included metabolites such as glutathione 
whose levels were consistently higher for all Mlh1-negative cells. Compared to the last part of 
this study (chapter 5) the glutathione changes seemed more random, with only the PEA1 & 
PEA2 isogenic pair “agreeing” with the first part of the study. Interestingly, though, hypoxia 
seemed to try and “correct” to a certain degree this anomaly created by PEO1 & PEO4 by 
reducing the concentration differences in glutathione between the isogenic lines. In the first part 
of the study there was a significant increase in intracellular alanine in all cells with Mlh1 loss 
(except in the mitochondrial DNA-depleted cells). In the isogenic study, alanine increased in all 
cells except PEO4 N. Interestingly again, hypoxia seemed to “correct” this discrepancy of the 
normoxic cells, with both resistant hypoxic resistant lines showing increased alanine 
concentrations. Intracellular glucose in resistant cells showed  declining levels for most lines 
compared to their isogenic sensitive ones (with the effect more exaggerated in hypoxic 
conditions while once again “correcting” the levels of PEO4 cells when compared to 
normoxia). In the Mlh1 study, the levels of intracellular lactate slightly decreased in all Mlh1-
negative cells across both models (with the exception of MutLα- which showed a small 
increase in the HEK-293T model). In the isogenic study, lactate levels in resistant cells also 
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declined compared to their isogenic sensitive ones (with the exception of one line, PEO4 H). 
Intracellular PC levels were seen to decrease in all the Mlh1-negative cells (but with the 
decrease in the mitochondrial DNA-depleted cells being miniscule at just 1%). On the contrary, 
phosphocholine increased in all resistant cells of the isogenic study, when compared to the 
sensitive ones. In the Mlh1 study Mlh1-negative cells exhibited a small decrease in their GPC 
concentration levels (with the exception of the ovarian Mlh1-negative CP70 cell line). In the 
isogenic study, GPC levels increased for the resistant cells (with the exception of PEO4 N). 
However, hypoxia apparently catered for this discrepancy once more by increasing the levels of 
said cell line in low oxygen conditions. Choline levels were increased intracellularly in all 
Mlh1-negative cells, however in the isogenic study resistant vs. sensitive its levels were more 
random. In the Mlh1 study, myo-inositol increased in the Mlh1-negative CP70 A2 cells from 
the PRM model and the MutLα- cells from the HEK-293T cell model. But it didn‟t change for 
the CP70 and the MutLα- ρ0 cells, where there was a miniscule decrease. In the isogenic study 
though, intracellular myo-inositol increased in the normoxic resistant but decreased in the 
hypoxic resistant ones as compared to the sensitive cells. 
  
All the above changes reveal some consistencies and some discrepancies between the two 
NMR-based studies. On some occasions however, hypoxia appeared to correct these 
disagreements as with the cases of alanine or GPC. Of course, this “correction” was not 
universal throughout the metabolic data, and on certain occasions as in the case of myo-
inositol, some of the changes appeared to be non-agreeable between the two studies or even 
within them. However, on such instances, it is important to mention that other known and 
unknown factors seem to come into play, and which include significant parameters such as the 
background genetic variability of the tested cancer cell lines.   
 
5.4.3 Concluding remarks 
In summary, this part of the study examined the baseline metabolic phenotype of platinum 
resistance cells under two different oxygen conditions and, as a result, it managed to observe 
meaningful concentration changes of metabolites in relation to cancer and platinum resistance. 
This way, further insight was added in the fight against chemotherapeutic resistance which was 
made possible through the study and identification of metabolic entities that seem to contribute 
to it.  
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Chapter 6 
 
Conclusions 
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6.1 Overview 
Cancer chemotherapy has developed to become the standard of patient care. However, the 
frequently arising clinical problems of acquired resistance to platinum based cancer drugs is a 
crucial determining factor and is usually associated with poor prognostic outcome. Studying 
and understanding the mechanisms of resistance, and especially its reversal, was therefore of 
critical significance in offering better chances of improvement in both treatment and outcome 
for the cancer patient.  
 
In general, metabolic profiling like the one presented in this study, could prove useful in 
delivering non-invasive biomarkers of resistance to assist with cancer detection as early as 
possible in the development of the disease. In other words, it could potentially identify patients 
who are either suitable or unsuitable to give a successful response to platinum-based 
chemotherapy.  
 
The general theme of this PhD thesis was the metabolic investigation of platinum resistance 
and cancer using a number of different approaches, employing NMR, cell culture- and 
bioinformatics-based methods, as approaching this multifactorial problem from different angles 
was deemed essential in assisting towards the general understanding of it. 
 
The first part of this investigation initiated with the study of Mlh1-specific metabolic signatures 
of two cell models in vitro: a transient Mlh1 expression cell model involving kidney cell lines 
of common genetic background after selective mitochondrial depletion, and a model of 
platinum resistance consisting of well-established ovarian cell lines. In this part of the study, 
the metabolites whose levels showed significant correlation with Mlh1 expression and platinum 
resistance included glutathione, alanine, lactate, branch-chained amino acids, myo-inositol and 
choline-related metabolites such as phosphocholine. Our findings offered a range of 
interpretations on the role of these metabolites and their association with Mlh1, platinum 
resistance and mitochondria, suggesting that cells with Mlh1 loss of expression can render cells 
more resistant to chemotherapeutic treatments. It also managed to identify a unique Mlh1 
metabolic signature as well as to connect mitochondrial metabolism to Mlh1 loss of expression. 
 
As a continuation of this study, a bioinformatics based approach was also applied for the 
comparison of the above metabolic findings to the results published in the NCI-60 gene 
expression database as well as to crosscheck possible correlations. The Mlh1-related genes that 
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were identified as important, using a bioinformatics-based methodology by exploiting the 
ConsensusPath online database, were ACOT4, FAS and FUT9 and NCAM1. At the same time, 
their significantly associated metabolites that helped towards their identification were oleic 
acid, palmitate, sialyl-3-paragloboside, and stearate. In general, this part of the study managed 
to test in practice a newly-developed NEST-based examination that involved complex 
pathways of genes and metabolites, using Mlh1 as the centre of investigation. 
 
The final part of this study explored platinum resistance in a different set of cancer cell lines, 
and involved isogenic ovarian cancer cells that offered to give a more accurate representation 
of in vivo situations and platinum resistance. The use of isogenetically matched cell lines which 
have been derived directly from cancer patient before and after the development of platinum 
resistance helped immensely in identifying and confirming possible causative or influencing 
factors of this phenomenon from a metabolic point of view. In addition, taking into account that 
hypoxia on many clinical occasions confers cancer aggressiveness, the experiments that took 
place also focused on examining metabolic alterations not only under standard oxygen 
conditions but also in response to reduced oxygen availability (hypoxia). At the same time, 
particular focus was given on metabolic changes that could be connected to increased platinum 
resistance under hypoxia. The results gave a variety of metabolic responses in both intracellular 
extracts and extracellular media, and included concentration changes in glucose, lactate, 
pyruvate, acetate, and choline-related metabolites.  
 
6.2 Clinical relevance and future directions 
From a clinical point of view, metabonomics is able to generate biomarkers that have been 
proven useful in detection, prediction of response as well as identification of new therapeutic 
avenues. Its predictive potential is considered a key parameter in translational research, because 
the methods employed (most commonly, NMR spectroscopy) provide minimal invasiveness, 
are non-destructive and frequently use miniscule amounts of sample fluids or tissues. The 
relatively small size of the number of metabolic entities when compared to genes, trasnscripts 
and proteins, in theory at least, also offer the ability to capture a snapshot of the cellular 
environment. And since, metabolomics is among the fastest systems to react to any changes in 
an organism‟s system it can reflect metabolic changes in response to stimuli such as platinum 
drugs.  
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In fact, the metabolic response to platinum drugs is actually one of the possible future 
investigations that can be considered when examining platinum resistance in cancer. Thus, 
apart from the baseline profiles generated in this study, a continuation of this investigation 
could involve a variety of isogenic cell lines being tested for a metabolic response to platinum 
drugs such as cisplatin.  
 
In addition, treatment of such cell lines with a type of modulator of resistance (i.e. aphidicolin) 
that, on some occasions,  are known to effectively “reverse” resistance by acting on metabolic 
entities/pathways would complete the metabolic picture between predictive biomarkers and 
biomarkers of response.  
 
In summary the current study as well as any related future investigations could: 
 
• Remove from consideration false positive or negative results in assays involving 
biomarkers for the disease. 
 
• Lead towards the development of less toxic and side-effect producing but more 
effective salvage chemotherapy regimens.  
 
• Identify early on the onset of the disease the patients that suffer from premalignant 
forms before they develop into active cancer so that curative treatment can be started without 
delay. 
 
• Identify causative gene(s) that could not be directly associated with resistance due to 
lack of insight into the wider picture, but could only be identified through multianalytical 
platforms and complex computational methods. Such a development would be possibly 
beneficial in producing gene-specific treatments, perhaps also finding potential future 
applications in gene therapy.  
 
As a conclusion, this study managed to give added insight into the metabolic universe of cancer 
and platinum resistance with the assistance of analytical tools such as NMR, molecular-based 
techniques and computational approaches. At the same time it may also help to pave the way 
for further in vitro and translational metabolic-based studies and assist in the fight towards 
better management and treatment of the deleterious disease that is cancer.   
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39784_HUMAN CAMK2D_HUMAN FBXO3_HUMAN KIAA0774_HUMAN LSM4_HUMAN PCDHGC3_HUMAN SIGIRR_HUMAN TRIM35_HUMAN 
AADACL2_HUMAN CAMSAP1_HUMAN FBXO45_HUMAN KIAA0999_HUMAN LUC7L2_HUMAN PCDHGC3_HUMAN SLC35F5_HUMAN TRIOBP_HUMAN 
ABCA6_HUMAN CCDC17_HUMAN FGF18_HUMAN KIAA0999_HUMAN LYRM5_HUMAN PCDHGC3_HUMAN SLC44A5_HUMAN TTLL11_HUMAN 
ABI2_HUMAN CCNI_HUMAN FLII_HUMAN KIAA1147_HUMAN MAN2A1_HUMAN PCDHGC3_HUMAN SLC8A1_HUMAN TUBGCP2_HUMAN 
ACOT4_HUMAN CDC42BPA_HUMAN FLJ13137_HUMAN KILLIN_HUMAN MAP3K7IP1_HUMAN PDLIM7_HUMAN SLC9A9_HUMAN TUG1_HUMAN 
AGBL5_HUMAN CGB_HUMAN FLT1_HUMAN KIR2DS2_HUMAN MAPK1_HUMAN PDLIM7_HUMAN SLMO2_HUMAN TWISTNB_HUMAN 
AGPS_HUMAN CHRNA10_HUMAN FSTL5_HUMAN KIR2DS5_HUMAN MATR3_HUMAN PGK1_HUMAN SMCR7L_HUMAN UBASH3B_HUMAN 
AGTPBP1_HUMAN CHST14_HUMAN FTH1_HUMAN KLF12_HUMAN MET_HUMAN PKD1_HUMAN SOBP_HUMAN UQCC_HUMAN 
AKR1C1_HUMAN CIZ1_HUMAN FUT9_HUMAN KLF3_HUMAN MGST1_HUMAN PNKD_HUMAN SPTLC3_HUMAN USP24_HUMAN 
AKR1C1_HUMAN CIZ1_HUMAN GAB3_HUMAN L3MBTL3_HUMAN MLH1_HUMAN PNPO_HUMAN SREBF2_HUMAN USP31_HUMAN 
AKR1C2_HUMAN CLCN4_HUMAN GAS5_HUMAN LAGE3_HUMAN MLL3_HUMAN PQLC1_HUMAN STAG3L4_HUMAN USP40_HUMAN 
AKR1C2_HUMAN CMIP_HUMAN GEMIN8_HUMAN LBA1_HUMAN MS4A6A_HUMAN PRKACB_HUMAN STARD13_HUMAN USP48_HUMAN 
ALDH3B2_HUMAN COG1_HUMAN GLCCI1_HUMAN LEO1_HUMAN MSL-1_HUMAN PRODH_HUMAN STK35_HUMAN UTP15_HUMAN 
ANGPT2_HUMAN CRTAP_HUMAN GLS_HUMAN LIPH_HUMAN MTERFD2_HUMAN PTCD3_HUMAN STK35_HUMAN VPS26A_HUMAN 
APLP2_HUMAN CSNK1A1_HUMAN GMEB2_HUMAN LMCD1_HUMAN NCAM1_HUMAN PVRL3_HUMAN SUOX_HUMAN WWTR1_HUMAN 
APPBP2_HUMAN CTBP1_HUMAN GRM7_HUMAN LMNA_HUMAN NDFIP2_HUMAN RAB12_HUMAN TAF1B_HUMAN XIST_HUMAN 
AZIN1_HUMAN CTDSPL_HUMAN HBE1_HUMAN LMO7_HUMAN NEGR1_HUMAN RABGGTB_HUMAN TBCD_HUMAN ZNF138_HUMAN 
BAZ1A_HUMAN CTSB_HUMAN hCG_1806964_HUMAN LOC100126784_HUMAN NFKBIB_HUMAN RDH13_HUMAN TEX9_HUMAN ZNF236_HUMAN 
C10orf46_HUMAN DAGLB_HUMAN HEG1_HUMAN LOC100130360_HUMAN NFKBID_HUMAN RHBDD3_HUMAN TM2D1_HUMAN ZNF404_HUMAN 
C10orf57_HUMAN DDHD1_HUMAN HNRNPC_HUMAN LOC100147773_HUMAN NLRC5_HUMAN RHEB_HUMAN TM2D1_HUMAN ZNF540_HUMAN 
C11orf24_HUMAN DENND2A_HUMAN HSPA4_HUMAN LOC116412_HUMAN NRP2_HUMAN RHO_HUMAN TMEM127_HUMAN ZNF546_HUMAN 
C11orf57_HUMAN DHX34_HUMAN ICAM2_HUMAN LOC129293_HUMAN NRP2_HUMAN RNF213_HUMAN TMEM173_HUMAN ZNF618_HUMAN 
C18orf54_HUMAN DHX57_HUMAN INSM2_HUMAN LOC201164_HUMAN NSMCE4A_HUMAN RPS15A_HUMAN TMEM178_HUMAN ZNF766_HUMAN 
C19orf54_HUMAN DLEU2_HUMAN INTS10_HUMAN LOC283666_HUMAN NUP153_HUMAN RRAD_HUMAN TMEM196_HUMAN ZNF787_HUMAN 
C1orf142_HUMAN DLG2_HUMAN INTS10_HUMAN LOC285908_HUMAN NY-SAR-48_HUMAN RSPRY1_HUMAN TMEM200A_HUMAN  
C2orf64_HUMAN EDIL3_HUMAN IRF2BP2_HUMAN LOC388610_HUMAN OSBPL11_HUMAN S100A16_HUMAN TMEM43_HUMAN  
C4orf30_HUMAN EPB41L2_HUMAN IVD_HUMAN LOC399884_HUMAN PARP14_HUMAN SAMD10_HUMAN TMEM56_HUMAN  
C6orf176_HUMAN FAM109A_HUMAN JMJD1C_HUMAN LOC440894_HUMAN PCDH20_HUMAN SEC22C_HUMAN TPPP_HUMAN  
C6orf201_HUMAN FAM80A_HUMAN JMJD1C_HUMAN LOC440934_HUMAN PCDHA6_HUMAN SERAC1_HUMAN TRIM22_HUMAN  
C6orf89_HUMAN FAM83A_HUMAN KCTD1_HUMAN LOC643733_HUMAN PCDHA6_HUMAN SFRS1_HUMAN TRIM3_HUMAN  
C7orf20_HUMAN FAS_HUMAN KIAA0391_HUMAN LOC644656_HUMAN PCDHA6_HUMAN SFT2D1_HUMAN TRIM3_HUMAN  
 Table A1 - List of all the Mlh1-associated NCI-60 protein names (Unirpot IDs) from chapter 4 
